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ABSTRACT 
 
The eosinophil is a leukocyte whose intracellular mediators are considered to play a 
central role in the pathogenesis of allergic diseases, including allergic asthma, allergic 
rhinitis and atopic dermatitis, and which is also involved in immunological responses to 
parasites. Eosinophil differentiation and maturation from bone marrow progenitors is 
regulated by interleukin-5 (IL-5), which may be secreted by T helper 2 (Th2) T 
lymphocytes, and is consistently upregulated in allergic conditions. Eotaxin is a potent 
chemoattractant for circulating and tissue eosinophils, and the production of this 
chemokine promotes eosinophil infiltration and accumulation within sites of allergic 
inflammation.  
 
Eosinophils obtained from inflammatory tissues and secretions display an altered 
phenotype in comparison to peripheral blood eosinophils, with increased surface 
expression of major histocompatibility complex (MHC) proteins and adhesion 
molecules (Hansel et al., 1991), and migration across the microvascular endothelium 
may also increase their capacity to generate an oxidative burst (Walker et al., 1993; 
Yamamoto et al., 2000). Eosinophils are phagocytic cells, and have been shown to 
present simple (no requirement for intracellular processing) and complex antigens to 
MHC-restricted, antigen-specific T lymphocytes (Del Pozo et al., 1992; Weller et al., 
1993). Furthermore, eosinophils express the costimulatory molecules required for 
effective antigen presentation (Tamura et al., 1996), and ligation of costimulatory 
molecules on the eosinophil cell surface can induce the release of eosinophil derived 
cytokines (Woerly et al., 1999; Woerly et al., 2002). Therefore the eosinophil may also 
regulate immune responses. 
 
To date, no studies have demonstrated the ability of eosinophils to modulate activated T 
lymphocyte function via presentation of relevant antigen in the context of MHC class II 
(MHC-II), concomitant with Th2 cytokine release. In the experiments described in this 
thesis, murine eosinophils have been observed to rapidly migrate to sites of antigen 
deposition within the airways mucosa of naïve mice, suggesting a potential role for this 
granulocyte in the primary response to inhaled antigen. However, human allergic 
diseases are often diagnosed after the establishment of allergic responses, and symptom 
development. Therefore, a murine model of allergic airways disease (AAD) was used to 
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investigate the ability for eosinophils to participate as antigen presenting cells (APCs), 
and thereby modulate activated T lymphocyte function both in vitro and in vivo.  
Detailed histological analysis of the pulmonary draining lymph nodes following antigen 
challenge in sensitised mice revealed a rapid infiltration of eosinophils into this tissue, 
which preceded the accumulation of eosinophils in bronchoalveolar lavage fluid 
(BALF). This suggested that eosinophils were preferentially translocating to the 
draining lymph nodes following antigen challenge, and that the subsequent 
accumulation of these cells in the BALF was a consequence of continued antigen 
delivery to the lower airways.  
 
Eosinophil trafficking to lymphoid tissue via the afferent lymphatics was substantiated 
using electron microscopy of lymph node sections and the intravenous (i.v.) transfer of 
fluorescently labeled eosinophils, which did not traffic to lymph nodes via the blood. 
During the resolution of AAD, eosinophils were noted for their persistence in the 
pulmonary draining lymph nodes. These observations suggested a continued modulation 
of T cell function by lymph node dwelling eosinophils during AAD resolution, 
particularly in light of recent observations for draining lymph node T cell proliferation 
following instillation of antigen-pulsed eosinophils into the allergic mouse lung (Shi et 
al., 2000).  
 
To further investigate the antigen presenting capacity, eosinophils were obtained from 
the BALF of mice with AAD, and their surface expression of MHC class II (MHC-II) 
proteins and costimulatory molecules confirmed using flow cytometric analysis. The 
ability to acquire and process complex antigen both in vitro and in vivo was also 
confirmed using naturally quenching fluorescenated ovalbumin (OVA), which is 
degraded into fluorescent peptides by the action of intracellular proteases. Thus, 
eosinophil expression of the surface molecules necessary for effective antigen 
presentation was confirmed, as was their ability to process complex antigen. Further 
investigations revealed that eosinophils can present complex OVA antigen to CD4+ T 
lymphocytes obtained from the allergic mouse, and to in vitro derived OVA-specific 
Th2 cells. In the presence of exogenous antigen, eosinophils co-cultured with T 
lymphocytes were able to induce Th2 cytokine production, and demonstrated an ability 
for eosinophils to modulate T lymphocyte function in vitro. 
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The ability for eosinophils to act as antigen presenting cells in vivo was also 
investigated. Eosinophils obtained from the antigen-saturated lungs of OVA sensitised 
and challenged mice were transferred to the peritoneal cavities of naïve host mice. 
When subsequently challenged with aerosolised OVA, eosinophil recipients developed 
a pulmonary eosinophilia similar to that of OVA sensitised and challenged mice. To 
validate this finding, the experimental procedure was altered to accommodate the use of 
non-allergy derived eosinophils, which were pulsed with OVA in vitro, prior to transfer 
into naïve recipients. When subsequently challenged with aerosolised OVA, eosinophil 
recipients developed a peripheral blood and pulmonary eosinophilia, and stimulation 
with OVA induced IL-5 and IL-13 cytokine production from pulmonary draining lymph 
node cells. Notably, the AAD induced by transfer of antigen pulsed eosinophils did not 
induce detectable OVA-specific IgG1, which may be attributed to the lack of soluble 
antigen required for B cell antibody production. 
 
During the course of these investigations, an OVA T cell receptor (TCR) transgenic 
mouse (OT-II) was procured with a view to defining the interaction between eosinophils 
and activated T lymphocytes (Barnden et al., 1998). Despite having specificity for the 
OVA323-339 peptide, an immunodominant epitope that skews naïve T cell responses 
towards Th2 cytokine release (Janssen et al., 2000), T lymphocytes from the OT-II 
mouse preferentially secreted IFN-γ in response to stimulation with either OVA peptide 
or OVA. These mice were further characterised in a mouse model of AAD, and found to 
be refractory to disease induction and progression, which may be attributed to 
significant IFN-γ secretion by transgenic CD4+ T lymphocytes during antigen 
sensitisation. Indeed, these cells were noted for their ability to attenuate pulmonary 
eosinophilia when transferred to OVA sensitised and challenged wild type mice, 
although serum OVA-specific IgG1, peripheral blood eosinophilia levels and airways 
response to methacholine challenge remained intact.  
 
Knowledge of the biased Th1 phenotype in naïve OT-II provided a unique opportunity 
to investigate the fate of T lymphocytes bearing high affinity OVA-specific TCRs 
following neonatal antigen exposure to soluble OVA. In a previous study, subcutaneous 
(s.c.) administration of soluble OVA to wild type neonatal mice was suspected to have 
deleted OVA-specific T cells from the T cell repertoire (Hogan et al., 1998a). Using 
flow cytometry and TCR specific antibody, the delivery of s.c. OVA to OT-II neonates 
IX 
did not alter transgenic T cell populations in adult mice. Instead, it was surprising to 
find a skewing towards the Th2 phenotype and loss of IFN-γ secretion following OVA 
sensitisation and challenge in adult mice. A mechanism for this reprogramming of the 
transgenic T cell from the Th1 to a Th2 phenotype following OT-II neonatal exposure 
to soluble OVA is proposed, and further experimentation may validate this hypothesis. 
 
In conclusion, eosinophils residing in the allergic lung have the capacity to interact with 
activated T cells, both within this tissue and the draining lymph nodes. Despite their 
relative inefficiency as antigen presenting cells (Mawhorter et al., 1994), eosinophils 
may participate en masse in the serial triggering of activated TCRs, and provide 
appropriate costimulatory signals that modulate T lymphocyte function. Through the 
elaboration of Th2 cytokines and stimulation of T cell proliferation, antigen presenting 
eosinophils may transiently prolong or exacerbate the symptoms of allergic diseases. 
Alternatively, eosinophils presenting relevant antigens may inhibit T cell activity via 
degranulation, and such activity has recently been observed in a parasite model (Shinkai 
et al., 2002). Finally, experiments in the OT-II mouse have provided valuable 
information to suggest that therapies designed to modulate eosinophil numbers in 
allergic tissues through the secretion of opposing cytokines such as IFN-γ, may be of 
limited benefit. The results shown here suggest that airways dysfunction remains intact 
despite significantly reduced pulmonary eosinophilia.  
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1.0 GENERAL INTRODUCTION 
 
Eosinophils are bone derived effector cells implicated in the pathogenesis of allergic 
inflammatory diseases such as asthma, and in the defense against some internal 
parasites (Gleich et al., 1993; Wardlaw et al., 1995). Extensive investigations into the 
effector roles attributed to eosinophils in the pathogenesis of inflammatory diseases 
have revealed that this cell may also participate as an immune modulator. In response to 
inflammatory cytokines, eosinophils can express surface MHC and the co-stimulatory 
molecules that are necessary for interaction with MHC-restricted T lymphocytes 
(Weller, 1994; Weller and Lim, 1997). Their relative abundance at sites of allergic 
inflammation suggests that eosinophils may be significant modulators of T cell 
function. An extensive study into the ability of eosinophils to perform 
immunoregulatory functions may define a new role for this cell in addition to the 
already suspected effector functions in the pathogenesis of atopic diseases.  
 
1.1 EOSINOPHIL BIOLOGY AND ROLE IN ALLERGIC DISEASE.  
Eosinophils are terminally differentiated bone marrow-derived leukocytes, noted for 
their membrane-bound granules and bilobed nucleus. The eosinophilic granules 
comprise proinflammatory molecules and cytotoxic proteins, including major basic 
protein (MBP), eosinophil peroxidase (EPO), eosinophil cationic protein (EPO), and in 
human cells, eosinophil derived neurotoxin (EDN), all of which have been extensively 
reviewed elsewhere (Gleich and Adolphson, 1986; Wardlaw et al., 1995). Inflammation 
of the airway mucosa and submucosa is thought to play a major role in the pathogenesis 
of allergic asthma (Bochner et al., 1994), and the eosinophil is regarded as a key 
effector cell in the pathogenesis of allergic diseases (Rothenberg, 1998).  
 
1.1.1 Regulation of eosinophilia by IL-5 and eotaxin. 
IL-5 is believed to regulate the growth, differentiation, and activation of eosinophils 
(Sanderson, 1992), although mature eosinophils with normal morphology may be found 
in the bone marrow, blood, and tissues of IL-5 deficient mice (Kopf et al., 1996), and 
these cells exhibit functional responses to IL-5 and eotaxin (Mould et al., 1997). In 
animal models of allergic airways inflammation, allergen inhalation increases the 
numbers of eosinophil progenitors in the bone marrow (Woolley et al., 1994; Inman et 
al., 1996; Inman et al., 1999), and in human asthma patients, allergen challenge induces 
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significant increases in progenitor cells expressing the IL-5 receptor α-chain, which 
favors the development of eosinophilia (Sehmi et al., 1997). While the bone marrow 
clearly contributes to blood and tissue eosinophilia (Denburg et al., 1996; Denburg et 
al., 1997), eosinophil differentiation is not restricted to this compartment, and there is 
evidence of IL-5 dependent differentiation at local sites of inflammation (Cameron et 
al., 2000).  
 
Peripheral blood eosinophilia is tightly regulated by IL-5, (Coffman et al., 1989; Kopf 
et al., 1996), which is thought to be produced primarily by CD4+ T cells in allergic 
disease (Corrigan et al., 1995; Till et al., 1995; Hogan et al., 1998c). Mice that are 
deficient for IL-5 display reduced tissue and blood eosinophilia, lung damage and AHR 
in a mouse model of asthma (Foster et al., 1996), and despite having readily detectable 
IL-5 in BALF, allergic mice deficient for the IL-5 receptor α-chain have attenuated 
tissue and BALF eosinophilia (Tanaka et al., 2000). Together, these data highlight the 
importance of IL-5 in generating a peripheral blood eosinophilia that is necessary for 
eosinophil recruitment to allergic tissues. 
 
Eotaxin is required for baseline tissue eosinophilia in the healthy state (Matthews et al., 
1998), and the gastrointestinal tract (GIT) is the largest compartment for eosinophil 
accumulation in healthy individuals. Eosinophils reside in the mouse GIT mucosa 
during embryonic development, and in both germ-free and non germ-free adults, 
indicating that the recruitment of eosinophils through constitutive eotaxin production by 
mononuclear cells in the lamina propria is independent of viable intestinal flora (Mishra 
et al., 1999). Eosinophil recruitment to the duodenal and colonic mucosa can occur 
independently of IL-5 in a model of allergic gastrointestinal disease (Hogan et al., 
2000), and increases in peripheral blood eosinophils resulting from allergic airways 
disease do not alter mucosal eosinophil numbers in the GIT (Mishra et al., 1999), 
indicating that recruitment of eosinophils to the GIT and allergic tissues are 
differentially regulated.  
 
Eosinophil recruitment into allergic tissue is thought to result from the concerted action 
of IL-5 and eotaxin, which act respectively, to mobilise eosinophils from bone marrow, 
and selectively recruit eosinophils into tissue. In the guinea pig, systemic administration 
of IL-5 induces a peripheral blood eosinophilia, which enhances eosinophil 
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accumulation in response to intradermal eotaxin administration (Collins et al., 1995), 
while the overexpression of IL-5 in IL-5 transgenic mice enables eotaxin to recruit 
eosinophils to the airways lumen following intratracheal administration (Rothenberg et 
al., 1996). In sensitised guinea pigs, eotaxin levels in BALF and lung tissue peak within 
6 hours following allergen challenge, and eosinophils appear in lung tissue and the 
airways lumen 6 and 12 hours following challenge, respectively (Humbles et al., 1997). 
In this model, the administration of antibodies to IL-5 prior to allergen challenge did not 
affect eotaxin expression, but significantly attenuated eosinophil numbers in BALF and 
lung tissue, demonstrating the necessity for IL-5 induced mobilisation of bone marrow 
eosinophils for eotaxin mediated recruitment to the allergic lung. 
 
Although the expression of IL-5 in the airways epithelium can lead to increased 
eosinophil numbers in peribronchial tissue and the airways lumen (Lee et al., 1997), 
circulating, and not lung IL-5 is thought to be necessary for the development of airways 
eosinophilia in a mouse model of allergic airways disease (Wang et al., 1998).  
In sensitised and challenged IL-5 deficient animals, both IL-4 and eotaxin levels 
produced in the lung are similar to that of wild type mice, yet eosinophil recruitment to 
the lung is severely attenuated. Circulating IL-5 can restore eosinophil recruitment to 
the allergic airways, whilst compartmentalised IL-5 expression within the lung does not. 
(Wang et al., 1998). There is some evidence for extra-pulmonary production of IL-5 by 
T cells in bone marrow following sensitisation and aeroallergen challenge in mice 
(Minshall et al., 1998), indicating that Th2 cells secreting IL-5 within the lung and 
during migration through the blood and bone marrow may contribute to peripheral 
blood eosinophilia.  
 
1.1.2 IL-4 and IL-13 regulate tissue eosinophilia of the lung. 
IL-4 and IL-13 are two cytokines released from Th2 cells that have been implicated in 
allergic airways disease. Although sensitised and airways challenged IL-4 deficient 
mice exhibit substantially reduced eosinophils in BALF and attenuated AHR in 
response to serotonin challenge (Brusselle et al., 1995), IL-4 is not essential for the 
development of IL-5 producing CD4+ T cells, and attenuated eosinophil recruitment to 
the lung does not translate to reduced AHR in response to methacholine challenge 
(Hogan et al., 1997b).  
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At the receptor level, Th2 driven tissue-eosinophilia and AHR in response to IL-4 
receptor (IL-4Rα) signaling is mediated by signal transducers and activators of 
transcription (STAT)-6 (Akimoto et al., 1998). IL-13 also signals via IL-4Rα (Zurawski 
et al., 1995), and provides an IL-4 independent pathway for STAT-6 regulation of Th2-
regulated eosinophilia (Yang et al., 2001), although the IL-13 specific receptor complex 
can also signal via STAT-6 independently of IL-4Rα, under some conditions (Mattes et 
al., 2001). 
 
In OVA sensitised and challenged mice, the removal of IL-4 or IL-13 does not totally 
abolish tissue eosinophilia, while the depletion of IL-4 in IL-13 deficient mice (but not 
wild type mice) significantly inhibits residual eosinophil recruitment to the lung (Webb 
et al., 2000). IL-4 upregulates adhesion molecule expression on the vascular 
endothelium (Patel, 1998), and both IL-4 and IL-13 can induce eotaxin expression from 
airway epithelial cells (Li et al., 1999; Matsukura et al., 1999), both of which may 
influence eosinophil recruitment to lung tissue. The depletion of IL-4 in OVA sensitised 
and challenged IL-13 deficient mice significantly decreases both IL-5 and eotaxin 
production in the lung, whilst an elevated peripheral blood eosinophilia is observed 
(Webb et al., 2000). It is tempting to speculate that in these experiments, IL-5 
producing T cells were released from the afferent lymphatics following repeated 
airways challenge with OVA, and their migration through the blood and bone marrow 
then promoted eosinophil maturation and differentiation. This idea is supported by 
observations of extra-pulmonary production of IL-5 by T cells in the bone marrow 
(Minshall et al., 1998). Thus, newly differentiated eosinophils accumulate in the blood 
of mice depleted of IL-4 and IL-13, due to systemic IL-5 production and absence of 
lung derived eotaxin and cell adhesion molecules. In wild type mice, integrated 
signaling between IL-4 and IL-13 promotes lung IL-5 and eotaxin production, and may 
also promote adhesion molecule expression on the vascular endothelium, all of which 
act in concert to promote eosinophil infiltration of allergic tissue. 
  
In summary, peripheral blood eosinophilia seen in allergic disease is regulated by 
systemic IL-5, and enables integrated signaling processes between IL-4 and IL-13 
originating within allergic tissues to promote eosinophil accumulation, which correlates 
with disease severity and tissue damage (Arm and Lee, 1992; Bochner et al., 1994; 
Hogan et al., 1997a). 
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1.2 THE ROLE OF THE EOSINOPHIL IN DEFENSE AGAINST 
PARASITES. 
Elevated levels of serum IgE and eosinophils and intestinal mastocytosis are 
characteristic of most parasite infections (Butterworth, 1977; Befus et al., 1979; Jarrett 
and Miller, 1982) and eosinophilia and IgE are hallmark features of Schistosome 
mansoni infection (Capron, 1992). Of the helminths, the parasitic trematode 
Schistosome mansoni is well studied, and responsible for schistosomiasis, a major 
tropical disease, wherein eggs and egg products become trapped in host tissue (Warren 
et al., 1967). The two major components of the pathological response to S. mansoni 
infection are the formation of hepatic granulomas and hepatic portal fibroses, and 
eosinophils are a predominant cell represented in the granuloma (Moore et al., 1977; 
Phillips and Lammie, 1986).  
 
Early studies on the host response to parasite infection revealed that in vitro damage to 
the larval stage of S. mansoni (schistosomula) was an antibody dependent mechanism 
(Butterworth et al., 1974), and effector function was later attributed to purified 
eosinophils (Butterworth et al., 1977), whose granule derived major basic protein could 
kill schistosomula in vitro (Butterworth et al., 1979). Following the identification of IgE 
receptors on human eosinophils (Capron et al., 1981), eosinophils from 
hypereosinophilic patients were demonstrated to effect the in vitro killing of 
schistosomula in the presence of IgE purified from S. mansoni infected sera (Capron et 
al., 1984). Pre-incubation of eosinophils with IgE immune complexes (but not IgG 
complexes), or antibody to FcεR (subtype not defined), inhibited eosinophil killing, and 
demonstrated the specificity for IgE mediated effector function. More recently, the use 
of antibodies to block FcεRI (α chain) inhibited cytotoxicity to schistosome targets 
(Gounni et al., 1994), and implicates the high affinity IgE receptor in eosinophil toxicity 
to schistosomula. The mouse eosinophil has since been shown to lack Fcε receptors, and 
it is thought that Fcγ receptors may compensate (de Andres et al., 1997). 
 
The elevated peripheral blood eosinophilia seen in helminth infection suggests the 
involvement of IL-5 in the protective response. An early study revealed that the effector 
function of eosinophils obtained from patients with eosinophilia (due to schistosomiasis 
or other infection with other helminths) correlated directly with the patient’s peripheral 
blood eosinophil levels (David et al., 1980). This suggested that enhanced activation in 
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vivo by an (as then) unknown factor or factors, translated to enhanced killing activity in 
vitro. In 1989, IL-5 was shown to be necessary for the induction of both blood and 
tissue eosinophilia in a mouse model of Nippostrongylus brasiliensis infection 
(Coffman et al., 1989), and in 1990, the regulation of parasite induced eosinophilia in 
helminth infected patients was attributed to selectively increased IL-5 production by 
circulating CD4+ T lymphocytes (Limaye et al., 1990). Therefore, IL-5 was proposed to 
regulate the peripheral blood and tissue eosinophilia seen during helminth infections.  
 
1.2.1 Animal models of parasite infection. 
Mouse and other rodent parasite models have provided valuable information on the cell 
types that are involved in protective immunity to parasites, although there are certain 
anomalies which may be related to using these non-natural hosts. 
 
Early studies in mice implicated eosinophils in the in vivo killing and clearance of S. 
mansoni. In egg-sensitized mice, the administration of anti-eosinophil serum suppressed 
peripheral blood eosinophils, and ablated eosinophils from granulomatous tissue lesions 
(Mahmoud et al., 1975a). In comparison to controls, mice infected with 10 cercariae of 
S. mansoni 16 and 32 weeks before challenge with 500 cercariae showed significant 
reductions in the recovery of schistosomula (40%) and adult worms (60%), indicating 
an acquired immune response to this parasite. In these immune mice, the administration 
of anti-eosinophil serum (but not anti-neutrophil or anti-leukocyte serum) increased the 
worm burden to levels previously seen in non-immune control mice, and suggesting a 
role for eosinophils in parasite clearance (Mahmoud et al., 1975b). Notably, the transfer 
of immune sera could confer protection to S. mansoni in uninfected mice (Sher et al., 
1975), and was inhibited by the administration of anti-eosinophil serum (Mahmoud et 
al., 1975b). Therefore, immune mouse sera contained transferable humoral components 
that relied on endogenous eosinophils, in order to confer protection to non-immune 
mice.  
 
More recently, it has been recognised that the importance for IL-5 and eosinophils in 
protective immunity to helminth infections varies according to choice of parasite or the 
host species. For example, IL-5 and eosinophils are not obligatory in the immune 
resistance to Mesocestoides corti (Kopf et al., 1996), Trichinella spiralis (Herndon and 
Kayes, 1992), nor S. mansoni (Sher et al., 1990; Brunet et al., 1999), however the 
elevated eosinophilia seen in IL-5 transgenic mice is detrimental to S. mansoni 
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clearance following immunisation (Dent et al., 1997). Conversely, IL-5 and eosinophils 
are required for protective immunity against Strongyloides ratti (Ovington et al., 1998), 
Strongyloides stercoralis (Rotman et al., 1996), and Onchocerca volvulus (Lange et al., 
1994), and resistant BALB/c mice display greater IL-5 gene expression and peripheral 
blood eosinophilia than susceptible C57BL/6 mice, during Nippostrongylus brasiliensis 
infection (Zhou et al., 1996).  
 
Most interesting is the altered dependency for IL-5 in primary and secondary immune 
responses. C57BL/6 mice are naturally resistant to the filarial parasite Litomosoides 
sigmodontis, which is a natural parasite of rats. Both wild type and IL-5 deficient mice 
display similar innate immunity to this parasite, as assessed by parasite attrition at 40 
days post infection. Immunisation with irradiated larvae confers protective immunity in 
wild type mice, and no parasites may be recovered following challenge. However, in 
IL-5 deficient animals, there is no protective immunity afforded by immunisation and 
these animals display a parasite recovery rate that is no different to non-immunised 
controls (Le Goff et al., 2000). Alternatively, Strongyloides ratti infection leads to 
lower body weights and larger worm burdens in IL-5 deficient mice when compared to 
wild types controls, yet IL-5 deficient mice display resistance to challenge infections 3 
weeks after the primary infection has been expelled (Ovington et al., 1998).  
 
1.2.1.1 Regulatory roles for eosinophils in primary responses to 
parasites. 
In murine schistosomiasis, granuloma formation is dependent on schistosome egg 
antigen specific CD4+ T cells (Mathew and Boros, 1986; Iacomini et al., 1995), and 
there is evidence for a requisite Th1 to Th2 shift in the developing granuloma, which is 
concomitant with egg deposition (Pearce et al., 1991; Pearce and Reiner, 1995). In the S 
mansoni infected mouse, splenocytes are seen to be dividing, and contain intracellular 
IL-2, whereas granuloma lymphocytes display an activated phenotype, and contain low 
yet detectable amounts of intracellular IL-4, and are prone to apoptosis (Rumbley et al., 
1998).  
 
Careful analysis of splenic eosinophils reveals a heterogeneous population of activated 
and hypodense cells, with no detectable intracellular IL-4. In contrast, granuloma 
eosinophils are characteristically activated, have significant amounts of intracellular IL-
4, and may be an important source of this cytokine during the development of Th2 
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responses to egg antigen (Rumbley et al., 1999). Schistosome eggs are strong inducers 
of a Th2 response (Sabin and Pearce, 1995), and the injection of eggs into the mouse 
peritoneum induces rapid IL-4 production by peritoneal eosinophils, which are recruited 
in response to IL-5 produced by mast cells (Sabin et al., 1996). IL-5 deficient mice are 
unable to mount a peripheral blood or tissue eosinophilia, yet produce basal numbers of 
eosinophils with normal morphology (Kopf et al., 1996). While Th2 development 
following immunisation with schistosome egg antigen is unaffected in IL-5 deficient 
mice, there is still evidence for a small population of IL-4 producing eosinophils that 
may participate in establishing Th2 mediated immunity (Brunet et al., 1999). Similarly, 
migration through the lung by the larval stage of Nippostrongylus brasiliensis induces a 
powerful Th2 response, and eosinophils were recently shown to be a significant source 
of early IL-4 during this period (Shinkai et al., 2002). Therefore, the eosinophil may be 
an important source of IL-4 during the induction of Th2 responses to parasites.  
 
Strongyloides stercoralis is a parasitic nematode of humans whose complete life cycle 
is not supported in the mouse (Grove et al., 1986). The innate response to primary 
infection leads to larval killing, which correlates with increased serum levels of IL-5, 
recruitment of eosinophils, and eosinophil peroxidase release adjacent to the parasite. 
Recently, the presence of eosinophils during immunisation to S. stercoralis was shown 
to be necessary for S. stercoralis-specific IgM antibody production, which is a 
component of the protective immune response to this parasite (Herbert et al., 2000). In 
this study, Herbert et al speculated that eosinophils may be an important source of IL-5 
during development of protective immunity, necessary for B cell activation and IgM 
production.  
 
In summary, the eosinophil may play functionally diverse roles in parasite elimination. 
In one instance, the eosinophil may be required during primary responses to parasites, 
whilst having no obligatory role during protective immunity (and vice versa). 
Alternatively, the eosinophil has the capacity to modulate adaptive responses to parasite 
infection, through the synthesis of cytokines including IL-4 and IL-5, and may be 
necessary for certain aspects of protective immunity. 
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1.3  IMMUNOMODULATORY ROLES FOR EOSINOPHILS. 
Eosinophils that line the gastrointestinal and urogenital tracts at baseline may play a 
role in immune surveillance (Matthews et al., 1998; Mishra et al., 1999). When 
recruited to sites of parasite infection or to inflamed allergic tissues, eosinophils may 
collectively act as large reservoirs for various T cell growth factors, costimulatory 
cytokines and inflammatory mediators (see Table 1). Whilst T and B cells have the 
capacity to rapidly synthesise and secrete many of these mediators, eosinophils are 
biologically different, in that they have the ability to synthesise and store these 
preformed mediators – often in close association with the crystalline granule proteins 
(Dubucquoi et al., 1994; Moqbel et al., 1995; Bosse et al., 1996). Within tissue, the 
release of stored mediators such as IL-3 (Moqbel et al., 1995), IL-5 (Dubucquoi et al., 
1994) and GM-CSF (Nakajima et al., 1996) may act in an autocrine fashion to promote 
eosinophil survival, whilst others including co-stimulatory IL-1, IL-6, and either IL-2 or 
IL-4 may enable the eosinophil to participate in immune regulation of T lymphocyte 
function during primary and secondary responses to antigen.  
 
1.3.1 TH1 CYTOKINE PRODUCTION BY EOSINOPHILS 
 
1.3.1.1  IL-2. 
IL-2 is essential for T cell growth and proliferation in vitro (Watson, 1979), and is also 
chemotactic for eosinophils that express the IL-2 receptor (Rand et al., 1991b). IL-2 
expression in human peripheral blood eosinophils may be upregulated in response to 
GM-CSF (Bosse et al., 1996), and IL-2 associated with the eosinophil crystalloid 
granule proteins may be released following incubation with immune complexes (Levi-
Schaffer et al., 1996). Of particular interest is the unexpected finding that eosinophils 
express surface CD28 (Woerly et al., 1999), which is normally expressed by T cells and 
is important in T cell activation (Gimmi et al., 1991; Gause et al., 1997). CD28 ligation 
induced by antibodies to CD28 promotes the release of biologically active IL-2 from 
peripheral blood eosinophils (Woerly et al., 1999). Activated T cells in human 
peripheral blood have been observed to express B7 (CD80) (Azuma et al., 1993),  
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TABLE 1 
Eosinophil Derived Cytokines and Chemokines 
 
Mediator 
Eosinophil 
Origin/Tissue 
Molecule 
Detected 
 
Release Factor/s 
 
Protein Location 
 
References 
CYTOKINES      
Interleukin-1α Human/Blood mRNA 
protein 
PMA 
 
- 
 
(Weller et al., 1993) 
 Mouse/Peritoneal cavity mRNA 
protein # 
LPS 
calcium ionophore 
 
 
(Del Pozo et al., 1990) 
Interleukin-2 Human/Blood 
 
mRNA 
protein 
GM-CSF &/or  
calcium ionophore  
serum coated beads 
CD28 ligation (IL-10 inhibits) 
crystalline granule core 
 
(Bosse et al., 1996) 
(Levi-Schaffer et al., 1996) 
(Lacy et al., 1998) 
(Woerly et al., 1999) 
 Mouse/Granuloma mRNA 
protein 
 
 
 
 
(Rumbley et al., 1999) 
Interleukin-3 Human/Blood mRNA 
protein 
immune complexes or TNF-α 
calcium ionophore 
 
 
(Nakajima et al., 1996)  
(Kita et al., 1991) 
 Human/Gut protein  granule matrix (Desreumaux et al., 1996) 
Interleukin-4 Human/CD34 Progenitor mRNA 
protein 
 diffuse (Velazquez et al., 2000) 
 Human/Blood mRNA 
 
protein 
immune complexes 
TNF-α  
serum coated particles 
calcium ionophore 
eotaxin, RANTES 
IL-16 (via eotaxin & RANTES) 
 
 
crystalline granule core 
crystalline granule core 
(Nonaka et al., 1995) 
(Nakajima et al., 1996) 
(Moqbel et al., 1995) 
(Bjerke et al., 1996) 
(Bandeira-Melo et al., 2001) 
(Bandeira-Melo et al., 2002) 
 Human/Lung mRNA 
protein 
 
 
crystalline granule core (Moller et al., 1996b) 
(Ying et al., 1997a) 
(Nonaka et al., 1995) 
 Mouse/Granuloma 
Mouse/Peritoneal cavity 
Mouse Lung 
mRNA 
protein 
protein 
 
Schistosome eggs 
 
 
(Rumbley et al., 1999) 
(Sabin et al., 1996) 
(Shinkai et al., 2002) 
      
 Eosinophil Molecule    
 Chapter 1 General Introduction 12 
Mediator Origin/Tissue Detected Release Factor/s Protein Location References 
Interleukin-5 Human/BALF mRNA   (Broide et al., 1992) 
 
 Human/Blood mRNA 
protein 
GM-SCF, IL-5, immune complexes granule matrix (Dubucquoi et al., 1994) 
(Desreumaux et al., 1993) 
(Lacy et al., 1998) 
 Human/Various tissues mRNA 
 
protein 
  
 
crystalline granule core 
 
granule matrix 
(Desreumaux et al., 1992) 
(Desreumaux et al., 1993) 
(Moller et al., 1996a) 
(Ying et al., 1997a) 
(Desreumaux et al., 1996) 
 Mouse/Granuloma mRNA   (Rumbley et al., 1999) 
Interleukin-6 Human/Blood mRNA 
protein 
 
IFN-γ 
 
 
crystalline granule core 
(Melani et al., 1993) 
(Hamid et al., 1992) 
(Lacy et al., 1998) 
Interleukin-10 Human/Blood mRNA 
protein 
 
sIgA immune complexes 
FcεRI engagement 
- (Nakajima et al., 1996) 
(Woerly et al., 1999) 
(Kayaba et al., 2001) 
Interleukin-12 Human/Blood mRNA 
protein 
IL-4 or GM-CSF >> IL-5 or IFN-γ - (Grewe et al., 1998) 
Interleukin-13 Human/Blood mRNA 
protein 
eotaxin >>IL-5 or GM-CSF 
CD28 ligation 
 
crystalline granule core 
(Schmid-Grendelmeier et al., 2002) 
(Woerly et al., 2002) 
 Human/Nasal polyp protein   (Schmid-Grendelmeier et al., 2002) 
GM-CSF Human/Blood mRNA 
 
protein 
calcium ionophore/PMA 
immune complexes  
LPS (IL-10 inhibits) 
 
c5a, FMLP, calcium ionophore 
CD40 ligation 
TNF-α and fibronectin 
 
 
 
crystalline granule core 
(Kita et al., 1991) 
(Nakajima et al., 1996) 
(Takanaski et al., 1994) 
(Levi-Schaffer et al., 1995) 
(Miyamasu et al., 1995) 
(Ohkawara et al., 1996) 
(Esnault and Malter, 2001) 
 Human/BALF mRNA 
protein 
  (Broide et al., 1992) 
(Esnault and Malter, 2001) 
 Human/Gut protein  granule matrix (Desreumaux et al., 1996) 
 
Mediator 
Eosinophil 
Origin/Tissue 
Molecule 
Detected 
 
Release Factor/s 
 
Protein Location 
 
References 
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Interferon-γ Human/Blood mRNA 
protein 
 
CD 28 ligation (IL-10 inhibits) 
- (Lamkhioued et al., 1996) 
(Woerly et al., 1999) 
 Mouse/Granuloma mRNA   (Rumbley et al., 1999) 
CHEMOKINES      
Interleukin-8 Human/Blood mRNA 
protein 
calcium ionophore 
LPS (IL-10 inhibits) 
c5a, FMLP (G protein dependent) 
GM-CSF/RANTES, PAF or PMA 
immune complexes 
IL-5/immune complexes 
- (Braun et al., 1993) 
(Takanaski et al., 1994) 
 
(Miyamasu et al., 1995) 
(Yousefi et al., 1995) 
(Nakajima et al., 1996) 
(Nakajima et al., 1997) 
Interleukin-16 
(LCF) 
Human/Blood mRNA 
protein 
 
GM-CSF 
 
cytoplasmic granules 
(Lim et al., 1995) 
(Lim et al., 1996) 
Eotaxin Human/Blood mRNA 
protein 
IL-3 
C5a, calcium ionophore 
IL-5, TNF-α 
IL-16 
 
granule associated 
(Garcia-Zepeda et al., 1996) 
(Nakajima et al., 1998) 
(Han et al., 1999) 
(Bandeira-Melo et al., 2002) 
RANTES Human/CD34+  mRNA 
protein 
 diffuse (Velazquez et al., 2000) 
 Human/Blood mRNA  
GM-CSF 
IFN-γ/serum coated particles 
 
IFN-γ  
 
 
 
 
extra granule associated  
(Lim et al., 1995) 
(Lim et al., 1996) 
(Ying et al., 1996) 
(Chihara et al., 1997) 
(Lacy et al., 1999) 
Adapted from Lacey et al., 1997 (Lacy and Moqbel, 1997).  
Abbreviations; FMLP, N-formyl-methionyl-leucyl-phenylalanine; LCF, leukocyte chemotactic factor; LPS, lipopolysaccharide; PAF, platelet activating factor; PMA, 
Phorbol myristate acetate.  
# An IL-1α “like-protein” was secreted."-" Not indicated.  
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and it is possible that any interaction with CD28 expressing eosinophils may elaborate 
eosinophil derived IL-2, and thus potentiate T cell activation and/or proliferation. 
 
1.3.1.2  IL-12 and IFN-γ. 
IL-12 is considered to be a macrophage derived cytokine that drives the differentiation 
of IFN-γ producing Th1 cells (Brunda, 1994), that selectively express the IL-12 receptor 
β2 chain (Rogge et al., 1997; Rogge et al., 1999), and in the absence of accessory cells, 
IL-12 can promote the differentiation of naïve CD4+ T lymphocytes into IFN-γ 
producing Th1-type cells (Schmitt et al., 1994). The mucosal delivery of IL-12 can 
abrogate airways eosinophilia hyperreactivity in a mouse model of allergic airways 
disease (Sur et al., 2000a), and may be mediated by the endogenous production of IFN-
γ (Hogan et al., 1998b). Therefore, IL-12 has the potential to abrogate allergic airways 
disease when delivered to the mucosal surface. 
 
Human peripheral blood eosinophils obtained from both atopic and non-atopic donors 
synthesise and secrete biologically active IL-12 in response to incubation with IL-4, IL-
5 or GM-CSF, which may enable eosinophils to promote a switch from Th2-like to Th1-
like immune responses in both atopic and parasitic diseases (Grewe et al., 1998). 
Human peripheral blood eosinophils may fall into two distinct groups that produce 
either Th1 (IFN-γ), or Th2 (IL-4, IL-5, IL-10) cytokines (Lamkhioued et al., 1996). 
Ligation of CD28 on a homogenous mixture of peripheral blood eosinophils promotes 
IL-2 and IFN-γ release, while secretory IgA complexes induce IL-10 production 
(Woerly et al., 1999). In the presence of both stimuli (anti-CD28 and secretory IgA-
anti-IgA), IL-2, IL-10 and IFN-γ production are all attenuated, suggesting that IL-10 
may inhibit IL-2 and IFN-γ release from eosinophils and vice versa. Clearly, there are 
multiple pathways that may operate during eosinophil synthesis and secretion of Th1 
cytokines, and eosinophils may also be categorised into Th1- and Th2-like 
subpopulations, that may potentially regulate cytokines released by each other. 
 
1.3.2. TH2 CYTOKINE PRODUCTION BY EOSINOPHILS 
 
1.3.2.1  IL-4, IL-13 and IL-10.  
IL-4 is an immunoregulatory cytokine of particular importance for T cell activation and 
differentiation into the Th2 phenotype (Snapper and Paul, 1987; Swain et al., 1990), 
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and for B cell isotype switching in favour of IgE production (Finkelman et al., 1988b; 
Finkelman et al., 1990). It may enhance eosinophil accumulation in inflamed tissues by 
selectively upregulating VCAM-1 expression on the vascular endothelium (Patel, 1998; 
Sanz et al., 1998a), and through the induction of eotaxin expression (Mochizuki et al., 
1998). Human eosinophils also express a functional IL-4 receptor, and priming by IL-4 
may enhance eosinophil chemotactic responses to RANTES (Dubois et al., 1998). 
  
In human peripheral blood eosinophils, IL-4 is associated with the crystalline granule 
core, and may be secreted in response to calcium ionophore, immune complexes 
(Moqbel et al., 1995; Bjerke et al., 1996), RANTES, eotaxin (Bandeira-Melo et al., 
2001), and IL-16 (Bandeira-Melo et al., 2002). In the bronchial mucosa of allergic 
asthmatics, a population of activated eosinophils display immunoreactivity for IL-4 
protein (Moller et al., 1996b), while eosinophils in nasal polyp tissue show even greater 
immunoreactivity (by comparison) (Nonaka et al., 1995). Interestingly, 
immunoreactivity for IL-4 may be localised to eosinophils from either atopic, or 
nonatopic asthmatics, but not to T cells, which contain greater amounts of IL-4 mRNA 
(Ying et al., 1997a). This may be due to the ability of eosinophils to store pre-formed 
IL-4 within their secondary granule structures, and eosinophils are unique in that IL-4 
starts to accumulate during early maturation and differentiation from CD34+ progenitor 
cells (Velazquez et al., 2000). 
 
IL-13 shares some common biological functions with IL-4, and IL-13 deficient mice 
show impaired development of Th2 cells (McKenzie et al., 1998). In a similar fashion 
to IL-4, IL-13 can enhance endothelial expression of VCAM-1 (Bochner et al., 1995), 
and P-selectin (Woltmann et al., 2000), which promote eosinophil adhesion via VLA-4 
and P-selectin glycoprotein ligand-1 respectively. IL-13 can also induce eotaxin 
production in nasal tissue fibroblasts (Terada et al., 2000), and airways epithelial cells 
(Li et al., 1999), although both IL-5 and eotaxin are required for IL-13 induced 
recruitment of eosinophils to lung tissue (Pope et al., 2001).  
 
IL-13 mRNA cannot be detected in human peripheral blood eosinophils from either 
atopic or non-atopic individuals, but can be induced following in vitro stimulation with 
IL-5 or GM-CSF (Schmid-Grendelmeier et al., 2002). Interestingly, peripheral blood 
eosinophils from atopic individuals already contain detectable IL-13 protein, which may 
be a direct result of differential levels of circulating IL-5 and other cytokines during 
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their differentiation and maturation. Incubation with IL-5 or GM-CSF can induce IL-13 
synthesis by peripheral blood eosinophils, and either eotaxin (Schmid-Grendelmeier et 
al., 2002) or CD28 ligation (Woerly et al., 2002) can effect IL-13 release.  
 
IL-10 was originally characterised as a factor generated by mouse Th2 cells, which 
inhibited the cytokine synthesis from Th1 cells (Fiorentino et al., 1989). However, IL-
10 has since been shown to down-regulate both Th1 and Th2 inflammatory responses 
(Pretolani and Goldman, 1997; Muraille and Leo, 1998). IL-10 is constitutively 
expressed in eosinophils (Nakajima et al., 1996), and secretory IgA complexes can 
induce IL-10 release from peripheral blood eosinophils obtained from allergic (Woerly 
et al., 1999), but not normal (Nakajima et al., 1996) subjects in vitro. Recently, human 
peripheral blood eosinophils were shown to express FcεRI (the high affinity receptor for 
IgE), and cross-linking this receptor using antibodies was shown to induce IL-10 release 
(Kayaba et al., 2001). It should be emphasised that eosinophils that coexpress IL-4 and 
IL-5 also coexpress IL-10, but not IFN-γ, identifying two distinct populations of 
eosinophils which express either Th1 or Th2 cytokines (Lamkhioued et al., 1996).  
 
1.3.2.2  IL-3, IL-5, and GM-CSF. 
IL-3, IL-5 and GM-CSF are eosinopoietic cytokines implicated in the inflammation of 
the airways specifically as seen in asthma, which has been reviewed elsewhere (Arm 
and Lee, 1992). Each molecule signals through a receptor comprising a ligand-specific 
α-chain, and a common shared subunit (βc), and each may prolong eosinophil survival 
in vivo (Corrigan et al., 1995; Till et al., 1995).  
 
In the human gut, IL-3 is associated with the eosinophil-crystalline granule core 
(Desreumaux et al., 1996), and human peripheral blood eosinophils incubated with 
calcium ionophore release both IL-3 and GM-CSF, which act in an autocrine fashion to 
promote eosinophil survival in vitro (Kita et al., 1991). IL-5 is a key cytokine involved 
in eosinophil regulation (Kopf et al., 1996), and it is interesting that this cytokine may 
be localised to crystalloid granules in eosinophils obtained from blood and gut tissue 
(Dubucquoi et al., 1994), and from the bronchial mucosa (Moller et al., 1996a). GM-
CSF is the main cytokine that enhances eosinophil survival in the airways of 
symptomatic asthmatics (Park et al., 1998), and like IL-3 and IL-5, has also been 
localised to the crystalline granules in blood (Levi-Schaffer et al., 1995) and tissue 
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(Desreumaux et al., 1996) eosinophils. Interestingly, GM-CSF may be released from 
peripheral blood eosinophils in response to CD40 ligation (Ohkawara et al., 1996), and 
suggests a role for CD40 ligand expressed by T cells in eosinophil survival in vivo. 
 
1.3.3 CHEMOKINE PRODUCTION BY EOSINOPHILS. 
 
1.3.3.1  RANTES.  
RANTES (Regulated on Activation, Normal T-cell Expressed and Secreted) is a CC 
chemokine that is a potent chemoattractant for CD4+/CD45RO+ memory T cells (Schall 
et al., 1990). RANTES is also chemotactic for eosinophils in vitro (Rot et al., 1992; 
Alam et al., 1993), and the cutaneous injection of RANTES induces eosinophil 
recruitment in human subjects, which is more rapid in allergic individuals (Beck et al., 
1997). Eosinophils obtained from the peripheral blood of normal subjects constitutively 
express mRNA and RANTES protein (Lim et al., 1996), and in peripheral blood 
eosinophils from atopics, constitutive RANTES expression may be upregulated by IFN-
γ (Ying et al., 1996).  
 
Recently, RANTES protein was localised to the granule matrix, and also to an extra-
granular compartment in human peripheral blood eosinophils. Transitory incubation 
with IFN-γ (10 minutes) induced rapid release of extra-granular RANTES, while 
prolonged incubation (60 minutes) reduced RANTES immunoreactivity associated with 
the granules (Lacy et al., 1999). Eosinophils express functional IFN-γ receptors 
(Ishihara et al., 1997), and IFN-γ can also modulate eosinophil expression of FcγRIII 
(low affinity IgG receptor) (Hartnell et al., 1992) and IL-6 (Hamid et al., 1992). 
Although commonly regarded as a Th1 type cytokine, increased IFN-γ may be found in 
serum of acute asthma sufferers (Saito et al., 1988; Corrigan and Kay, 1990; ten Hacken 
et al., 1998), and an expanded population of IFN-γ secreting CD8+ T cells are also 
found in lung tissue of patients dying of asthma (O'Sullivan et al., 2001). Therefore, 
eosinophils in acute asthma patients may be exposed to IFN-γ in either the blood, or the 
lung, which may modulate eosinophil activation and function via release of chemotactic 
RANTES, IL-6, and Fc receptor expression.  
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1.3.3.2  IL-16. 
IL-16 is increased in the bronchial mucosa of subjects with asthma (Laberge et al., 
1997), and in BALF following segmental allergen challenge (Krug et al., 2000). IL-16 
is a chemotactic factor for CD4+ T cells (Cruikshank et al., 2000) and human (but not 
mouse) CD4+ eosinophils cells (Rand et al., 1991a). IL-16 is constitutively expressed in 
peripheral blood eosinophils from healthy donors, and lysis of these cells releases 
detectable IL-16 protein (Lim et al., 1995). When cultured in vitro with GM-CSF, 
peripheral blood eosinophils from healthy donors may be induced to secrete IL-16 (Lim 
et al., 1996), which may act in an autocrine manner to promote RANTES, eotaxin, and 
eventual IL-4 release (Bandeira-Melo et al., 2002).  
 
1.3.3.3  IL-8.  
IL-8 is a member of the C-X-C family of proinflammatory cytokines, initially identified 
as a chemoattractant for neutrophils (Schroder et al., 1987; Gusella et al., 1993), but 
which also has chemotactic activity for T cells (Larsen et al., 1989; Gesser et al., 1996) 
and eosinophils (Sehmi et al., 1993; Schweizer et al., 1994). However, the evidence for 
IL-8 induced chemotaxis in human peripheral blood eosinophils has recently been 
contested, and a lack of IL-8 receptors CXCR1 and CXCR2 on peripheral eosinophils 
suggests that IL-8 may not contribute in vivo to the influx of eosinophil granulocytes 
into sites of allergic inflammation (Petering et al., 1999).  
 
Peripheral blood eosinophils may be induced to release IL-8 in response to various 
stimuli, including LPS (Takanaski et al., 1994) and immune complexes (Nakajima et 
al., 1996). Peripheral blood eosinophils from atopic dermatitis and bronchial asthma 
sufferers express IL-8 mRNA and protein, which is released following priming with 
GM-CSF, and incubation with either RANTES, PAF or PMA (Yousefi et al., 1995). In 
this study, IL-8 levels in BALF from asthma sufferers were also found to correlate with 
eosinophil numbers, suggesting that eosinophils may be a source of this cytokine in the 
asthmatic lung (Yousefi et al., 1995), and may contribute to neutrophil and T cell 
recruitment to the airways.  
 
1.3.3.4  Eotaxin. 
Eotaxin is a CC chemokine that activates guinea-pig eosinophils in vitro, and is a 
selective eosinophil chemoattractant in vivo (Griffiths-Johnson et al., 1993). The 
purification and partial sequencing of eotaxin from BALF of allergic guinea pigs (Jose 
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et al., 1994b), has led to the subsequent cloning of guinea pig (Jose et al., 1994a), 
murine (Rothenberg et al., 1995a), and human eotaxin (Garcia-Zepeda et al., 1996). 
Eotaxin-2 has also been identified, and is a distantly related protein sharing 39% 
homology to eotaxin (Forssmann et al., 1997). Eotaxin signals via CC chemokine 
receptor 3 (CCR3) (Combadiere et al., 1995; Kitaura et al., 1996), and acts in concert 
with IL-5 to promote tissue eosinophilia (Collins et al., 1995; Mould et al., 1997). 
Functional CCR3 is also expressed on a subset of T cells having the Th2 phenotype, and 
enables T cells to migrate in response to eotaxin (Gerber et al., 1997; Sallusto et al., 
1998).  
 
In human peripheral blood eosinophils, eotaxin expression may be induced in response 
to IL-3 (Garcia-Zepeda et al., 1996), and eotaxin protein may be synthesized and stored 
in association with granule proteins (Nakajima et al., 1998). Complement (C5a), IL-5, 
and IL-16 can all promote the release of eotaxin from peripheral blood eosinophils in 
vitro (Nakajima et al., 1998; Han et al., 1999; Bandeira-Melo et al., 2002), and 
identifies a pathway wherein eosinophils may promote their own recruitment into sites 
of inflammation.  
 
In summary, eosinophils have the ability to synthesise and store a variety of cytokines 
and pre-formed mediators. These mediators may act in auto- and para-crine fashions to 
modulate both eosinophil and T cell trafficking into tissues, and in turn affect their 
activation status, and subsequent responses to various stimuli including antigen.  
 
1.4 ACCESSORY CELL FUNCTION OF EOSINOPHILS. 
Eosinophils frequently localise to sites of allergen deposition in allergic disorders such 
as allergic rhinitis and asthma (Gleich et al., 1993; Martin et al., 1996a), and may reside 
in the lymph nodes draining allergic and inflamed tissues (Roberts, 1966; Friend et al., 
2000; Shi et al., 2000). Their ability to express immunomodulatory cytokines, MHC-II 
proteins, and costimulatory cytokines suggests that eosinophils may also participate as 
immune regulators (Weller and Lim, 1997).  
 
1.4.1  MHC expression by eosinophils. 
For effective antigen presentation to T lymphocytes, APCs must express MHC-II 
proteins (Watts, 1997; Weenink and Gautam, 1997). Numerous studies have shown that 
surface MHC-II expression by eosinophils may be upregulated during disease, and in 
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vitro studies have identified both soluble and endothelial factors that may be responsible 
for increased MHC-II expression.  
 
1.4.1.1  Enhanced MHC-II expression in vivo. 
The recruitment of eosinophils into inflamed tissues is associated with the induction of 
MHC-II protein expression above that which is seen on peripheral blood eosinophils. 
There are limited data available for enhanced MHC-II protein expression on mouse 
eosinophils in vivo, although peritoneal cavity eosinophils from mice with acquired 
resistance to Brugia malayi (Th2 mediated) have increased MHC-II expression 
compared to non-resistant mice (Mawhorter et al., 1993), and BALF eosinophils from 
the allergic mouse lung are also MHC-II positive (Shi et al., 2000). In humans, the 
MHC is known as HLA (human leukocyte antigen), of which HLA-DP, DQ, and DR 
represent functional class II molecules. Eosinophil progenitors initially express HLA-
DR (Koeffler et al., 1980; Butterfield et al., 1982), but shed this molecule during 
differentiation and/or maturation, and normal peripheral blood eosinophils do not 
express this surface antigen (Hansel et al., 1991; Celestin et al., 2001). Segmental 
antigen challenge in allergic asthmatics reveals that eosinophils residing in the airways 
exhibit increased HLA-DR expression when compared with peripheral blood 
eosinophils (Sedgwick et al., 1992), and this trend has also been reported for non-
challenged asthma sufferers (Hansel et al., 1991; Beninati et al., 1993; Mengelers et al., 
1994). Furthermore, a direct comparison between allergic and non-allergic individuals 
has also demonstrated increased HLA-DR expression on peripheral blood eosinophils 
from asthmatics compared to non-allergic controls (Sakamoto et al., 1996). It is 
interesting to note that the glucocorticoids dexamethasone and hydrocortisone may 
synergise with IL-3, IL-5 or GM-CSF to enhance HLA-DR expression on peripheral 
blood eosinophils from normal healthy subjects (Guida et al., 1994), and the 
administration of either of these drugs to atopic individuals may be reasonably expected 
to transiently enhance HLA-DR expression on eosinophils residing in the lung.  
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1.4.1.2  Induction of MHC-II expression in vitro. 
The enhanced expression of MHC-II proteins by eosinophils in vivo has prompted many 
elegant in vitro studies to determine what soluble factors may be responsible. In the 
mouse, peritoneal eosinophils obtained from IL-5 transgenics (Tamura et al., 1996), or 
mice infected with M. corti larvae (Del Pozo et al., 1992) may be induced to express 
MHC class II following incubation with GM-CSF, which is a prominent cytokine in 
acute airways inflammation (Arm and Lee, 1992; Ohkawara et al., 1997), and GM-CSF 
induced expression may either be further enhanced by IL-4, or inhibited by IFN-
γ (Mawhorter et al., 1993).  
 
Incubation of human peripheral blood eosinophils with anti-CD3 stimulated and pooled 
T cell supernatants obtained from either healthy (Hansel et al., 1992) or allergic (Hansel 
et al., 1991) individuals can induce eosinophil HLA-DR expression. This may be due to 
a synergistic effect between IL-3 and IFN-γ to induce HLA-DR (Hansel et al., 1992), 
and synergy between GM-CSF and IFN-γ for HLA-DR expression has also been 
reported (Guida et al., 1994). When looking at the single cytokine level, IL-3 (Guida et 
al., 1994; Luttmann et al., 1998; Celestin et al., 2001), IL-5 (Guida et al., 1994), and 
GM-CSF (Beninati et al., 1993; Guida et al., 1994; Mawhorter et al., 1994; Luttmann et 
al., 1998; Celestin et al., 2001) can all induce in vitro expression of HLA-DR and HLA-
DP (Guida et al., 1994) on peripheral blood eosinophils from normal healthy donors. 
Furthermore, antibodies to either of IL-3 or GM-CSF do not inhibit IL-5 induced HLA-
DR expression on human peripheral blood eosinophils, indicating that the autocrine 
production of either of these two molecules in response to IL-5 does not necessarily 
regulate IL-5-induced HLA-DR expression (Guida et al., 1994). Interestingly, 
peripheral blood eosinophils co-incubated with fibroblasts require lower effective doses 
of either IL-3 or GM-CSF to induce HLA-DR expression (Lucey et al., 1989; Beninati 
et al., 1993; Weller et al., 1993), suggesting that fibroblasts and extracellular matrix 
may provide co-stimulatory signals for HLA-DR expression by eosinophils. It is also 
interesting to note that HLA-DR expression induced by either IL-3 or GM-CSF may be 
inhibited by TGF-β (Luttmann et al., 1998), which has been identified as a suppressor 
of immune lymphocyte growth and regulation (Kehrl et al., 1986), and indicates a 
degree of plasticity for the induction of HLA-DR expression by circulating eosinophils.  
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1.4.2 Costimulatory molecule expression. 
Costimulatory molecules provide necessary second signals for positive T cell activation, 
and a lack of costimulation during MHC-peptide/TCR interaction can lead to clonal 
anergy (Schwartz, 1990; Van Gool et al., 1999; Corrigall et al., 2000). CD80 (B7.1) and 
CD86 (B7.2) are expressed by antigen presenting cells, and provide the most potent 
costimulatory signals through interaction with CD28/CTLA-4 on the T cell surface (Wu 
et al., 1997). Following TCR engagement by MHC-II (or MHC-I), the costimulatory 
signal provided by B7 interaction with CD28 stabilises T cell IL-2 mRNA, and 
increases IL-2 secretion, which results in T cell proliferation and clonal expansion 
(Linsley et al., 1991; Freeman et al., 1993). Effective CD80 and CD86 costimulation is 
necessary for allergic airways disease induction and progression in animal models 
(Krinzman et al., 1996; Harris et al., 1997; Keane-Myers et al., 1997; Tsuyuki et al., 
1997; Harris et al., 2001), and demonstrates the importance of these co-signaling 
pathways.  
 
1.4.2.1  CD80 and CD86 expression. 
Eosinophil isolated from the peritoneal cavity of IL-5 transgenic mice constitutively 
express both CD80 and CD86, which can be further increased by in vitro incubation 
with GM-CSF (Tamura et al., 1996). Airways eosinophils from mice with AAD express 
both CD80 and CD86, and may also translocate to the draining lymph node, which is a 
recognised site of T cell activation (Shi et al., 2000). In humans, peripheral blood 
eosinophils from normal healthy donors lack constitutive expression of CD80 
(Mawhorter et al., 1994), and incubation with either GM-CSF or a synergistic mixture 
of IFN-γ and GM-CSF can induce HLA-DR, but not CD80 surface expression (Guida et 
al., 1994). IL-3 has been shown to induce CD86 but not CD80 expression on normal 
peripheral blood eosinophils (Celestin et al., 2001), while peripheral blood eosinophils 
from hypereosinophilic donors show some constitutive CD86 but not CD80 expression 
(Woerly et al., 1999). Another costimulatory molecule known as CD40 can interact 
with CD40 ligand (CD40L) on the T cell surface (Van Gool et al., 1999), and this 
molecule is expressed by peripheral blood eosinophils. When CD40 expressed by 
eosinophils is ligated using anti-CD40 antibodies, eosinophil survival is enhanced by 
the autocrine production of GM-CSF (Ohkawara et al., 1996), and suggests another 
putative costimulatory pathway for eosinophils to communicate directly with T cells. 
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1.4.2.2  Adhesion molecule expression. 
Adhesion molecules provide for stable intercellular interactions and cross-
communication. In addition to B7 molecules, intercellular adhesion molecule 1 (ICAM-
1) expressed on the surface of APCs may interact with leukocyte functional antigen 1 
(LFA-1) on T cells to reinforce T cell activation by MHC-peptide/TCR interactions. 
ICAM-1 is not normally found on peripheral blood eosinophils from normal healthy 
individuals, but may be upregulated by the mixture of soluble factors in pooled anti-
CD3 stimulated T cell supernatants, and increases eosinophil adhesion to autologous T 
cells (Hansel et al., 1992). At the single cytokine level, peripheral blood eosinophils 
from healthy (Guida et al., 1994) and atopic (Handzel et al., 1998) individuals increase 
their surface expression of ICAM-1 in response to GM-CSF incubation, while airways 
eosinophils obtained from asthmatics show greater ICAM-1 (Hansel et al., 1991; 
Mengelers et al., 1994) and LFA-3 (Mengelers et al., 1994) expression than peripheral 
blood eosinophils from the same individuals, and identifies a possible pathway for 
eosinophil-T cell adhesion and interaction via LFA-1 and CD2, respectively.  
 
1.4.2.3  Costimulatory IL-1α, and IL-6. 
IL-1α serves as a costimulatory signal for lymphocyte proliferation (Tosato et al., 1990; 
Weaver and Unanue, 1990), and IL-6 is an important helper factor in primary antigen-
dependent T cell activation and proliferation (Heinrich et al., 1990). Incubation of 
mouse peritoneal cavity eosinophils with lipopolysaccharide can induce IL-1α mRNA, 
and an IL-1α “like” protein is released following incubation with calcium ionophore 
(Del Pozo et al., 1990). In human peripheral blood eosinophils, both mRNA transcripts 
and IL-1α protein have been identified, and its expression may be upregulated by PMA 
(Weller et al., 1993). The costimulation afforded by IL-1α ad IL-6 is most effective 
when given in conjunction with other accessory molecule co-receptors (Joseph et al., 
1998), and the ability to express and secrete either IL-1α or IL-6 in conjunction with 
surface expression of MHC-II and B7 co-stimulatory molecules may enable eosinophils 
to modulate primary T cell responses to antigen. 
 
1.4.3 Intracellular antigen processing. 
The ability to take up and process antigen prior to presentation of antigenic peptides on 
MHC molecules is essential for effective antigen presentation (Watts, 1997). 
Superantigens such as Staphylococcus enterotoxins do not require any intracellular 
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processing by APCs, nor significant costimulatory molecule activity in order to 
stimulate T cells (Dellabona et al., 1990; Damle et al., 1993). While eosinophils are 
quite capable of presenting superantigens (Mawhorter et al., 1994; Tamura et al., 1996), 
little is known about the eosinophil’s ability to capture and present complex exogenous 
antigens. Incubation with the lysosomotropic agent chloroquine can inhibit eosinophil 
uptake and processing of M. corti (Del Pozo et al., 1992), and phospholipase A2 (Hansel 
et al., 1992) complex antigens, suggesting that eosinophils have the capacity to process 
intracellular antigens.  
 
In the respiratory tract, inhaled allergens are primarily particulate, and may be carried 
by small dust particles that act as adjuvants (Ormstad et al., 1998; Ormstad, 2000). 
Although particulate aeroallergens are processed by macrophages, alveolar 
macrophages are not effective APCs due to lack of co-stimulatory B7 and adhesion 
molecules (Chelen et al., 1995), and unlike B cells and dendritic cells (van Rooijen, 
1990), eosinophils readily interact with this form of antigen in the presence of 
immunoglobulin (Kassis et al., 1979; Weller, 1991).  
 
The colocalisation of allergen-specific IgE, IgG, IgA, and eosinophils (which express 
receptors for these immunoglobulins) in mucosal surfaces may facilitate enhancement 
of antibody-mediated antigen uptake and presentation (Shi et al., 2000) as is observed 
for other APCs (Gosselin et al., 1992; Maurer et al., 1995). Therefore, eosinophils may 
engage, internalise, and process particulate antigens, before presenting them in the 
context of MHC-II. 
 
1.4.4 Eosinophils functioning as antigen presenting cells. 
Our knowledge about the ability of eosinophils to present antigen is growing. It has 
been suggested that eosinophils have distinct spatial locations in tissues and functional 
characteristics that endow them with unique roles as APCs in contrast to APCs such as 
dendritic cells, macrophages, and B cells (Shi et al., 2000). These cells are well placed 
to encounter exogenous antigen within various tissues and mucosal surfaces (Rytomma, 
1960; Moller et al., 1996b; Stokes et al., 1996; Mishra et al., 1999), can express MHC 
antigens and necessary costimulatory molecules , and are able to translocate to the 
draining lymph nodes, carrying antigenic peptides (Roberts, 1966; Friend et al., 2000; 
Shi et al., 2000).  
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1.4.4.1  Presentation of simple antigens. 
Eosinophils from IL-5 transgenic mice treated with GM-CSF and incubated with 
Staphylococcal enterotoxin B superantigen can stimulate the proliferation of both lymph 
node and thymus T cell populations, in a manner that is dependent on CD80 and CD86 
signaling (Tamura et al., 1996). Similarly, GM-CSF treated HLA-DR+ eosinophils may 
present Staphylococcal enterotoxin A to resting human peripheral blood T cells, but are 
notably less efficient than macrophages (Mawhorter et al., 1994). Interestingly, 
dexamethasone synergises with GM-CSF to induce HLA-DR expression on peripheral 
blood eosinophils from healthy donors. When cultured with influenza hemaglutinin 
peptide307-319 (does not require processing), increasing numbers of HLA-matched (but 
not HLA-mismatched) dexamethasone/GM-CSF treated eosinophils promotes 
increasing amounts of T cell proliferation, demonstrating that eosinophils of the correct 
haplotype may present relevant peptide antigens to T cell clones (Guida et al., 1994). 
Although simple antigens may not require extensive intracellular processing by 
eosinophils, the requirement for functional CD86 signaling remains. Recently, purified 
peripheral blood eosinophils from normal patients were induced to express HLA-DR 
and CD86 following incubation with IL-3, and these cells were shown to present tetanus 
toxoid peptide1273-1284 to peptide-specific T cell clones in a manner that was sensitive to 
anti-CD86 antibody (Celestin et al., 2001), highlighting the importance of B7 molecules 
in eosinophil presentation of simple peptide antigens.  
 
1.4.4.2  Presentation of complex antigens by mouse eosinophils. 
In 1966, heavily tritiated porcine γ-globulin (3H-PγG) injected into the right hind 
footpad of the naïve mouse was observed to travel rapidly to the right inguinal and 
axillary lymph nodes, and eventually the draining popliteal lymph node. A careful 
comparison of autoradiographs and lymph node tissue sections revealed that 3H-PγG 
protein was predominantly localised to eosinophils residing in these tissues. These 3H-
PγG containing eosinophils were seen to cluster in the medulla and cortex regions, and 
remained in these areas for the duration of the experiment (24 hours) (Roberts, 1966). 
These results differed from earlier observations of eosinophil trafficking to lymph nodes 
following internalisation of antigen/antibody complexes (Litt, 1963, 1964a, 1964b), in 
that they demonstrated a potential role for eosinophil participation during the primary 
response to complex antigen 
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In the late 1900’s, eosinophils were identified as phagocytic cells (Lopez et al., 1981), 
having the ability to secrete costimulatory IL-1α (Del Pozo et al., 1990), and capable of 
expressing functional IL-2 receptor (Plumas et al., 1991). All of these observations 
coupled with the (then) recent finding that eosinophils could express MHC-II (Lucey et 
al., 1989) compelled Del Pozo et al to explore the capacity for mouse eosinophils to 
acts as antigen presenting cells in vitro (Del Pozo et al., 1992). They observed that GM-
CSF treated eosinophils pulsed with M. corti antigen or OVA prior to fixation in 
paraformaldehyde, were respectively, capable of stimulating the proliferation of M. 
corti or OVA-specific T cell clones. This induced proliferation was MHC-restricted, 
and required intracellularly processing of the relevant antigens prior to fixation. In 
particular, incubation with anti I-Ad antibody abrogated OVA pulsed eosinophil ability 
to induce IL-2 production when co-cultured with OVA-specific T cell hybridomas, 
demonstrating a necessity for MHC-II proteins in eosinophil presentation of complex 
antigen.  
 
Elegant in vitro experiments have indicated the requirement for CD80 and CD86 
costimulation during OVA presentation by GM-CSF treated mouse eosinophils (Tamura 
et al., 1996). In this study, MHC-II+/CD80+/CD86+ eosinophils induced proliferation of 
lymph node derived T cells from OVA sensitised C3H/He mice in the presence of 
exogenous OVA, which was inhibited by antibodies to CD80, CD86, and I-Ak (but not 
I-Ab). Thus, mouse eosinophils can present complex antigens to T cells in vitro, 
following antigen processing and presentation of peptides in the context of MHC-II. 
Furthermore, mouse eosinophils may utilise the costimulatory molecules CD80 and 
CD86, to enhance antigen-specific T cell proliferation and activation.  
 
These in vitro observations of antigen presentation by mouse eosinophils were recently 
validated by Shi et al., who have demonstrated MHC-II+/CD80+/CD86+ eosinophil 
ability to translocate to the paratracheal lymph nodes following intra-tracheal 
instillation into the allergic mouse lung (Shi et al., 2000). In this report, GM-CSF 
treated and OVA pulsed eosinophils derived from the BALF of allergic mice promoted 
OVA-specific T cell proliferation in vitro. When instilled into the mouse trachea, 
bovine serum albumin (BSA), OVA, or human gamma globulin pulsed eosinophils were 
shown to stimulate the proliferation of lymph node T cells in only those mice that were 
previously sensitised to relevant antigen, and further analysis showed that only CD4+ 
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but not CD8+ T cells were proliferating in response to the instillation of antigen pulsed 
eosinophils (Shi et al., 2000).  
 
1.4.4.3  Presentation of complex antigens by human eosinophils. 
Peripheral blood eosinophils express HLA-DR in response to GM-CSF, and can present 
tetanus toxoid antigen to autologous T cells (Weller et al., 1993). In this study, fixing 
eosinophils in paraformaldehyde following incubation with antigen was required for T 
cell proliferation, and fixing in paraformaldehyde prior to incubation with antigen 
inhibited intracellular processing of tetanus toxoid antigen (Weller et al., 1993). A 
separate study has demonstrated that live eosinophils expressing HLA-DR in response 
to pre-treatment with IL-3 and IFN-γ could present phospholipase 2 (PLA2) to PLA2 
specific autologous T cells (Hansel et al., 1992). In both of these studies, antibodies to 
HLA-DR significantly inhibited eosinophil mediated T cell proliferation, and a 
requirement for ICAM-1 during antigen presentation was also identified (Hansel et al., 
1992). When compared to macrophages, however, human eosinophils appear relatively 
inefficient at presenting complex antigen that requires intracellular processing 
(Mawhorter et al., 1994; Celestin et al., 2001), and quantitative presentation by 
eosinophils may be more significant than qualitative presentation events.  
 
1.4.4.4  Presentation of viral antigens. 
Respiratory virus infections trigger exacerbations of human asthma (Busse and Gern, 
1997), and activated virus-specific CD8+ T cells can endure in the lungs for up to 
several months following respiratory infections (Hogan et al., 2001). Human 
eosinophils can bind rhinovirus on the cell surface, and subsequently present viral 
antigens to autologous T cells that produce IFN-γ (Handzel et al., 1998). ICAM-1 
expression on airways epithelial cells can be selectively induced by IFN-γ (Look et al., 
1992), and rhinovirus induced IFN-γ resulting from eosinophil/CD8+ T cell interactions 
may therefore modulate inflammatory cell infiltration and contribute to viral 
exacerbations of asthma. Mouse eosinophils can synthesise and store pre-formed IL-4 
(Sabin et al., 1996; Shinkai et al., 2002), and are a predominant feature in the allergic 
mouse lung (Foster et al., 1996; Hamelmann et al., 1997a). Within the allergic lung, 
virus-specific CD8+ T cells can switch to IL-5 production, by a mechanism that is 
dependent on IL-4 (Coyle et al., 1995). Unlike eosinophils, T cells do not have the 
capacity to store pre-formed IL-4, and it is tempting to speculate that IL-4+ eosinophils 
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may drive the switching of CD8+ T cells to IL-5 production during the presentation of 
viral antigens.  
 
In summary, eosinophils are phagocytic cells with the capacity to process complex 
antigens, and to present antigenic peptides in the context MHC proteins to T cells. 
These cells also produce a range of immune regulatory molecules, are key features of 
allergic inflammation, and translocate to draining lymphoid tissues following antigen 
provocation. Mouse models of experimental asthma provide valuable tools to study the 
disease mechanisms that underpin this disorder. Eosinophil recruitment to the mouse 
lung correlates with the development of pathogenic features that are characteristic 
hallmarks of asthma in humans (Brusselle et al., 1995; Foster et al., 1996; De Sanctis et 
al., 1997; Tomkinson et al., 2001), and mouse models may therefore be used to further 
corroborate postulate roles for eosinophils as modulators of T cell function.  
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1.5 AIMS OF THIS STUDY. 
 
Eosinophils have a demonstrated ability to process and present complex antigens in 
vitro, which is dependent on MHC-II and costimulatory molecule expression. 
Numerous eosinophils are recruited to the allergic lung in response to antigen 
deposition, and obtain an activated phenotype. Within the lung, they may actively 
sample the antigen-rich extracellular milieu, before modulating CD4+ Th2 lymphocyte 
function through presentation of relevant antigenic peptides. These modulatory events 
may occur locally at the site of antigen deposition, or distally within draining lymphoid 
tissues. Ultimately, eosinophils recruited to sites of allergic inflammation may 
exacerbate Th2 mediated disease, by regulating memory T cell function.  
 
To date, there has been no demonstration of Th2 cytokine release resulting from 
eosinophil-T lymphocyte interactions. The general aims of this thesis were to examine 
eosinophil trafficking into the allergic lung and draining lymph nodes, and to 
investigate antigen presentation by eosinophils in vitro and in vivo. 
  
Specific aims: 
 
1. Analyse the temporal and spatial distribution of eosinophils in lung and lymphoid 
tissues during the induction, progression, and resolution of allergic airways disease. 
2. Investigate eosinophil surface molecule expression of MHC-II and costimulatory 
proteins, and determine their capacity to process complex antigen. 
3. Analyse eosinophil antigen presenting function in vitro, by measuring proliferative 
responses and any cytokine production resulting from eosinophil-T cell interactions.  
4. Determine eosinophil antigen presenting function in vivo, by transferring antigen 
pulsed eosinophils to naïve mice, and measuring the characteristic parameters of 
allergic airways disease. 
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2.1  INTRODUCTION 
 
In studies of eosinophil homing to respiratory tissue, past attention has been focused on 
the effects of inflammatory mediators that regulate eosinopoiesis, and those that 
promote selective eosinophil recruitment. It is generally accepted that IL-5 regulates the 
growth, differentiation and activation of eosinophils (Lopez et al., 1988; Yamaguchi et 
al., 1988; Ingley et al., 1991; Ingley and Young, 1991; Foster et al., 2001), and also 
regulates eosinophil infiltration, airways hyperreactivity and lung damage in mouse 
models of AAD (Foster et al., 1996; Hamelmann et al., 1997a). For instance, the 
compartmentalised expression of IL-5 within the airways epithelium of naïve (and 
unchallenged) mice leads to eosinophil and lymphocyte recruitment to the lung and 
airways lumen, with concomitant expansion of bronchus-associated lymphoid tissue, 
airway hyperresponsiveness to methacholine, and airways tissue remodeling (Lee et al., 
1997). GM-SCF is another eosinopoietic molecule (Arm and Lee, 1992), that enhances 
eosinophil survival in the asthmatic lung (Park et al., 1998). In a mouse model of 
allergic airway disease, transient expression of this molecule within the respiratory 
epithelium leads to increased eosinophil recruitment to the lung and to the airways 
lumen, and alters the resolution kinetics to such an extent that eosinophils persist in 
lung tissue for a sustained period of time following cessation of antigen challenge (Lei 
et al., 1998).  
 
Eotaxin is a potent and selective eosinophil chemoattractant that induces eosinophil 
recruitment to tissues (Rothenberg, 1998). Systemic IL-5 administration in naïve mice 
has been shown to increase peripheral blood eosinophilia, and acts in synergy with 
eotaxin to promote eosinophil accumulation into tissues of guinea pigs, and mice 
(Collins et al., 1995; Mould et al., 1997). In eotaxin deficient mice, eosinophil 
accumulation in the allergic lung is attenuated (Rothenberg et al., 1997), and 
collectively, these studies demonstrate the capacity for eosinopoietic molecules and 
selective chemoattractants to cooperatively promote tissue eosinophilia. 
  
Antigen administration to the airways of naïve mice may closely parallel the processes 
associated with initial human exposure to environmental allergens, and may provide 
further understanding of the local and systemic cellular responses generated from within 
this tissue. In mice, exclusive sensitisation via the airways with OVA induces antigen-
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specific T cell responses, IgE production and increased airways hyperreactivity upon re-
challenge (Haczku et al., 1997; Hamelmann et al., 1997a; Hamelmann et al., 1997c).  
 
Interestingly, the administration of inhibitory antibodies to IL-5 during airways 
sensitisation attenuates eosinophil recruitment to lung tissue and airways 
hyperreactivity to cholinergic stimuli, whilst ultimately leaving T- and B-cell responses 
intact (Hamelmann et al., 1997a). In another model, airways sensitisation in mice using 
aerosolized OVA required concomitant GM-CSF transgene expression in the 
respiratory epithelium (Stampfli et al., 1998). Thus, the depletion of IL-5 - which 
regulates eosinophil maturation from bone marrow, and the expression of eosinopoietic 
GM-CSF during airways sensitisation can respectively attenuate or promote 
sensitisation via the airways. Collectively, these data suggest that eosinophils recruited 
to the lung during airways sensitisation may participate in the priming for AAD. 
Eosinophils may be a potential source of early IL-4 during primary responses to antigen 
(Sabin et al., 1996), and it is interesting to observe that IL-4 deficient mice are resistant 
to sensitisation via the airways (Herrick et al., 2000). 
 
Of particular interest is the elegant work conducted by Mould et al., wherein transient 
expression of both IL-5 and eotaxin within the lung was shown to synergistically 
promote a pronounced airways eosinophilia in the absence of complex tissue signals 
associated with AAD (Mould et al., 2000). In this study, eosinophil degranulation and 
airways hyperreactivity were absent, however the delivery of OVA to the airways both 
prior to and in the context of IL-5 and eotaxin transgene expression led to degranulation 
of infiltrating eosinophils and the development of airways hyperreactivity via a 
mechanism acutely sensitive to CD4+ T cell depletion. It is tempting to speculate that in 
this study, lung-recruited eosinophils promoted allergic sensitisation via the airways in 
a manner not dissimilar to that of Stampfli et al., (Stampfli et al., 1998), and provides a 
rationale for the dependency of degranulation and airways hyperreactivity upon CD4+ T 
cells. In Mould et al., eosinophil degranulation may have been dependent on OVA-
specific serum antibodies (not measured, but noted in similar work by Stampfli et al.), 
or possibly due to bi-directional signaling between recruited eosinophils and the 
emerging population of OVA-specific CD4+ T cells. Ultimately, the expression of 
eosinophil active agents (GM-CSF, IL-5, eotaxin), in the lungs of naïve mice, can lead 
to Th2 mediated responses following airways exposure to antigen, and eosinophils may 
be implicated in this process.  
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It is further interesting to note that underlying factors exist to mask Th2-type responses 
following airways sensitisation. Earlier work in rats (McMenamin and Holt, 1993) 
shows that a strong airways sensitisation regime can lead to transient CD4+ T cell-
mediated OVA-specific IgE antibody production, which is then suppressed by the 
appearance of MHC-I-restricted OVA specific IFN-γ-producing CD8+ T cells. In this 
study, prolonged exposure to inhaled antigen led to a tolerant state, wherein rats 
normally predisposed to high IgE antibody production became unresponsive to 
subsequent immunisation with OVA in adjuvant. Therefore, a window of opportunity 
may exist within which Th2 type responses may be generated, and extended exposure of 
the airways to environmental antigen may lead to the generation of opposing regulatory 
Th1 type responses. 
 
While the kinetics of cellular – particularly eosinophil infiltration into the allergic 
mouse airways can be measured following antigen sensitisation and challenge 
(Brusselle et al., 1995; Foster et al., 1996; Schneider et al., 1997; Walker et al., 1998; 
Hertz et al., 2001) it is somewhat harder to quantify these events when antigen is 
deposited in the airways of naïve mice. To date, no experiments conducted by others 
have documented eosinophil infiltration of the antigen-challenged lung at baseline - i.e. 
in the absence of transient cytokine expression.  
 
In this Chapter, experiments have been designed to investigate eosinophil responses to 
antigen deposition within the naïve lung. Naïve wild type and eotaxin deficient mice 
having a non-allergy driven peritoneal eosinophilia and a low peripheral blood 
eosinophilia were exposed via the airways to aerosolised OVA. The surprising results 
suggest that eotaxin has an important role in recruiting eosinophils to the naïve airways 
following antigen deposition, and that these recruited eosinophils may go on to 
participate in the priming for AAD. 
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2.2  MATERIALS AND METHODS 
 
2.2.1  Animals. 
Wild type C57BL/6 and eotaxin deficient (-/-) mice (129/sv background crossed into 
C57BL/6 to N10) (Rothenberg et al., 1997) were obtained from the Specific Pathogen 
Free (SPF) unit of the Australian National University (ANU), and housed in an 
approved containment facility. All mice (male, 4-8 wk old) were treated according to 
ANU animal welfare guidelines.  
 
2.2.2  Polymyxin B Sulfate induced peritoneal eosinophilia. 
Male 4 wk old wild type and eotaxin-/- mice received twice weekly intra-peritoneal 
injections of Polymyxin B Sulfate (PMBS, Sigma, 0.2mg in 200 µl saline) to induce a 
peritoneal eosinophilia (Pincus, 1978). A pronounced infiltration of eosinophils into the 
peritoneal cavity was observed after 12 injections/6 weeks. To determine total 
eosinophils in the peritoneal exudate cell (PEC) population, mice were sacrificed by 
CO2 asphyxiation and the peritoneal cavity lavaged 3 times with 5 ml ice cold Hank’s 
Buffered Salt Solution (HBSS). After centrifugation at 500 g and 4oC for 10 minutes, 
the cell pellet was resuspended in HBSS and cell numbers were determined using a 
standard haemocytometer. PEC cells were suspended at 2 x 105/100 µl and 
cytocentrifuged at 500 g for 5 minutes before air-drying and subsequent differential 
staining with May-Grunwald-Giemsa solution. Eosinophils were identified by 
morphological criteria, with 200-250 cells counted on each slide.  
 
2.2.3 Antigen delivery to naïve PMBS-treated mice. 
Naïve PMBS-treated (at least 6 weeks of twice weekly injections) wild type and 
eotaxin-/- mice were exposed to an OVA aerosol (10 mg/ml in 0.9% saline) for 3 x 30 
minute periods (at 30 min intervals) on days 1, 3, 5 and 7. The OVA aerosol was 
generated by a RapidFlo nebuliser bowl (Allersearch, Australia) with an airflow rate 
greater than 10 Litres/minute in order to produce particles of 2 microns in diameter. 
Blood samples were drawn from the tail vein for differential cell counts on days 0, 2, 4, 
6 and 8, and stained with May-Grunwald-Giemsa solution prior to differential cell 
counting (~210 cells). Mice were sacrificed by cervical dislocation on day 8 for 
collection and analysis of peritoneal cavity and bronchoalveolar lavage fluids. In a 
separate experiment, naïve PMBS-treated (at least 6 weeks of twice weekly injections) 
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wild type mice were exposed to OVA aerosol (10 mg/ml in 0.9% saline) for 3 x 30 
minute periods (at 30 min intervals) on days 1, 3, and 5. Blood samples were drawn at 
24 hours following each aerosol, and mice were then sacrificed by cervical dislocation 
for collection and analysis of peritoneal cavity and bronchoalveolar lavage fluids. 
  
2.2.4  Collection and analysis of bronchoalveolar lavage fluid. 
Following cervical dislocation, the trachea was exposed by a ventral midline incision 
through the skin and subcutaneous tissue, and further separation of the submandibular 
salivary glands and sternohyoid muscle tissue by blunt dissection. A blunted 18-gauge 
needle (Terumo, USA) was inserted as a cannula through an incision in the upper 
trachea, providing a good seal. A 1 ml syringe (Temuro, USA) was then fitted to the 
cannula and the airways were washed with 2 x 1 ml ice-cold HBSS, giving an average 
return of 1.6 ml bronchoalveolar lavage fluid (BALF) in total. The BALF from each 
animal was centrifuged at 500 g and 4oC for 10 minutes and the cell pellet was 
resuspended in 500 µl red blood cell (RBC) lysis solution and incubated at 37oC for 5 
minutes before the addition of 1 ml ice cold PBS. The cells were then centrifuged again 
at 500 g and 4oC for 10 minutes, and the cell pellet resuspended in 500 µl ice-cold PBS 
before determining cell numbers in a standard haemocytometer. BALF cells (2 x 105) 
were then suspended in 100 µl HBSS and cytocentrifuged at 500 g for 5 minutes before 
differential staining with May-Grunwald-Giemsa solution. Lymphocytes, eosinophils, 
macrophage and neutrophils were identified by morphological criteria, with 200-250 
cells counted on each slide. 
 
2.2.5 Eosinophil purification by fluorescence activated cell sorting. 
PMBS-treated wild type mice were sacrificed by CO2 asphyxiation and the peritoneal 
cavity lavaged as in Section 2.2.2. Eosinophils in the PEC population were purified by 
fluorescence activated cell sorting (FACS) on the basis of size (forward scatter), 
granularity (side scatter), and the ability to polarise light. The purity of the enriched 
population of eosinophils was >98% as determined by differential staining with May-
Grunwald-Giemsa. Purified eosinophils were diluted as required into RPMI-1640 
(RPMI) culture medium.  
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2.2.6 Calcium signaling in PMBS eosinophils. 
Purified PMBS eosinophils were incubated at a density of 5 x 105 cells per well in 
round-bottomed 96 well cell culture plates (NUNC) in a total of 200 µl of Mixed 
Lymphocyte Culture (MLC) medium containing 10% FCS and in the presence or 
absence of recombinant murine IL-5 (10-11 M) for 12 hours at 37oC. Recombinant 
murine IL-5 was a generous gift from Professor Ian Young (John Curtin School of 
Medical Research (JCSMR), ANU) and was expressed and purified from the 
baculovirus expression system (Ingley et al., 1991). The cells were then harvested, 
washed in RPMI, and incubated at a density of 2 x 106 cells/ml in RPMI medium 
containing 1% FCS and 5 µM Indo-1 AM (1-[2-Amino-5-(6-carboxy-2-
indolyl)phenoxy]-2-(2-amino- 5-methylphenoxy)ethane- N,N,N',N'-tetraacetic acid, 
pentaacetoxymethyl ester) for 60 minutes at 37oC. Cells were then washed twice in ice 
cold calcium flux buffer containing (mM) NaCl, 145; KCl, 4; NaH2PO4, 1; MgCl2, 0.8; 
HEPES, 25; glucose, 22; CaCl2, 1.8, (pH 7.4) before being resuspended at 1 x 106 
cells/ml in flux buffer and stored on ice prior to calcium signaling experiments. For 
calcium signaling, 1 ml of Indo-1 AM loaded eosinophils were introduced into a water-
jacket-heated and stirred (~ 60 rpm) cuvette, contained within a Hitachi F-3000 
fluorescent scanning spectrophotometer (Japan), with excitation at 340 nm and emission 
at 390 nm. The cells were allowed to equilibrate at 37oC (typically taking 30-40 
seconds), before addition of exogenous factors. The calcium ionophore A23187 (1 µM 
in flux buffer) and SDS (10% in flux buffer) were used (respectively) to confirm the 
ability of Indo-1 AM loaded eosinophils to respond to exogenous stimuli, and to 
measure maximum attainable signals. Where indicated, recombinant mouse eotaxin 
(rEOT, 5 µg/ml, a gift from A. Mould, JCSMR, ANU) was added to the stirred cuvette 
system. 
 
2.2.7 Intraperitoneal IL-5 administration to PMBS-treated wild type mice. 
IL-5 is an activator of eosinophil function (Lopez et al., 1988). To study the effects of 
intraperitoneal (i.p.) IL-5 administration on eosinophil homing to sites of antigen 
deposition, PMBS-treated wild type mice (as in Section 2.2.2) were given a single dose 
of recombinant murine IL-5 (200ng i.p. in 200 µl 0.9% saline) or vehicle alone 24 hours 
prior to the first aerosol with antigen (as in Section 2.2.3). BALF was analysed on day 8 
(as in Section 2.2.4). 
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2.2.8 OVA specific IgG1 determination by ELISA. 
Serum samples were taken from the tail veins of naïve PMBS-treated wild type mice on 
day 0, 24 hours prior to exposure to antigen. Flat bottomed 96-well microtiter plates 
(Dynatech, Chantilly, VA) were coated with OVA (100 µg/ml in NaHCO3 buffer, pH 
9.6) and incubated overnight at 4oC. Plates were then blocked with 3% skim milk 
powder/PBS for 1 hour at 37oC. After incubation with dilutions of serum samples and 
standard murine IgG1 for 1.5 hours at 37oC, OVA-specific immunoglobulins were 
detected with biotinylated goat anti-mouse IgG1 (Biosource International, Camarillo, 
CA). Plates were then incubated with streptavidin-conjugated alkaline phosphatase 
(Amersham International plc, Buckinghamshire, UK), for 1 hour at 37oC and alkaline-
phosphatase substrate solution (Sigma Chemical Co., St Louis, MO), was added. 
Reactions were stopped with 0.1 M citric acid and the plates read at 405 nm in a 
Microplate reader (BIO-TEK Instruments Inc., Winooski, VT). 
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2.3 RESULTS 
 
2.3.1 Eosinophils migrate to antigen deposition in the lung in an eotaxin dependent 
manner. 
Naïve, PMBS-treated wild type and eotaxin-/- mice were exposed to antigen to 
investigate whether eosinophils would traffic to the airway mucosal surface in response 
to antigen deposition. Both wild type and eotaxin-/- mice had a pronounced peritoneal 
eosinophilia in response to PMBS treatment (Figure 2.1), with 2.5 and 1.5 million 
recoverable eosinophils located in the peritoneal cavity, respectively. Control mice had 
substantially lower numbers of recoverable eosinophils (17 x 104). There was no 
significant difference in eosinophil numbers in the peritoneal cavity between wild type 
or eotaxin-/- mice.  
 
Surprisingly, wild type mice developed a pronounced peripheral blood eosinophilia 
following the first exposure to OVA, which peaked at 12.5% of total white blood cells 
after the third OVA challenge on day 5 (Figure 2.2). This strong response was not seen 
in either eotaxin-/- mice or untreated wild type controls. Subsequent analysis of BALF 
revealed a pronounced eosinophil infiltration of the airways lumen in naïve PMBS-
treated wild type mice (Figure 2.3a), and to a much lesser extent in eotaxin-/- mice, 
where inhibition of eotaxin function is known to attenuate antigen induced tissue 
eosinophilia (Rothenberg et al., 1997). Eotaxin-/- mice had significantly more 
eosinophils/ml BALF than wild type controls, suggesting that an alternative pathway to 
eotaxin signaling may have been acting to draw eosinophils into the airways lumen. 
While not significantly different from each other, both wild type and eotaxin-/- mice had 
significantly greater lymphocytes/ml BALF than wild type controls (Figure 2.3b).  
 
2.3.2 PMBS eosinophils pre-incubated with IL-5 show enhanced in vitro responses 
to eotaxin. 
Interleukin-5 has been identified as a key regulator of eosinophil development, 
migration and activation (Lopez et al., 1988; Yamaguchi et al., 1988; Coffman et al., 
1989; Walsh et al., 1990; Lee et al., 1997), and regulates CCR3 expression (Tiffany et 
al., 1998). Recombinant IL-5 was used to demonstrate increased PMBS-derived 
eosinophil responses to eotaxin in vitro. Eosinophils enriched from PMBS-treated mice 
and cultured overnight in the absence of IL-5 showed slightly increased intracellular 
calcium levels following the addition of 10 µl of rEOT. This increase in intracellular 
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Figure 2.1. Recoverable eosinophils in the peritoneal cavities of naïve PMBS treated mice. (a) Recoverable eosinophils in PMBS treated wild type 
(WT PMBS), eotaxin-/- (EKO PMBS), and untreated control (WT Control) mice prior to airways exposure to OVA antigen (day 0). Both WT PMBS 
and EKO PMBS mice had significantly greater numbers of eosinophils residing in the peritoneal cavity than WT Controls. (b) Recoverable eosinophils 
on day 8, following repeated airways exposure to OVA on days 1, 3, 5, and 7. There was no significant difference in recoverable peritoneal eosinophils 
between WT PMBS and EKO PMBS mice following repeated exposure to OVA. Data represents mean ± SEM from groups of 6 mice. Significant 
differences in means were determined by Student’s unpaired t test (p < 0.05), and are indicated by bars (¬). 
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Figure 2.2. Peripheral blood eosinophilia in naïve PMBS treated mice exposed to 
airways antigen. WT PMBS treated mice developed a pronounced peripheral blood 
eosinophilia in response to OVA deposition in the naïve airways (days 1, 3, 5, and 7), 
which was significantly different from EKO PMBS and WT Controls on day 2, and 
peaked at 12.5% on day 6. Data represents mean ± SEM from groups of 4 mice. 
Significant differences in means were determined by Student’s unpaired t test (P < 
0.05). * P < 0.05 compared to EKO PMBS, and ** P < 0.05 compared to EKO PMBS 
and WT Control mice. 
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Figure 2.3. Eosinophils and lymphocytes in BALF of naïve PMBS treated mice following airways exposure to antigen. (a) WT PMBS mice had 
significantly greater eosinophils/ml BALF than EKO PMBS and WT Control mice. EKO PMBS mice had significantly greater eosinophils/ml BALF 
than WT Control mice. (b) WT PMBS and EKO PMBS mice had significantly greater lymphocytes/ml BALF than WT Controls. Data represents mean 
± SEM for groups of 6 mice. Significant differences in means were determined by Student’s unpaired t test (P < 0.05), and are indicated by bars (¬). 
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calcium was sustained until the addition of calcium ionophore (Figure 2.4a). The 
addition of 10 µl rEOT to eosinophils incubated overnight with rMIL-5 resulted in a 
markedly increased response (Figure 2.4b), which was further sustained until the 
addition of calcium ionophore, and demonstrates an increased responsiveness to eotaxin 
for PMBS-derived eosinophils incubated with IL-5.  
 
2.3.3 IL-5 administration in vivo does not enhance PMBS eosinophil homing to the 
lung after antigen deposition. 
IL-5 (200ng) was administered i.p. to PMBS-treated wild type mice (PMBS+IL-5), in an 
attempt to increase peritoneal eosinophil activation and to accentuate homing to antigen 
deposition in the naïve lung. For comparison, a subset of PMBS-treated mice received 
vehicle alone (PMBS+vehicle), and untreated wild type mice were used as a control. 
Recoverable eosinophils were measured in the peritoneum of PMBS-treated mice and 
untreated wild type control animals prior to and following challenge with OVA. Prior to 
OVA exposure, PMBS-treated mice had significantly greater numbers of recoverable 
eosinophils than untreated controls (Figure 2.5a). Following airways exposure to OVA 
on days 1, 3, 5, and 7, there was no significant difference in recovered peritoneal 
eosinophils between PMBS+IL-5 and PMBS+vehicle mice (Figure 2.6b). Both PMBS+IL-5 
and PMBS+vehicle mice developed a pronounced peripheral blood eosinophilia in 
response to OVA deposition in the lung (Figure 2.6), with peripheral blood eosinophils 
peaking at 22% after the third aerosol exposure in PMBS+IL-5 mice. Differences in 
peripheral blood eosinophils between PMBS+IL-5 and PMBS+vehicle mice were significant 
on days 2 and 6, which followed aerosol exposures to OVA on days 1 and 5. Analysis 
of BALF showed no significant differences between PMBS+IL-5 and PMBS+vehicle mice 
with respect to eosinophils or lymphocytes/ml BALF (Figure 2.7a and b). Both 
PMBS+IL-5 and PMBS+vehicle mice had significantly greater amounts of eosinophils and 
lymphocytes/ml BALF than WT Controls.  
 
2.3.4 Eosinophils migrate to the lung in naïve PMBS-treated mice immediately 
following antigen exposure. 
The kinetics of eosinophil migration to sites of antigen deposition were measured using 
naïve PMBS treated wild type mice exposed to aerosolised OVA on days 1, 3, and 5. 
Peripheral blood eosinophils were significantly elevated in PMBS treated mice 
following the 3rd exposure to aerosolised antigen, but not in WT Controls (Figure 2.8). 
Analysis of BALF revealed a significant infiltration of eosinophils following the first 
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Figure 2.4. Intracellular calcium signaling in FACS sorted PMBS eosinophils pre-incubated in the presence or absence of IL-5 (10-11 M). (a) 1 x 106 
FACS sorted eosinophils were allowed to equilibrate at 37oC prior to the addition of 10 µl (50ng) of eotaxin, which induced a moderate increase in 
intracellular calcium levels (measured on the Y axis). (b) The addition of 10 µl (50ng) of eotaxin to eosinophils pre-incubated with IL-5 produced a 
pronounced and sustained increase in intracellular calcium levels. In both instances, the addition of calcium ionophore (CI) further increased 
intracellular calcium levels, demonstrating cell membrane integrity, and ability of FACS sorted eosinophils to respond to exogenous stimulus. The 
addition of SDS lysed all cells, giving a maximum attainable signal. Duration in minutes is shown on the x-axis.  
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Figure 2.5. Recoverable eosinophils in the peritoneal cavity of naïve PMBS treated mice: effects of i.p. IL-5 administration. (a) Recoverable 
eosinophils in wild type C57BL/6 PMBS treated mice (PMBS) mice and untreated controls (WT Control) prior to IL-5 administration and airways 
exposure to OVA antigen. (b) Following exposure to OVA antigen, IL-5 (PMBS+IL-5) and vehicle treated (PMBS+vehicle) mice had significantly greater 
recoverable eosinophils than WT Controls. There was no significant difference in the numbers of recovered peritoneal eosinophils between 
PMBS+vehicle and PMBS+IL-5 mice exposed to OVA antigen. Data represents mean ± SEM from groups of 4 mice. Significant differences in means were 
determined by Student’s unpaired t test (P < 0.05), and are indicated by bars (¬). 
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Figure 2.6. Peripheral blood eosinophilia in naïve PMBS treated mice exposed to 
antigen: effects of i.p. IL-5 administration. Both PMBS+IL-5 and PMBS+vehicle mice 
developed a pronounced peripheral blood eosinophilia in response to OVA antigen 
exposure to the airways (days 1, 3, 5, and 7), which was significantly different from WT 
Control mice following the first antigen exposure on day 1. There was a significant 
difference in peripheral blood eosinophils between PMBS+IL-5 and PMBS+vehicle treated 
mice on days 2 and 6. Data represents mean ± SEM from groups of 4 mice. Significant 
differences in means were determined by Student’s unpaired t test (P < 0.05). * P < 0.05 
compared to WT Control; and ** P < 0.05 compared to PMBS+vehicle and WT Control 
mice. 
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Figure 2.7. Eosinophils and lymphocytes in BALF of naïve PMBS treated mice following airways exposure to OVA antigen: effects of i.p. IL-5 
administration. (a) PMBS+IL-5 and PMBS+vehicle mice had significantly greater eosinophils/ml BALF than WT Controls, but were not significantly 
different from each other. (b) PMBS+IL-5 and PMBS+vehicle mice had significantly greater lymphocytes/ml BALF than WT Controls, but were not 
significantly different from each other. Data represents mean ± SEM for groups of 4 mice. Significant differences in means were determined by 
Student’s unpaired t test (P < 0.05), and are indicated by bars (¬). 
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OVA aerosol on day 1 (Figure2.9a), with a trend towards greater eosinophil infiltration 
following each aerosol. Lymphocytes/ml BALF were also measured, and were 
significantly increased following 2 aerosols (Figure2.9b).  
 
2.3.5 PMBS-treated mice lack detectable serum OVA-specific IgG1. 
To ensure the phenomenon of eosinophil homing to the lung was independent of prior 
sensitisation to OVA, serum samples from 5-7 mice were analysed for OVA-specific 
IgG1 antibodies both prior to and following airways exposure to antigen. In comparison 
to OVA sensitised and challenged mice (Hogan et al., 1997b), PMBS mice had no 
detectable OVA-specific IgG1 above background prior to exposure to OVA (Figure 
2.10). Following airways exposure to OVA, PMBS treated mice had detectable serum 
OVA-specific IgG1, which was significantly less than the levels seen in OVA sensitised 
and challenged mice.  
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Figure 2.8. Peripheral blood eosinophilia in naïve PMBS treated mice exposed to 0, 1, 
2 or 3 OVA antigen aerosols. PMBS treated mice developed a peripheral blood 
eosinophilia greater than 6% following 3 aerosols, which was significantly different 
when compared to pre-exposure levels. Peripheral blood eosinophil levels in PMBS 
mice were not significantly different to WT Controls at any time point. WT Controls did 
not develop a peripheral blood eosinophilia significantly different to pre-exposure 
levels. Data represents mean ± SEM from groups of 4 mice. Significant differences in 
means were determined by Student’s unpaired t test (P < 0.05). * P < 0.05 compared to 
PMBS treated mice prior to airways exposure to OVA antigen.  
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Figure 2.9. Eosinophils and lymphocytes in BALF of naïve PMBS treated mice exposed to 0, 1, 2 or 3 OVA aerosols. (a) PMBS treated mice 
exhibited significant eosinophil infiltration of the airways following 1 exposure to aerosolised antigen, and cell numbers rose appreciably with each 
consecutive exposure to OVA antigen. (b) Lymphocytes in BALF were only significantly elevated from pre exposure levels following the 2nd exposure 
to OVA, but not after the 3rd exposure. Data represents mean ± SEM for groups of 4 mice. Significant differences in means were determined by 
Student’s unpaired t test (P < 0.05), and are indicated by bars (¬). 
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Figure 2.10. OVA-specific IgG1 antibody titers in OVA sensitised and challenged mice 
compared to PMBS treated mice. Serum from wild type PMBS treated mice prior to 
(pre) and following (post) airways exposure to novel antigen was analysed for OVA-
specific IgG1 and compared to that of wild type OVA sensitised and challenged mice. 
Data represents mean ± SEM for groups of 5-7 mice. Significant differences in means 
were determined by Student’s unpaired t test (P < 0.05), and are indicated by bars (¬). 
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2.4 DISCUSSION 
 
The extent to which eosinophils may participate during the early immune response to 
antigen is poorly understood, and is currently restricted to the measurement of surface 
molecules associated with antigen presentation and observations of cellular interactions 
ex-vivo. While the eosinophil is certainly equipped with the necessary surface 
molecules required for effective antigen presentation to antigen-specific T cells (Del 
Pozo et al., 1992; Hansel et al., 1992; Weller et al., 1993; Tamura et al., 1996; Handzel 
et al., 1998; Celestin et al., 2001), there remains a poor understanding of its ability to 
interact with naïve (and memory) T lymphocytes at sites of antigen deposition. 
Furthermore, the participatory role of eosinophils in the early stages of airways 
sensitisation have not been investigated to date. The experiments presented in this 
Chapter were designed to evaluate what effect (if any) antigen deposition in the naïve 
airways had upon a distal pool of eosinophils located within the peritoneal cavity. 
 
Eotaxin is an eosinophil specific chemokine, constitutively expressed in various tissues 
including small intestines, the colon, heart, kidneys and lung (Jose et al., 1994a; 
Rothenberg et al., 1995b; Kitaura et al., 1996; Matthews et al., 1998). Eotaxin 
expression is upregulated in response to IL-4 (Rothenberg et al., 1995a; Mochizuki et 
al., 1998; Sanz et al., 1998b), and eotaxin expression in the allergic lung has since been 
linked to both IL-4 and IL-13 secretion from CD4+ T-cells (Mattes et al., 2001; Webb et 
al., 2001; Foster et al., 2002). In this Chapter, chronic PMBS treatment induced a 
pronounced peritoneal eosinophilia (Figure 2.1) in both wild type and eotaxin-/- mice, 
providing an animal model in which to study distal eosinophil responses to local antigen 
exposure within the airways. When exposed to repeated aerosols of antigen, PMBS-
treated wild type mice developed a significant peripheral blood eosinophilia (Figure 
2.2). Surprisingly, analysis of BALF on day 8 revealed a pronounced pulmonary 
eosinophilia in PMBS-treated wild type mice (Figure 2.3a), suggesting that a signaling 
pathway generated from within lung tissue was acting distally, to induce migration of 
peritoneal and peripheral blood eosinophils to the lung. This migration was dependent 
on antigen deposition in the airways, as PMBS-treated wild type mice that were 
exposed to aerosolized vehicle (0.9% saline) did not generate a BALF eosinophilia 
(data not shown). When exposed to repeated aerosols of OVA, eotaxin-/- mice did not 
develop a peripheral blood eosinophilia significantly different from that of untreated 
wild type controls (Figure 2.2). Analysis of BALF on day 8 revealed a very slight 
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eosinophil infiltration of the airways lumen in eotaxin-/- mice (Figure 2.3a) which was 
significantly greater than that of wild type controls, yet 8-fold less than that seen in 
PMBS-treated wild type mice. This data strongly suggests that distally located 
eosinophils can respond to antigen deposition in the naïve airways in a manner that is 
heavily dependent on eotaxin, which is most likely generated within the respiratory 
epithelium. The small but significant number of eosinophils recruited to the airways 
seen in eotaxin-/- mice suggests that another factor or factors may be acting in the 
absence of eotaxin to promote eosinophil recruitment to antigen deposition in the lung. 
 
IL-5 administration has been shown to increase peripheral blood eosinophilia, and to 
synergise with local eotaxin administration to promote eosinophil accumulation into 
tissues (Collins et al., 1995; Mould et al., 1997). Peritoneal eosinophils derived from 
PMBS mice pre-incubated with IL-5 displayed increased intracellular calcium 
responses to eotaxin in vitro (Figure 2.4). This effect of IL-5 upon PMBS eosinophils 
suggested that IL-5 administration to PMBS-treated mice could augment eosinophil 
homing to sites antigen deposition in the lung. However, IL-5 administration was shown 
to have no significant effect upon peripheral blood eosinophilia in PMBS-treated mice 
exposed to OVA (Figure 2.6), nor were there any increases in the numbers of 
eosinophils and lymphocytes infiltrating the airways lumen (Figure 2.7), suggesting that 
there was no synergy between distally acting IL-5 and the locally generated signal from 
the naïve lung in response to OVA deposition.  
 
In an airways sensitisation model, IL-4 and IL-5 in the BALF can be measured 
following 5 days of consecutive antigen exposure, albeit in the context of GM-CSF 
transgene expression (Stampfli et al., 1998). In the results presented in this Chapter, it is 
unlikely that emerging antigen-specific IL-4, IL-5 and IL-13 secreting CD4+ T-cells 
were responsible for the early induction of eotaxin expression within the lung and 
subsequent trafficking of eosinophils from the peritoneum to this site. This assumption 
is based on the kinetics of the response (Figures 2.8 and 2.9), which suggest that an 
immediate early signal generated in the lung results in eosinophil homing to sites of 
OVA deposition. Furthermore, the lack of OVA specific IgG1 in serum of PMBS treated 
mice prior to antigen exposure does not indicate previous sensitisation to OVA (Figure 
2.10), and lymphocytes/ml BALF in wild type and eotaxin-/- mice were typically 5-fold 
less than those seen in OVA sensitised and challenged mice (Foster et al., 1996).  
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In summary, antigen deposition in the airways of naïve mice induces an immediate 
early signal (IES) that can induce eosinophil homing from a distal site to the lung, and 
these experiments strongly suggest that eotaxin is a major component in the signaling 
pathway. Thus, at least two mechanisms for eosinophil recruitment may operate in the 
lung: one that is dependent on antigen-specific T cells, and another IES that is non-T 
cell dependent and reliant on eotaxin.  
 
Notably, detectable OVA-specific IgG1 in serum was seen in PMBS treated mice on day 
8, following repeated airways exposure to OVA (Figure 2.10). It is possible that 
eosinophils recruited by the IES to the naïve lung may have participated in the primary 
response to OVA deposited in the airways. Eosinophil recruitment to the airways lumen 
preceded observable increases in lymphocyte numbers (Figure 2.9), and eosinophils 
have previously been identified as a source of IL-4 (Sabin et al., 1996; Rumbley et al., 
1999). Mouse eosinophils are known to have some antigen presenting capability (Del 
Pozo et al., 1992), and provide necessary costimulatory signals during antigen 
presentation to T cells (Tamura et al., 1996). Therefore, eosinophils that were recruited 
to the lung soon after antigen deposition may have provided early IL-4, which is 
necessary for OVA specific IgG1 and the development of Th2 responses following 
sensitisation via the airways.  
 
It would be interesting to determine the spatial and temporal aspects of eosinophil 
trafficking to regions of antigen deposition (airways lumen) and presentation (draining 
lymph nodes) in sensitised mice following aeroallergen challenge. Monitoring 
parameters such as eosinophil infiltration into lung tissue, the airways lumen, and 
possibly the draining lymph nodes may further our understanding of the processes 
involved in the selective recruitment of eosinophils into allergic tissues following 
antigen exposure, and may further delineate their participation in airways responses to 
antigen. 
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3.1 INTRODUCTION 
 
Animal models of allergic airways disease provide a useful tool in which to investigate 
the cellular and humoral response to allergen deposition within the sensitised organism. 
An initial i.p. sensitisation using antigen and adjuvant is often necessary for disease 
induction, although exclusive sensitisation via the airways is possible (Haczku et al., 
1997; Hamelmann et al., 1997a; Hamelmann et al., 1997c). Subsequent aeroallergen 
challenge allows detailed analysis of the selective accumulation of eosinophils and 
activated CD4+ T cells, which is now accepted as a central event in the progression and 
maintenance of allergic airways disease (Anderson and Coyle, 1994; Hetzel and Lamb, 
1994; Fowell et al., 1997; Hogan et al., 1998c).  
 
Using an OVA sensitisation and aeroallergen challenge model in BALB/c mice, 
Ohkawara and colleagues (Ohkawara et al., 1997) have measured the kinetics of the 
eosinophil response in both the blood and lung compartments. They observed 
inflammatory cell infiltration (predominantly neutrophils, eosinophils, and some 
lymphocytes) in lung tissue and the airways lumen within 3 and 24 hours of 
aeroallergen challenge respectively, while peripheral blood eosinophilia also increased 
significantly within 3 hours of airways challenge. Notably, IL-4 and IL-5 expression 
were detected in the lung 3 and 5 hours, respectively, following airways challenge. 
During disease resolution, eosinophils were the predominant leukocyte remaining in the 
airway lumen (as measured by BALF) for up to 15 days following cessation of 
aeroallergen challenge, a feature which was also reflected in peripheral blood 
eosinophilia. Histological analysis revealed a return to a normal bronchial epithelium 21 
days after challenge of the airways. Recently Gajewska and colleagues (Gajewska et al., 
2001) have expanded upon this body of work and monitored the expansion of APC 
populations and further detailed the expression of cytokines following aeroallergen 
challenge. Using flow cytometrical analysis, macrophage and dendritic cell populations 
were greatly increased in lung tissue 24 hours following airways challenge, and 
accompanied a significant increase in MHC-II/B7.2 double positive cells in draining 
thoracic lymph nodes. Measurement of cytokine expression in the lung revealed a 
significant increase in mRNA for IL-4, IL-13, IL-5 and IL-6 in as little as 3 hours 
following airways challenge, and modest yet significant increases in message for each 
of these cytokines in draining lymph nodes. It is of particular interest to note that in 
these two very similar models, lung IL-4 expression was detected within 3 hours of 
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antigen deposition of the airways. IL-4 has been shown to induce eotaxin expression 
(Rothenberg et al., 1995a; Mochizuki et al., 1998), and this may have been a 
contributing factor to the rapid infiltration of eosinophils into the allergic lung and 
airways lumen (Ohkawara et al., 1997).  
 
In these and other described models, airways challenge with OVA would ultimately 
lead to a mixture of soluble antigen, lung derived cytokines and antigen bearing APCs 
entering the draining lymphatic vessels and progressing towards the draining thoracic 
lymph nodes. Soluble OVA has been shown to enter the draining lymphatics and to 
penetrate beneath the subcapsular sinus, before associating with the reticular network 
and eventually reaching the high endothelial venules (HEVs) (Gretz et al., 2000), a site 
where naïve T cells may gain access to the lymph node (Gretz et al., 1996; McEvoy et 
al., 1997). The arrival of soluble OVA into the draining lymph nodes would then allow 
resident APCs such as interdigitating dendritic cells which actively sample the 
extracellular milieu to internalise and process OVA, prior to presenting antigenic OVA 
peptides to resident naïve T cells in the context of MHC-II. Alternatively, OVA 
deposited in the airways may be taken up in situ by resident professional APCs such as 
immature dendritic cells, which then undergo a maturation process involving increased 
B7.1/B7.2 and MHC-II expression and concomitant migration to the draining lymph 
nodes and eventual stimulation of naïve T cells (Lambrecht, 2001).  
 
Eosinophils have been observed to present superantigens (Weller et al., 1993; 
Mawhorter et al., 1994; Tamura et al., 1996; Celestin et al., 2001), viral antigens 
(Handzel et al., 1998), and antigen requiring intracellular processing (Del Pozo et al., 
1992; Hansel et al., 1992; Tamura et al., 1996) to antigen specific T cells in a B7.2 
dependent manner (Tamura et al., 1996; Celestin et al., 2001). Eosinophils in the 
allergic lung and airways lumen are well situated to sample the extracellular milieu and 
to traffic via the afferent lymphatics to the draining lymph nodes, where antigen may 
either be presented to resident naïve T cells or be sequestered by professional APCs and 
subsequently presented to naïve T cells. Eosinophil recruitment to lymph nodes after 
antigen loading is not a recent observation and dates back at least to 1966 (Roberts, 
1966), and during helminth infection in mice, eosinophils have been observed to 
translocate to the draining lymph node during the recovery phase (Friend et al., 2000). 
Ultimately, eosinophils carrying soluble antigen to the draining lymph nodes in allergic 
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airways disease models may exacerbate established Th2 responses, by interacting with 
naïve T cells and generating memory T cells with an OVA specific Th2 phenotype.  
 
In this Chapter, the kinetics of eosinophil trafficking and spatial distribution into the 
lung and airways lumen are studied following antigen deposition, as well as monitoring 
the resolution of eosinophilia in both pulmonary and thoracic lymphoid tissues. The 
results presented here suggest that eosinophils can migrate to draining lymphoid tissue 
following antigen deposition in the airways, and then dwell in draining lymphoid tissue 
for extended periods of time during resolution of allergic airways inflammation. 
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3.2 MATERIALS AND METHODS 
 
3.2.1 Animals. 
Wild type and IL-5 transgenic mice (Dent et al., 1990) of the C57BL/6 strain (male, 4-8 
wk old) were obtained from the SPF unit of the ANU and housed in an approved 
containment facility. Mice were treated according to ANU animal welfare guidelines.  
 
3.2.2 Induction of allergic airways inflammation in wild type mice, collection and 
analysis of peripheral blood and BALF. 
Male wild type C57BL/6 mice were sensitized by i.p. injection with 50 µg OVA/1 mg 
Alhydrogel (alum, Commonwealth Serum Laboratories, Parkville, Australia) in 0.9% 
sterile saline on days 0 and 12 (Figure 3.1a). To qualitatively measure subtle increases 
in resident eosinophil numbers within BALF, the mice were then subjected to a very 
mild antigen challenge regime. On days 24, 25, and 26, the mice were aeroallergen 
(OVA, 10 mg/ml in 0.9 % saline) challenged for 30 minutes using a RapidFlo nebuliser 
bowl. BALF (see Section 2.2.4) was analysed at 0, 3, 6, 9, 24, 48 and 72 hours from the 
first aerosol on day 24. Blood samples were drawn from the tail vein for differential cell 
counts at the same time points, and stained with May-Grunwald-Giemsa solution prior 
to differential cell counting (~210 cells). 
 
3.2.3 Airways and peribronchial lymph node (PBLN) histology in allergic wild type 
mice. 
To measure eosinophil migration into the airways and also into PBLN tissue, sensitised 
and challenged mouse lungs (Section 3.2.2) were immediately removed and fixed in 
10% phosphate-buffered formalin solution, pH 7.0 for at least 2 hours. Later, sections 
representing the central (bronchi-bronchiole) and peripheral (alveolar) airways were cut 
and immersed in 10% phosphate buffered formalin solution for a minimum of 72 hours. 
PBLN were harvested concomitantly with lung tissue, and fixed whole in 10% 
phosphate buffered formalin for a minimum of 72 hours. The samples were paraffin-
embedded, sectioned and stained with Lendrum’s carbolchromotrope stain (Lendrum, 
1944). Leukocytes were identified by morphological criteria and quantified. Eosinophils 
per high-powered field (40x objective) were counted from histological sections of 
tissue. As a control, brachial lymph nodes were also sampled at all time points to 
compare eosinophil trafficking in extra-pulmonary lymphoid tissue. 
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Figure 3.1. Sensitisation and aerosol challenge regimes. (a) To study eosinophil 
migration into allergic tissue, mice were given intraperitoneal injections of OVA in 
alum on days 0 and 12 (i.p.), and challenged with an OVA aerosol (Aero) on days 24, 
25 and 26. Mice were sacrificed (<) at 0, 3, 6, 9, 12, 24, 48 and 72 hours following the 
first aerosol on day 24, with BALF, PBLN and peripheral blood samples taken at these 
times. (b), to generate a strong allergic response with which to monitor resolution of 
tissue eosinophilia, mice were i.p. sensitised with OVA in Alum on days 0 and 12, and 
challenged with 3 OVA aerosols on days 24, 26, 28 and 30. (c). To study the resolution 
of tissue eosinophilia in the allergic lung and draining lymphoid tissue, mice from 
regime (b) were sacrificed 3, 6, 9, 12, and 15 days after the last aerosol (Aero*) on day 
30, and appropriate tissues sampled. 
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3.2.4 Visualisation of eosinophils in PBLN using electron microscopy. 
Peribronchial lymph nodes from sensitised and challenged mice (Section 3.2.2) were 
immersed in a fixative consisting of 2% glutaraldehyde in 0.1-M cacodylate buffer, pH 
7.4. The specimens were fixed overnight and then post-fixed in 1% osmium tetroxide 
for 90 minutes. They were then dehydrated in graded acetone solutions and embedded 
in Spur’s Resin (ProSciTech, Australia). For high-resolution light microscopy, semi-thin 
(1 µm) sections of the embedded tissue were cut and stained with Toludine Blue. These 
sections were used to select areas of interest for electron microscopic examination. 
Ultra-thin sections (80-85 nm) were cut on a Reichert-Jung Ultracut E ultramicrotome 
(Germany) and routinely contrasted with uranyl acetate and lead citrate. The sections 
were examined using a Hitachi 7000 transmission electron microscope (Japan). 
 
3.2.5 Cessation of allergic airways inflammation in wild type mice, collection and 
analysis of peripheral blood and BALF. 
Male wild type C57BL/6 mice were sensitized by i.p. injection with 50 µg OVA/1 mg 
Alhydrogel (Commonwealth Serum Laboratories, Parkville, Australia) in 0.9% sterile 
saline on days 0 and 12 (Figure 3.1b). On days 24, 26, 28, and 30, the mice were 
aeroallergen challenged (OVA, 10 mg/ml in 0.9% saline) for 3 x 30 minutes at half hour 
intervals using a RapidFlo nebuliser bowl. BALF and PBLN (as in sections 2.2.4 and 
3.2.3) were sampled at 3, 6, 9, 12, 15 and 18 days following the last aerosol challenge 
on day 30 (Figure 3.1b and c). Blood samples were drawn from the tail vein for 
differential cell counts on the same days, and stained with May-Grunwald-Giemsa 
solution prior to differential cell counting (~210 cells). This antigen delivery regime 
induced maximal eosinophil recruitment to BALF and PBLN, and changes in lymph 
node diameter by day 31, providing a satisfactory model to investigate resolution of 
eosinophilia from these compartments. As a control, brachial lymph nodes were also 
sampled at all time points to compare eosinophil trafficking in extra-pulmonary 
lymphoid tissue. 
 
3.2.6 Eosinophil purification by flow cytometry. 
IL-5 transgenic C57BL/6 mice (Dent et al., 1990) were sacrificed by CO2 asphyxiation 
and the peritoneal cavity lavaged as in Section 2.2.2. Eosinophils were purified by 
FACS as in Section 2.2.5. The purity of the enriched population of eosinophils was 
>98% as determined by differential staining with May-Grunwald-Giemsa. Purified 
eosinophils were diluted as required into RPMI-1640.  
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3.2.7 Fluorescent labeling of IL-5 transgenic eosinophils and analysis of trafficking 
to lung and lymphoid tissues in vivo. 
FACS sorted IL-5 transgenic eosinophils (>98% purity) were stained in vitro with the 
fluorescent nuclear dye Hoechst 33342 (H33342, 20 µg/ml, Molecular Probes) in PBS 
(1% BSA) at a concentration of 5 x 107 cells/ml for 30 minutes at 37oC. The cells were 
then washed (x3) in ice cold PBS and placed on ice. Stained cells (4x 106) were then i.v. 
injected into OVA sensitised and challenged mice following the third aerosol challenge 
(as described above in Section 3.2.5). At each step, the labeled cells were protected 
from incident light. At 2 and 20 hours post-transfer, peripheral blood, BALF, lung, 
PBLN, spleen and gut (jejunum) were sampled. Mice were rendered unconscious with 
ether, and respective tissues were excised following cardiac perfusion with PBS. The 
tissues were separately homogenised (the jejunum was irrigated with ice cold PBS prior 
to homogenisation) in HBSS/10% FCS at 4oC, and the resulting cell suspensions were 
then filtered through sterile nylon mesh (70µM) before centrifugation at 500 g for 5 
minutes at 4oC. Each pellet was then resuspended in PBS. The cell homogenates were 
protected from incident light during each step. Fluorescent cells in each tissue were then 
detected with a Becton and Dickinson FACScan® flow cytometer in conjunction with 
Cellquest (Becton and Dickinson, San Jose, CA) and WinMDI software packages 
(kindly provided by J. Trotter, Scripps Research Institute, La Jolla, CA). 
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3.3 RESULTS 
 
3.3.1 Eosinophils migrate to lung and PBLN tissue following aeroallergen 
challenge in sensitised mice. 
Ovalbumin aerosol was periodically delivered to the sensitised airways over a period of 
72 hours, and eosinophil numbers characterized in the blood, airways lumen (as 
measured by BALF), and PBLN compartments. Blood eosinophilia peaked at 6 hours 
following the first aerosol challenge on day 24, and was sustained for the duration of the 
experiment (Figure 3.2a). Eosinophils in BALF were significantly elevated at 48 hours, 
i.e. following exposure to aerosolised OVA on days 24 and 25 (Figure 3.2b). 
Interestingly, eosinophil numbers in PBLN were significantly elevated with 3 hours of 
the first exposure to aerosolised OVA on day 24, and were elevated again at 48 hours 
following the second exposure on day 25 (Figure 3.2c). Microscopic analysis of 
carbolchromotrope stained PBLN sections indicated that eosinophils infiltrated the 
lymph node, residing predominantly within the medullary sinus (Figure 3.3a-c), and 
were notably absent from follicular structures. Electron microscopy analysis of PBLN 
tissue sections at 48 hours revealed eosinophils residing in the draining lymphatic duct 
and within tissues beneath the subcapsular sinus of the lymph node (Figures 3.4a and b). 
In some sections, eosinophils were observed in close proximity to lymphocytes (Figure 
3.4b) and displayed characteristics of activation, including loss of granule matrix and 
crystalloid core. Although these cells showed loss of secondary granules, the majority 
showed no signs of degranulation nor condensation of nuclear chromatin, which are 
indicative of the late stages of apoptosis.  
 
3.3.2 Eosinophil numbers in PBLN, lung and BALF return to basal levels 18 days 
after cessation of aeroallergen challenge. 
The kinetics of resolution of eosinophilia in the lung and lymphoid tissues during the 
refractive phase of allergic inflammation is poorly defined. To characterize the 
clearance of eosinophils, a strong aeroallergen challenge regimen was used to generate 
large numbers of eosinophils in pulmonary compartments and in the blood of allergic 
mice. The BALF, lung tissue, PBLN and blood were then characterized for 18 days 
following cessation of aeroallergen exposure. Allergic mice were sacrificed every 3 
days, beginning after the last aerosol challenge at day 30. Eosinophil numbers in the 
blood steadily declined over 12 days to baseline levels (Figure 3.5a). Eosinophils/HPF 
for each tissue were counted and compared with residual numbers of eosinophils in the 
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Figure 3.2. Eosinophil numbers in Blood, BALF and PBLN compartments following antigen provocation in allergic mice. (a) A significant rise in 
peripheral blood eosinophils was observed at 6 hours after the first aerosol and persisted for the duration of the experiment. (b) Significant numbers of 
eosinophils appeared in BALF at 48 hours, and remained elevated at 72 hours. (c) Eosinophils were significantly increased in PBLN 3 hours following 
the initial aeroallergen challenge, and were greatly increased at 48 hours. Data represents mean ± SEM for groups of 4 mice. Significant differences in 
means were determined by Student’s unpaired t test (P <0.05), and are indicated by bars (¬).* P <0.05 compared to 0 and 3 hours. 
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Figure 3.3. Eosinophils infiltrate the lymph node medulla following antigen deposition in the airways of sensitised mice. (a) Carbolchromotrope 
stained sections of the peribronchial lymph node showing follicle development (10x). (b) Eosinophils can be seen in the medullary sinus (arrowed) but 
not in follicular structures (20x). (c) Eosinophils can be observed in discrete clusters within the cortex (arrowed, 40x).   
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Figure 3.4. Eosinophils localise to PBLN after antigen provocation of the lung. (a) following antigen provocation in allergic mice, electron microscopy 
showed that eosinophils (*) were caught in transit within the draining lymphatic duct. (b) Electron microscopy showed that eosinophils localised within 
the subcapsular sinus region in PBLN of allergic mice. Some evidence of activation was noted (arrowheads) by the loss of crystalloid core and matrix 
of eosinophil granules. Here an eosinophil appears to be interacting with a lymphocyte, as evidenced by extended processes (*). 
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Figure 3.5. Resolution of eosinophilia from blood, lung and lymphoid tissues following cessation of aeroallergen challenge. (a) At the end of the 
aerosol regime, peripheral blood eosinophilia was 13%, and gradually declined to basal levels within 12 days of cessation of aeroallergen challenge. (b) 
Eosinophil numbers in BALF declined rapidly after cessation of aerosol and were undetectable by day 15. (c) Eosinophils per high powered field 
(HPF) in lung tissue (plotted on second Y axis), were elevated for 12 days after cessation of aeroallergen challenge, while eosinophils in PBLN did not 
peak until day 6, before gradually declining. Brachial lymph node eosinophil numbers did not change significantly. Data represents mean ± SEM for 
groups of 4 mice. 
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BALF (Figures 3.5b and c). Brachial lymph nodes were also sampled for comparative 
purposes. BALF eosinophil numbers rapidly declined after cessation of allergen 
exposure (~50% within 3 days), returning to baseline levels by day 15 (Figure 3.5b). By 
contrast, the number of eosinophils residing within the tissue (Figure 3.5c) did not 
significantly decline until day 12, when the pool of eosinophils in the airways lumen 
was almost completely depleted (Figure 3.5b). PBLN eosinophil numbers continued to 
increase to day 6 after cessation of allergen exposure and then fell in parallel with tissue 
levels over the next 12 days to baseline levels (Figure 3.5c). In all compartments, 
eosinophil levels had returned to baseline within 18 days of the last allergen exposure. 
Eosinophil numbers in brachial lymph nodes did not change significantly in response to 
allergen provocation, suggesting that eosinophil trafficking to the lung and airways-
draining lymph nodes was specifically related to allergic inflammation of the airways. 
 
3.3.3 Eosinophils do not directly enter PBLN from the blood following allergen 
provocation of the allergic lung. 
To further identify the migration pathway of eosinophils to pulmonary compartments 
during allergen provocation, 2 x 106 fluorescently labeled eosinophils from IL-5 
transgenic mice were injected i.v. into allergic wild type mice following the third 
aeroallergen challenge. Within 2 hours of transfer, labeled cells were detected in the 
lung, spleen, and blood, but not in BALF, PBLN tissue, nor the gut (Figures 3.6 and 
3.7). By 20 hours, labeled eosinophils were still migrating into the lung tissue, and 
fluorescent cells were still undetected within PBLN tissue (not shown). These results 
suggest that eosinophils do not passage directly via the blood and high endothelial 
venules to PBLN following allergen provocation, but migrate via the pulmonary 
parenchyma and draining lymphatics. 
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Figure 3.6. Trafficking of labeled eosinophils to pulmonary and lymphoid tissue following allergen provocation. Within 2 hours of i.v. transfer, 
labeled cells were detected in spleen, lung and blood, but not in PBLN tissue. Region 1 (R1) represents the area in which eosinophil would fall based 
on forwards (FSC-Height) and side scatter (SSC-Height). Detection of H33342 fluorescence (F32-Height) for each tissue is given below each window, 
and is gated for cells within R1 only. Fluorescent cells are represented in the upper left quadrant. 
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Figure 3.7. Trafficking of labeled eosinophils to pulmonary and lymphoid tissue following allergen provocation. Within 2 hours of i.v. transfer, 
labeled cells were not detected in BALF nor the small intestines (GUT). Region 1 (R1) represents the area in which eosinophil would fall based on 
forwards (FSC-Height) and side scatter (SSC-Height). Detection of H33342 fluorescence (F32-Height) for each tissue is given below each window, 
and is gated for cells within R1 only. Fluorescent cells are represented in the upper left quadrant. Eosinophils stained with H33342 dye prior to transfer 
(H33342) are shown in comparison to unstained cells (NEG CONTROL). 
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3.4 DISCUSSION 
 
In the experiments described in Chapter 2, it was shown that antigen deposition in the 
naïve lungs of PMBS-treated mice could induce eosinophil accumulation in the airway 
lumen via an eotaxin dependent mechanism. Eosinophils are prominent features in 
allergic mucosal surfaces of the lung and gastrointestinal tract (Gleich et al., 1993; 
Rothenberg, 1998), and these cells are currently thought to act as effector cells, that 
induce pathological changes through the release of granular proteins and 
proinflammatory mediators. The degranulation status of mouse eosinophils in allergic 
airways disease models is currently under intense scrutiny (Stelts et al., 1998; Persson 
and Erjefalt, 1999; Denzler et al., 2001; Malm-Erjefalt et al., 2001), however the results 
presented in this Chapter do not attempt to delineate a pathological role for eosinophils. 
Rather, attention has been focused on other potential roles for eosinophils in the 
regulation of allergic airways disease through characterisation of their spatial and 
temporal distribution during the development and resolution of allergic inflammation of 
the lung. 
 
Detailed analysis of eosinophil trafficking to the lung and draining lymphoid tissue 
during both the progression and resolution of allergic airways disease has provided a 
valuable insight into the potential role eosinophils may play in disease regulation. In 
this Chapter, eosinophils were observed to traffic to sites of antigen deposition (airways 
lumen) and T cell expansion (PBLN) in response to antigen provocation of the airways. 
An increase in peripheral blood eosinophils was observed in as little as 6 hours 
following antigen provocation (Figure 3.2a), and a significant increase in eosinophils in 
the airways lumen was observed within 48 hours (Figure 3.2b). These results agree with 
those of Ohkawara et al., who have also used a mouse model of allergic airways disease 
to measure the kinetics of eosinophil migration into pulmonary tissues (Ohkawara et al., 
1997). In their model, Ohkawara et al. observed eosinophil adhesion to pulmonary 
endothelial cells in as little as 3 hours following airways challenge, which paralleled an 
increase in peripheral blood eosinophilia and subsequently led to infiltration of the 
airways lumen within 24 hours.  
 
Antigen specific lymphocytes circulating through the allergic mouse lung can quickly 
respond to relevant antigen deposition through rapid synthesis and secretion of IL-4, IL-
5 and IL-13 (Gajewska et al., 2001), which act in concert to promote tissue 
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eosinophilia. In this Chapter, a significant increase in the numbers of eosinophils 
residing in the draining PBLN was noted 3 hours following the initial exposure to 
antigen, and preceded the accumulation of eosinophils in the BALF (Figures 3.2b and 
c). It is tempting to speculate that eosinophils may preferentially translocate to the 
lymph node during the early phase of airways inflammation, and that repeated exposure 
to antigen then promotes the accumulation of eosinophils in the lung and BALF. This 
effect may be seen in Figures 3.2b and c, wherein eosinophils accumulate in both 
draining PBLN and the airways lumen following repeated exposure to OVA on days 25 
and 26 (i.e. at 48 and 72 hours following the initial exposure).   
 
Following the cessation of antigen provocation, airways eosinophils become apoptotic 
and may be engulfed by airway macrophages (Kodama et al., 1998), or small airway 
epithelial cells (Walsh et al., 1999). This may be directly related to the loss of antigen 
induced inflammatory cytokines such as IL-5, IL-3 and GM-CSF (Stern et al., 1992; 
Simon and Blaser, 1995), and suggests a mechanism whereby eosinophils are removed 
from lung tissue following the cessation of antigen provocation. In this Chapter, 
peripheral blood eosinophil levels and the numbers of eosinophils in BALF returned to 
baseline within 12 and 15 days, respectively, following the cessation of airways 
challenge with OVA (Figures 3.5a and b). Notably, the numbers of eosinophils residing 
in lung tissue remained elevated until the pool of eosinophils in the airway lumen were 
depleted (Figures 3.5b and c). These results correspond to the observations made by 
Ohkawara et al., who in a similar model, have noted resolution of BALF and blood 
eosinophil levels at 15 and 21 days, respectively, and a return to a normal bronchial 
epithelium by day 21 (Ohkawara et al., 1997).  
 
Interestingly, PBLN eosinophil numbers continued to increase until day 6 following the 
cessation of antigen challenge, before falling in parallel with lung tissue levels over the 
next 12 days and finally to baseline levels by day 18 (Figure 3.5c). Mouse eosinophils 
traffic to the draining lymph nodes during the recovery phase of helminth infection 
(Friend et al., 2000), and in conjunction with data presented in this Chapter, suggests a 
potential role for eosinophils in the regulation of draining lymph node function during 
the resolution of Th2 cytokine driven diseases. In the rat, peripheral lymph node high 
endothelial cells express VCAM-1, the expression of which is upregulated by cytokines 
(May et al., 1993). Antibodies to the cognate receptor VLA-4 have been shown to 
reduce eosinophil recruitment to tissue in vivo (Weg et al., 1993), and thus identifies a 
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possible route of entry for peripheral blood eosinophils into the lymph node via high 
endothelial venules. In this Chapter, fluorescently labeled eosinophils were not 
observed to enter draining thoracic lymph nodes via the blood (Figures 3.6 and 3.7), 
suggesting that the afferent lymphatics are the major entry point for eosinophils found 
to reside in peribronchial lymphoid tissue following antigen challenge of the airways.  
 
Eosinophils are phagocytic cells with antigen presenting capacity (Del Pozo et al., 
1992; Weller et al., 1993), and the ability of eosinophils situated in the airways lumen 
to migrate via the lymphatics to sites of antigen presentation has recently been 
confirmed (Shi et al., 2000). Thus, eosinophils that are recruited to the antigen 
challenged lung in sensitised mice may then sample the extracellular milieu, and 
phagocytose endogenous antigen. Within inflamed lung tissue, eosinophils may then 
process and present endogenous antigen to activated memory T lymphocytes, and 
thereby modulate local T cell function and disease progression/resolution. Alternatively, 
recruited eosinophils may sample the contents of the airway lumen, before translocation 
back across airways epithelium and subsequent trafficking to the draining lymph nodes. 
In these tissues, eosinophils may reside for prolonged periods of time following antigen 
challenge in the sensitised organism (Figure 3.5c), and may actively present airways 
derived antigens to antigen-specific T lymphocytes. Thus, the numerous eosinophils 
that are recruited to the antigen challenged lung in the sensitised organism are well 
placed to modulate T lymphocyte function within local tissues and distally via the 
draining lymphatics. It is interesting to note that low numbers of eosinophils were 
present in the blood, airways lumen, and draining lymphoid tissue prior to antigen 
inhalation (Figure 3.2, zero time points), which suggests a role for baseline eosinophils 
in immunological responses associated with immune surveillance and potentially, T cell 
expansion.  
 
It would be interesting to assess the surface expression of MHC-II and associated 
costimulatory molecules, and to further investigate any antigen presenting function 
attributable to lung eosinophils. This may further our understanding of the potential for 
eosinophil/T cell interactions wherein eosinophils may regulate T cell function during 
chronic antigen exposure to the lung. 
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4.1 INTRODUCTION 
 
In Chapter 2, mouse eosinophils were shown to localise to sites of antigen deposition, a 
phenomenon specific to non-allergic mice having a large pool of responsive 
eosinophils. In Chapter 3, eosinophils were observed to populate the draining lymph 
nodes of antigen sensitised and challenged mice during disease progression, and 
persisted in this compartment until well after the cessation of antigen exposure. These 
data showed that eosinophils are well placed to interact with antigen-specific 
lymphocytes during these stages of disease (priming and induction).  
 
The antigen presenting capacity of eosinophils has been partially explored by others, 
and has tended to focus on the surface expression of MHC-II (mouse), HLA-DR 
(human), and costimulatory molecules CD80/B7.1 and CD86/B7.2. Class II MHC 
molecules bind exogenous peptides during their biosynthetic maturation prior to their 
appearance on the cell surface (Watts, 1997; Weenink and Gautam, 1997), and 
subsequent recognition by the TCR provides the first signal necessary for T cell 
activation. Mouse eosinophil expression of MHC-II can be upregulated by in vitro 
incubation with GM-CSF (Del Pozo et al., 1992; Tamura et al., 1996), IL-4 (Mawhorter 
et al., 1993), or by an in vivo disease state, such as parasite infection (Mawhorter et al., 
1993) or AAD (Shi et al., 2000). Human eosinophils can be induced to express surface 
HLA-DR in response to GM-CSF (Lucey et al., 1989), IL-3 (Celestin et al., 2001), and 
this molecule is upregulated in vivo on airways, but not peripheral blood eosinophils 
from allergic asthmatics (Hansel et al., 1991; Sedgwick et al., 1992; Mengelers et al., 
1994; Sakamoto et al., 1996). 
 
The second signal required for T cell activation is an interaction between 
counterreceptors on the surface of antigen presenting cells with the costimulatory 
receptors on T cells (June et al., 1994). The B7-CD28/CTLA-4 costimulatory pathways 
have been shown as essential for development of AAD in mice (Krinzman et al., 1996; 
Keane-Myers et al., 1997). The interaction between CD80 and CD28 is essential for 
eosinophil recruitment to the lung (Harris et al., 1997), and lack of costimulatory 
activity is linked to a defect in IL-4 and IL-5 production by T cells (Harris et al., 2001). 
Alternatively, blocking CD86 but not CD80 function using monoclonal antibodies 
during sensitisation attenuates AAD development in mice (Tsuyuki et al., 1997; Keane-
Myers et al., 1998). The expression of CD80 and CD86 by mouse eosinophils can be 
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upregulated by incubation with GM-CSF (Tamura et al., 1996), and has also been noted 
on activated airway eosinophils from mice with AAD (Shi et al., 2000). In human 
eosinophils, there is less data available for B7 expression, although resting cells can 
express CD86 (but not CD80) in response to IL-3 incubation (Celestin et al., 2001), and 
increased expression by activated eosinophils from eosinophilic donors has also been 
noted (Woerly et al., 1999). 
 
Research using artificial antigen presenting cells has established the minimum 
requirements for T cell activation. Prakken et al. have shown that liposomes bearing 
MHC-II/peptide complexes are engaged by MHC-II restricted T cells, and leads to 
physiological capping of the T cell receptor (Prakken et al., 2000). Alternatively, cells 
infected with recombinant vaccinia virus (rVV) encoding both MHC-II and antigen can 
induce CD4+ T cell proliferative responses, which are further enhanced by the co-
expression of CD80 and CD86 (Oertli et al., 1997). Mouse eosinophils express surface 
MHC-II and B7 costimulatory molecules, and have a demonstrated ability to present 
antigen. Paraformaldehyde-fixed eosinophils that were previously activated with GM-
CSF and incubated with complex antigen, are able to stimulate the proliferation of T 
cell clones and hybridomas in a manner sensitive to anti-MHC-II antibody (Del Pozo et 
al., 1992). The expression of CD80 and CD86 by murine eosinophils obtained from IL-
5 transgenic mice is reported to be essential for antigen presentation to OVA-primed 
lymph node T cells (Tamura et al., 1996). Similarly, live airway eosinophils pre-
cultured with GM-CSF can stimulate allergic T cell proliferation in the presence of 
OVA (Shi et al., 2000). At the completion of the investigations in this thesis, antigen 
presentation by eosinophils had previously been limited to measurement of in vitro T 
cell proliferation and IL-2 production only, with no reports of Th2 cytokine release in 
response to antigen presentation by either mouse or human eosinophils.  
 
In this Chapter the capacity for effective antigen presentation by mouse eosinophils in 
vivo and in vitro is investigated, by (1) examining eosinophil surface expression of both 
MHC-II and co-stimulatory molecules, (2) assessing the eosinophils ability to take up 
and process antigen both in vitro and in vivo, and (3) demonstrating T lymphocyte 
proliferation and cytokine release in response to antigen presentation by mouse 
eosinophils.  
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4.2 MATERIALS AND METHODS 
 
4.2.1 Animals. 
Wild type and IL-5 transgenic mice (Dent et al., 1990) in the C57BL/6 and BALB/c 
backgrounds (N10, male, 4-8 wk old), and C57BL/6 T cell receptor OVA transgenics 
(OT-II, N10) (Barnden et al., 1998), were obtained from the SPF unit of the ANU and 
housed in an approved containment facility. Mice were treated according to ANU 
animal welfare guidelines.  
 
4.2.2 Surface expression of class II MHC by eosinophils isolated from the allergic 
mouse lung. 
BALB/c mice* (H-2d) were OVA sensitised and airways challenged as in Section 3.2.5, 
airways lavaged as in Section 2.2.4, and BALF eosinophils were purified by FACS as in 
Section 2.2.5. Purified BALF eosinophils (105 cells) were then incubated with 
biotinylated M5/114 anti-I-A/I-E antibody (a kind gift from A Gautam, JCSMR, ANU) 
in HBSS for 30 minutes on ice before fetal calf serum underlay to remove any dead 
cells. The cells were then centrifuged at 500 x g for 5 minutes at 4oC, and the 
supernatant removed. The cell pellet was then resuspended in HBSS with streptavidin-
phycoerythrin and incubated for a further 30 minutes on ice. In a separate tube, purified 
BALF eosinophils (105 cells) were incubated with FITC-conjugated conformation-
dependent anti-I-A (MKD6) (Germain and Hendrix, 1991) for 30 minutes on ice. All 
cells were then underlaid with fetal calf serum and centrifuged at 500 x g for 5 minutes 
at 4oC prior to removal of the supernatant and resuspension of cell pellets in ice cold 
HBSS. All tubes were protected from incident light at all times, and kept on ice before 
prompt analysis of fluorescence by Becton and Dickinson FACScan® flow cytometer 
using Cellquest (Becton and Dickinson, San Jose, CA). Data was further analysed using 
WinMDI software (kindly provided by J. Trotter, Scripps Research Institute, La Jolla, 
CA), and eosinophil-gated regions determined based on forward and side scatter 
signals. Fluorescent cells (MHC II+) were detected in the FL-1 (MKD6-FITC) and FL-2 
(MHC II-PE) channels, and compared to cells incubated with streptavidin-PE alone, or 
unlabelled control cells.  
* At the time, only the M5/114 antibody was available to detect surface MHC-II (H-2d), which restricted 
this particular aspect of the experimental procedures to BALB/c mice.  
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4.2.3 Surface expression of CD80 and CD86 by eosinophils isolated from the 
allergic mouse lung. 
C57BL/6 mice were OVA sensitised and airways challenged as in Section 3.2.5, 
airways lavaged as in Section 2.2.4, and BALF eosinophils were purified by FACS as in 
Section 2.2.5. Purified C57BL/6 BALF eosinophils (105 cells) were then separately 
incubated in HBSS with PE-conjugated anti-mouse CD80 or CD86 (BD PharMingen, 
San Diego, CA) for 30 minutes on ice before FCS underlay to remove any dead cells. 
As a control, disaggregated mouse spleen cells (erythrocytes lysed) were also incubated 
(105 cells) in HBSS with PE-conjugated anti-mouse CD80 as for purified eosinophils. 
Cells were then centrifuged at 500 x g for 5 minutes at 4°C, and the supernatant 
removed. Cell pellets were resuspended in ice cold HBSS. Labeled cells were protected 
from incident light at all times, and kept on ice before prompt analysis of fluorescence 
by Becton and Dickinson FACScan® flow cytometer using Cellquest (Becton and 
Dickinson, San Jose, CA). Data was further analysed using WinMDI software (kindly 
provided by J. Trotter, Scripps Research Institute, La Jolla, CA), and eosinophil-gated 
regions determined based on forward and side scatter signals. Fluorescent cells (CD80+ 
or CD86+) were detected in the FL-2 channels and compared to unlabelled control cells.  
 
4.2.4 Eosinophil internalisation and processing of OVA in vitro. 
Purified eosinophils from C57BL/6 IL-5-transgenic mice were used to demonstrate 
cellular internalization and processing of OVA in vitro. Briefly, IL-5-transgenic mice 
were sacrificed by CO2 asphyxiation and the peritoneal cavity lavaged as in Section 
2.2.2. Eosinophils in the PEC population were then purified by FACS as in Section 
2.2.5, and diluted as required into HBSS and kept on ice. Eosinophils (105) were 
incubated with 1 mg/ml OVA (Sigma) or DQ-OVA (Molecular Probes) in 1 ml of 
HBSS for 30 or 240 minutes at 37°C. Cells were then washed three times in 10 ml of 
PBS before fixing in 4% paraformaldehyde in PBS. Analysis of fixed cells was 
performed using a Becton and Dickinson FACScan® flow cytometer using Cellquest 
(Becton and Dickinson, San Jose, CA), and data further analysed using WinMDI 
software (kindly provided by J. Trotter, Scripps Research Institute, La Jolla, CA). 
Eosinophil-gated regions were determined based on forward and side scatter signals and 
fluorescent cells (DQ-OVA+) detected in the FL-1 channel were compared with cells 
incubated with unconjugated OVA.  
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4.2.5 Eosinophil internalisation and processing of OVA in vivo. 
To demonstrate cellular internalization and processing of OVA in vivo, wild type 
C57BL/6 mice were sensitized and airways challenged with OVA as in Section 3.2.5. 
Following airways challenge on days 24, 26, 28, and 30, mice were given 1 x intranasal 
doses of OVA or DQ-OVA (1 mg) in HBSS. The DQ-OVA challenges were done in 
this manner to directly coincide with each individual aerosol. Twenty-four hours after 
the last aerosol challenge and DQ-OVA administration, mice were sacrificed by 
cervical dislocation and their airways were lavaged as in Section 2.2.4. Intracellular 
processing of DQ-OVA by BALF cells was detected using flow cytometry as in Section 
4.2.4. 
 
4.2.6 OVA transgenic splenocyte proliferation in response to co-incubation with 
OVA peptide-pulsed and paraformaldehyde treated eosinophils. 
To generate antigen loaded eosinophils, C57BL/6 mice were OVA sensitised and 
airways challenged as in Section 3.2.5, and eosinophils in BALF (Section 2.2.4) were 
then purified by FACS as in Section 2.2.5. Purified BALF eosinophils (5 x 106) were 
then incubated in PBS containing 1 mg/ml OVA323-339 peptide (ISQAVHAAHAEIN-
EAGR) at 37oC for 15 minutes, before being centrifuged at 500 x g for 5 minutes at 
4°C, and the supernatant removed. Cell pellets were resuspended in ice cold PBS 
containing 4% paraformaldehyde for 30 minutes on ice, before being centrifuged at 500 
x g for 5 minutes at 4°C, and the supernatant removed. Cell pellets were then incubated 
overnight in 20ml PBS at 4oC to leech out any residual paraformaldehyde. Cells were 
again centrifuged at 500 x g for 5 minutes at 4°C, and the supernatant removed, before 
resuspension in MLC medium containing 10% FCS. Freshly isolated BALF eosinophils 
were also fixed in paraformaldehyde as OVA323-339 peptide free controls.  
 
OT-II transgenic mice (male) were chosen for their specific responses to OVA, and in 
particular OVA323-339 peptide (Barnden et al., 1998; Robertson et al., 2000). Mice were 
sacrificed by cervical dislocation and their spleens excised. Splenocytes were 
disaggregated using sterile wire gauze (0.5mm) and suspended in ice cold PBS. 
Erythrocytes were then lysed, and the washed splenocytes resuspended at 107 cells/ml 
in MLC medium containing 10% heat-inactivated FCS, 2 mM L-glutamine, and 50 
mg/L neomycin sulfate. Fixed and OVA323-339 peptide-pulsed eosinophils were co-
cultured with 2 x 106 OT-II splenocytes at the following concentrations. A; no stimulus 
control, B-E; 1 x 104, 5 x 104, 1 x 105, 5 x 105 peptide-pulsed eosinophils, F; 5 x 105 
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peptide-free eosinophils. OT-II splenocytes were also incubated with OVA323-339 
peptide as a control (G). Cultures were in 200 µl final volume, in 96-well tissue culture 
plates. At 48 hours, the tissue culture plates were centrifuged at 300 x g for 5 minutes at 
RT, and spent media replaced with fresh media (200 µl) containing tritiated thymidine 
(3H-thymidine, 1µCi/well). At 72 hours of co-culture, the contents of each well were 
harvested onto a glass fibre filter (Packard, Canberra) using a Filtermate 196 cell 
harvester (Packard, Canberra). Fibre mats were then assembled in the appropriate 
cassette with MicroScint-O fluid (Packard, Canberra) and tritiated thymidine 
incorporation as represented by counts per minute (CPM) measured using a Packard 
TopCount NXT (Packard Instrument Company INC, IL). Data are presented as means ± 
SEM from triplicate wells.  
 
4.2.7 Allergic splenocyte proliferation in response to soluble OVA: co-incubation 
with eosinophils. 
C57BL/6 mice were OVA sensitised and airways challenged as in Section 3.2.5, and 
eosinophils in BALF (Section 2.2.4) were then purified by FACS as in Section 2.2.5. 
For co-incubation, excised spleens from OVA sensitised and airways challenged 
C57BL/6 mice were disaggregated using sterile wire gauze (0.5mm) and splenocytes 
suspended in ice cold PBS. Erythrocytes were then lysed, and the washed splenocytes 
resuspended at 107 cells/ml in MLC medium containing 10% heat-inactivated FCS, 2 
mM L-glutamine, and 50 mg/L neomycin sulfate. Purified BALF eosinophils (1 x 105) 
were then co-incubated with allergic splenocytes (2 x 106) in 96 well tissue culture 
plates with or without added OVA (100 µg/well). At 48 hours, the tissue culture plates 
were centrifuged at 300 x g for 5 minutes at RT, and spent media replaced with fresh 
media (200µl) containing tritiated thymidine (1µCi/well). At 72 hours of co-culture, the 
contents of each well were harvested and 3H-thymidine incorporation measured as in 
Section 4.2.6.  
 
4.2.8 Isolation of in-vivo generated OVA specific CD4+ T cells. 
C57BL/6 mice were OVA sensitised and airways challenged as in Section 3.2.2, and 
excised spleens from these mice were disaggregated using sterile wire gauze (0.5mm) 
and, splenocytes suspended in ice cold PBS. Erythrocytes were then lysed, and the 
washed splenocytes (~ 1 x 108) were suspended in 90 µl HBSS/5% FCS with 10 µl anti 
CD4 mAb (L3T4) coated microbeads and incubated for 20 minutes at 6-12oC. 
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Suspensions were then centrifuged at 500 x g for 5 minutes at 4oC and the resultant cell 
pellet resuspended in 1 ml PBS/0.5 % BSA. Bead-bound CD4+ cells were then isolated 
using high-gradient magnetic MiniMacs separation columns (MACS separation, 
Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) as per manufacturers 
instructions. Isolated cells were then washed and resuspended in MLC medium/10% 
FCS. The CD4- fraction (unbound cells) were retained as a source of antigen presenting 
cells. The purity of the enriched CD4+ cell fraction were then determined by flow 
cytometry. 
 
4.2.8.1 Assessment of isolated CD4+ T cell purity by flow cytometry. 
MACS enriched CD4+ cells (105) from Section 4.2.8 were resuspended in HBSS 
containing PE-conjugated anti mouse CD4 (CD4+-PE) (PharMingen, San Diego, CA, 
clone L3T4) for 30 minutes on ice and underlaid with foetal calf serum. The cells were 
then centrifuged at 500 x g for 5 minutes at 4oC. The supernatant was then removed, 
and the cell pellet resuspended in HBSS at 4oC and promptly analysed by flow 
cytometry, using a Becton and Dickinson FACScan® flow cytometer and Cellquest 
software (Becton and Dickinson, San Jose, CA). Raw data was further analysed using 
WinMDI software (kindly provided by J. Trotter, Scripps Research Institute, La Jolla, 
CA).  
 
4.2.8.2 Cytokine production from isolated OVA-specific CD4+ T cells incubated with 
eosinophils and soluble OVA. 
C57BL/6 mice were OVA sensitised and airways challenged as in Section 3.2.5, and 
eosinophils in BALF (Section 2.2.4) were then purified by FACS as in Section 2.2.5. 
Purified CD4+ T cells (5 x 105 cells/well) were incubated in 96-well tissue culture plates 
with purified BALF eosinophils (3 x 104, 5 x 104, and 1 x 105 cells/well) in MLC 
medium/10% FCS with 200 µg/ml OVA. Cell-free culture supernatants were collected 
96 h later and stored in aliquots at -70°C before measurement of IL-4, IL-5, and IL-13. 
For comparison, CD4+ cells (5 x 105 cells/well) were also cultured under the same 
conditions with mitomycin C (25 µg/ml)-treated splenocytes (5 x 105 cells/well, the 
CD4- fraction of Section 4.2.8) as a source of conventional antigen presenting cells. 
Supernatants were collected 96 hours later for cytokine analysis.  
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4.2.9 In vitro generation of OVA-specific CD4+ Th2 cells. 
OVA-specific CD4+ T cells were derived from BALB/c mice (6–8 wk of age). Mice 
were sensitized by i.p. injection with 50 µg OVA/1 mg Alhydrogel (Commonwealth 
Serum Laboratories, Parkville, Australia) in 0.9% sterile saline. Six days after 
sensitization, donor mice were sacrificed by cervical dislocation, the spleens were 
excised, and the splenocytes were disaggregated. Erythrocytes were lysed, and the 
washed splenocytes were resuspended at 5 x 106 cells/ml in complete tissue culture 
medium consisting of HL-1 (BioWhittaker, Walkersville, MD) with 10% heat-
inactivated FCS, 2 mM L-glutamine, and 50 mg/L neomycin sulfate. Splenocytes were 
then cultured for 4 days at 37°C in the presence of 200 µg/ml OVA, recombinant 
murine IL-4 (20 ng/ml), and anti-IFN-γ antibody (clone R46A2, 40 µg/ml) to generate 
Th2 cells. CD4+ Th2 cells were then isolated using high-gradient magnetic MiniMacs 
separation columns as described in Section 4.2.8. The purity of the enriched CD4+ T 
cell fraction was uniformly above 95% as determined by flow cytometry (as in Section 
4.2.8.1, result not shown).  
 
4.2.9.1 Eosinophil incubation with OVA-specific CD4+ Th2 cells generated in vitro. 
In vitro derived Th2 cells were cocultured with and without eosinophils, to determine 
their ability to act as antigen presenting cells. Eosinophils enriched from the peritoneal 
cavities of BALB/c IL-5-transgenic mice (as for PMBS mice in Section 2.2.5), were 
cultured in equal numbers with Th2 cells (5 x 105 cells/well) in complete medium in the 
presence of 200 µg/ml OVA in 96-well plates (250 µl/well). For comparison, Th2 cells 
(5 x 105 cells/well) were also cultured under the same conditions with mitomycin C (25 
µg/ml)-treated splenocytes (5 x 105 cells/well) (as a source of conventional antigen 
presenting cells). Supernatants were collected 96 hours later for cytokine analysis.  
 
4.2.10 Cytokine analysis. 
IL-13, IL-4 and IL-5 concentrations were determined in the supernatants from OVA-
stimulated CD4+ T cells by ELISA. Briefly, round bottomed immunoassay plates were 
coated with 50µl anti-mouse IL-13 (R&D Systems, Minneapolis, MN), anti-mouse IL-4 
(BD PharMingen), or anti-mouse IL-5 (TRFK5) and incubated at 4oC overnight. Plates 
were then blocked with 2% skim milk powder in PBS-Tween20 (0.04%) for 1 hour at 
37oC, and incubated with serial dilutions of cultured supernatants or standard IL-13, IL-
4 or IL-5. Mouse IL-13, IL-4 and IL-5 were detected with biotinylated anti-mouse IL-
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13 (R&D Systems, Minneapolis, MN), anti-mouse IL-4 (BD PharMingen), or anti-
mouse IL-5 (BD PharMingen) respectively. Plates were then incubated with 
streptavidin-conjugated alkaline-phosphatase (Amersham International plc, 
Buckinghamshire, UK) for 1 hour at 37oC, washed, and alkaline-phosphatase substrate 
solution (Sigma Chemical Co. St Louis, MO) was added. Where necessary, reactions 
were stopped with 1M citric acid, or promptly analysed. Plates were read by a 
Microplate reader (BIO-TEK Instruments Inc., Winooski, VT) at 490 nm with reference 
to 405 nm. 
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4.3 RESULTS 
 
4.3.1 Eosinophils from the allergic lung express surface MHC-II and costimulatory 
molecules CD80 and CD86.  
Eosinophil expression of molecules necessary for presentation of exogenous antigens to 
T cells was assessed using M5/114 and MKD6 antibodies, which recognise mouse 
MHC-II. Eosinophils from allergic BALB/c mice (H-2d) were chosen for MHC-II 
analysis in view of the fact that MKD6 is an anti-Aβd antibody, having demonstrated 
affinity for peptide loaded MHC-II (Germain and Hendrix, 1991). The M5/114 antibody 
is specific for both I-A and I-E subregion-encoded glycoproteins (I-Ab, I-Ad, I-Aq, I-Ed, 
I-Ek, not I-Af, I-Ak, or I-As) (Bhattacharya et al., 1981; Germain et al., 1982). 
Eosinophils purified from the BALF of allergic BALB/c mice expressed MHC-II as 
measured by M5114 antibody binding (Figure 4.1e), and further expressed peptide-
loaded MHC-II molecules as measured by MKD6 antibody binding (Figure 4.1f). The 
surface expression of costimulatory molecule by eosinophils was also assessed. 
Eosinophils obtained from the lung of allergic C57BL/6 mice had detectable 
CD80/B7.1 (Figure 4.2c) and CD86/B7.2 expression (Figure 4.2d).  
 
Collectively, these data confirm recent observations of eosinophil MHC-II and B7 
molecule expression (Tamura et al., 1996; Keane-Myers et al., 1997; Tsuyuki et al., 
1997; Shi et al., 2000), which are intimately involved in antigen presentation and 
delivering costimulatory signals during T cell priming with antigen.  
 
4.3.2 Eosinophils can acquire and process exogenous antigen in vitro and in vivo. 
The uptake of exogenous antigen by mouse eosinophils was investigated using the self 
quenching antigen DQ-OVA, which is OVA that has been heavily labeled with the 
fluorescent dye 3-10 Bodipy-FL, resulting in almost total quenching of the conjugate 
fluorescence (Santambrogio et al., 1999). It was hypothesised that upon uptake and 
subsequent intracellular proteolysis, Bodipy-labeled fluorescent peptides would be 
released, and any measurable increase in cellular fluorescence would imply cellular 
uptake and processing of exogenous antigen. The ability of eosinophils from BALF of 
allergic animals to take up and process DQ-OVA in vitro was investigated and the 
results shown in Figure 4.3. It is clear that eosinophils can take up and process 
exogenous DQ-OVA, as demonstrated by increased fluorescence observed with longer 
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Figure 4.1. Eosinophils express surface MHC-II. Enriched BALF eosinophils from BALB/c mice with AAD (a) were gated (R1) on the basis of 
forwards and side scatter, and auto fluorescence (d, open histogram) compared with streptavidin-PE incubated eosinophils (d, red). Eosinophils stained 
with anti I-A/I-E antibody (b) show increased fluorescence intensity (e, red) in comparison to eosinophils incubated with streptavidin-PE (e, open 
histogram). To determine surface expression of MHC-II bearing cognate peptide, eosinophils were incubated with MKD6-FITC (c), and increased 
fluorescence intensity (f, red) demonstrated in comparison to control cells (f, open histogram). 
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Figure 4.2. Eosinophils express CD80 and CD86 costimulatory molecules. Enriched 
eosinophils from C57BL/6 mice with AAD (a) stained with anti-CD80-PE were gated 
(R1) on the basis of forwards and side scatter, and auto fluorescence of unstained cells 
(c, open histogram) compared with CD80+ cells (c, red). Enriched eosinophils (b) 
stained with anti-CD86-PE were gated (R1) on the basis of forwards and side scatter, 
and auto fluorescence of unstained cells (d, open histogram) compared with CD86+ cells 
(d, red). 
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Figure 4.3. Eosinophils take up and process exogenous antigen in vitro. Enriched BALF eosinophils mice with AAD were incubated in vitro with DQ-
OVAtm for intervals of 30 and 240 minutes. Control cells (a) were gated on the basis of forwards and side scatter, and auto fluorescence of unstained 
cells illustrated (d, red). Eosinophils incubated with DQ-OVAtm for 30 minutes (b) showed increased fluorescence (e, red) when compared to control 
cells (e, open histogram). Eosinophils incubated with DQ-OVAtm for 240 minutes (c) showed further increased fluorescence (f and g, red) when 
compared to control cells (f, open histogram), and to cells incubated for 30 minutes (g, open histogram in blue). 
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incubation times (Figure 4.3d-g). To investigate this phenomenon in vivo, mice with 
allergic airways inflammation were administered either DQ-OVA or OVA via the 
intranasal route following each exposure to aeroallergen. On investigation, BALF 
eosinophils were shown to have increased fluorescence when compared to controls 
(Figure 4.4), indicating uptake and processing of this exogenous antigen in vivo. 
Increased fluorescence was not detected in the lymphocyte population of BALF (not 
shown).  
 
4.3.3 Peptide pulsed and fixed eosinophils promote 3H-thymidine incorporation in 
OT-II splenocytes. 
Previous work by Del Pozo et al. has demonstrated the ability of fixed mouse 
eosinophils to promote antigen specific T cell proliferation in vitro (Del Pozo et al., 
1992). Similarly, human eosinophils pulsed with tetanus toxoid can promote T cell 
proliferation in vitro, in a manner sensitive to anti HLA-DR antibodies (Weller et al., 
1993). In this section, OT-II mice (Barnden et al., 1998), were chosen for their OVA 
specificity and ease in preparation of uniform populations of responder cells. 
Eosinophils from BALF of allergic mice were incubated with OVA peptide (OVA323-
339) and fixed prior to co-incubation with OT-II splenocytes. Figure 4.5a shows that 
peptide loaded eosinophils promoted 3H-thymidine uptake in OT-II splenocytes in a 
dose and peptide dependent manner, suggesting BALF eosinophils have the capacity to 
present OVA peptides to OVA specific T cells. However, subsequent attempts to further 
investigate eosinophil/OT-II interactions using live eosinophils, isolated CD4+ 
transgenic splenocytes, and whole OVA were unsuccessful, for reasons that are further 
explored in Chapter 6. 
 
4.3.4 Eosinophils augment 3H-thymidine incorporation by allergic splenocytes 
incubated with soluble OVA. 
The ability of live eosinophils to augment 3H-thymidine uptake in splenocytes from 
allergic mice was investigated. Previous attempts by others (Del Pozo et al., 1992) 
suggested that live eosinophils may degranulate during co-incubation unless fixed. To 
overcome this, low numbers of eosinophils (1 x 105/well) were co-incubated with 
responders (2 x 106/well) giving a final ratio of 20:1 for responders to eosinophils. At 
this concentration, live eosinophils were found to supplement 3H-thymidine 
incorporation in splenocytes in the presence of soluble antigen (Figure 4.5b), suggesting 
a possible role for eosinophils in antigen presentation to splenocytes from allergic mice.   
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Figure 4.4. Eosinophils take up and process exogenous antigen in vivo. OVA sensitised 
and challenged mice were administered intranasal DQ-OVAtm or unlabelled OVA in 
HBSS following each exposure to aerosolised allergen. BALF from control mice (a) 
that received unlabelled OVA were gated on the basis of forwards and side scatter, and 
auto fluorescence of control eosinophils is illustrated (c, red). BALF from DQ-OVAtm 
treated mice (b) show increased fluorescence (d, red) when compared to control cells (d, 
open histogram).  
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Figure 4.5. Eosinophils promote splenocyte proliferation. (a) Fixed and OVA323-339 peptide-pulsed eosinophils were co-cultured with 2 x 106 OT-II 
splenocytes at the following concentrations. A; no eosinophils, B; 5 x 105 peptide-free eosinophils, C-F; 1 x 104, 5 x 104, 1 x 105, 5 x 105 peptide-
pulsed eosinophils, and G; splenocytes incubated with OVA323-339 peptide only. (b) Eosinophils (1 x 105) purified from BALF of mice with AAD were 
co-incubated with splenocytes (2 x 106) from AAD mice in the presence or absence of 100 µg OVA. Incubation conditions were as follows A; 
splenocytes alone, B; splenocytes and eosinophils, C; splenocytes and 100 µg OVA, D; splenocytes, eosinophils and 100 µg OVA. Data represents 
mean ± SEM for triplicate wells. Significant differences in means were determined by Student’s unpaired t test (P < 0.05), and are indicated by * 
(when compared to condition A) or by bars (¬).  
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4.3.5 Eosinophils promote IL-5 production from CD4+ T cells isolated from mice 
with AAD.  
Purified CD4+ T cells (Figure 4.6) were used to investigate the antigen presenting 
capacity of BALF eosinophils in vitro. Purified eosinophils from the BALF of mice 
with AAD were co-incubated with MiniMacs enriched OVA-specific CD4+ T cells in 
the presence of soluble OVA, and IL-4, IL-5, and IL-13 secretion measured as an 
indicator of antigen presentation. Figure 4.7 shows that increasing the numbers of 
eosinophils from 3 x 104 to 1 x 105/well in the presence of soluble OVA resulted in 
greater IL-5 production by CD4+ T cells. Very small amounts of IL-4 and IL-13 were 
detected, but were not significantly different between the different treatment conditions 
(not shown), and prompted the search for a more tightly controlled in vitro culture 
condition whereby Th2 cytokine production could be investigated.  
 
4.3.6 Eosinophils promote IL-4, IL-5 and IL-13 production from Th2 cells 
generated in vitro.  
Purified eosinophils from IL-5-transgenic mice were able to induce IL-4, IL-5, and IL-
13 production in Th2 cells in an antigen specific manner (Figure 4.8), and in amounts 
comparable to mitomycin C treated APCs. The amount of IL-5 production (~189 ng/ml) 
was greater than that seen when using C57BL/6 CD4+ splenocytes (Figure 4.7, ~8-11 
ng/ml), and detectable levels of IL-4 and IL-13 justified the choice of using BALB/c 
eosinophils and in vitro derived Th2 cells. Thus, murine eosinophils are able to induce 
proinflammatory cytokine secretion from CD4+ Th2 cells polarized in vitro.  
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Figure 4.6. Flow cytometry analysis of CD4+ splenocytes purified by high-gradient 
magnetic MiniMacs separation columns. (a) Representative dotplot of MiniMacs 
enriched CD4+ splenocytes from C57BL/6 mice with AAD incubated in HBSS alone, 
and autofluorescence (c) illustrated below. The lymphocyte gated region (R1) was 
determined based on forward- and side-scatter signals. (b) Representative dotplot of 
MiniMacs enriched CD4+ splenocytes from allergic airways disease (AAD) mice 
stained with PE-cojugated anti-mouse CD4, and fluorescence (d) shown below. (e) 
Representative histogram of MiniMacs enriched CD4+ splenocytes from AAD mice. 
Filled histogram shows that CD4+ cells were consistently >95% (under marker, M1) of 
total cells. Open histogram represents unstained CD4+ splenocytes.  
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Figure 4.7. Eosinophils induce IL-5 production when co-incubated with CD4+ 
splenocytes. Enriched BALF eosinophils from C57BL/6 mice with AAD stimulated IL-
5 secretion from MiniMacs purified CD4+ splenocytes in the presence of exogenous 
OVA (100µg/well) (EOS/CD4/OVA). Increasing the numbers of eosinophils from 3 x 
104 (30K) to 1 x 105 (100K) resulted in greater production of IL-5 by CD4+ T cells. For 
comparison, CD4+ T cells from allergic C57BL/6 mice secreted IL-5 when stimulated 
with APCs (1x105, CD4- fraction) in the presence of exogenous OVA (100µg/well) 
(CD4/APC/OVA). For controls, 5 x 104 eosinophils (50K Eos) and 2 x 106 CD4+ 
splenocytes (CD4) were plated individually with no other stimuli. Data represents mean 
± SEM for triplicate wells. Significant differences in means were determined by 
Student’s unpaired t test (P < 0.05). 
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Figure 4.8. Eosinophils promote IL-4 and IL-5 production from in vitro derived Th2 cells. Co-culture of eosinophils (5 x 105 cells/well) isolated from IL-5-
transgenic BALB/c mice with in vitro-polarized Th2 cells (5 x 105 cells/well) resulted in elevated levels of IL-4 (a), IL-5 (b), and IL-13 (c). Th2 cells incubated with 
eosinophils (Eos/Th2/OVA) or mitomycin C-treated splenocytes (Th2/APC/OVA) in the presence of OVA produced similar levels of cytokines. Th2 cells incubated 
with eosinophils (Eos/Th2) or mitomycin C-treated splenocytes (Th2/APC) without OVA did not promote measurable production of cytokine (ND: not detected). 
Data represents mean ± SEM for triplicate wells.  
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4.4 DISCUSSION 
 
In this Chapter, the capacity for mouse airway eosinophils to present antigen in vitro 
was assessed, in an attempt to establish the potential for these cells to exacerbate AAD 
in vivo. During the maintenance of AAD, the inflamed lung and draining lymphoid 
tissue provides an ideal microenvironment rich in IL-5 (Jarjour et al., 1997; Ohkawara 
et al., 1997; Gajewska et al., 2001), which is conducive to eosinophil survival and 
persistence (Yamaguchi et al., 1988). In Chapter 3, eosinophils were shown to populate 
the lung and draining lymphoid tissues during AAD maintenance and disease 
resolution, leaving them well placed to present exogenous antigen to T cells and to 
modulate disease progression. Although eosinophils are regarded as relatively 
inefficient in comparison to professional APCs (Del Pozo et al., 1992; Mawhorter et al., 
1994), their abundance in allergic airway and draining lymphoid tissues may permit a 
cumulative and en masse presentation of antigen to responding T cell populations, 
irrespective of their relative efficiency as APCs.  
 
Expression of functional MHC-II on APCs is necessary for effective antigen 
presentation to T lymphocytes (Martin et al., 1996b), and eosinophils from mice with 
AAD were consequently investigated for MHC-II expression. Airway eosinophils from 
mice with AAD express surface MHC-II (Figure 4.1), which agreed with the results of 
Shi et al, who have also demonstrated expression of these molecules in BALB/c mice 
(Shi et al., 2000). In Figure 4.1f, airway eosinophils are stained with MKD6, which 
reportedly recognises the altered tertiary structure of surface MHC-II combined with 
cognate peptide (Germain and Hendrix, 1991), and suggests that airway eosinophils in 
mice with AAD may associate exogenous antigens with MHC-II dimers, prior to their 
appearance on the cell surface. 
 
The costimulatory molecules CD80 and CD86 enhance T cell responses to antigen 
presentation (Oertli et al., 1997), and are important for AAD induction and progression. 
In a mouse model of AAD, use of CTLA4-IG fusion protein to block CD28-B7 
costimulatory interactions prior to sensitisation (Keane-Myers et al., 1997), and during 
exposure to aeroallergen (Krinzman et al., 1996), inhibits inflammatory infiltrate, 
airways hyperreactivity and T cell responses to antigen. In Figure 4.2, airway 
eosinophils from C57BL/6 mice with AAD are shown to express both CD80 and CD86 
co-stimulatory molecules to an extent comparable with reported levels for allergic 
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BALB/c mice (Shi et al., 2000). Thus, in addition to expression of MHC-II, airway also 
express the co-stimulatory molecules necessary for effective antigen presentation.  
 
However, expression of surface MHC-II and costimulatory molecules does not 
automatically infer antigen presenting capability of eosinophils. Prior to MHC-mediated 
presentation at the cell surface, exogenous proteins must be subjected to intracellular 
processing by endosomal and lysosomal proteases, before stable association with MHC-
II molecules within MHC-II compartments (Weenink and Gautam, 1997). In the allergic 
mouse lung, eosinophils may constitute 60-70% of the inflammatory infiltrate 
responding to repeated aeroallergen challenge. Although this granulocyte population 
express MHC-II and the costimulatory molecules effective for antigen presentation to T 
cells, their ability to take up and process aeroallergen in situ is unknown. Self 
quenching fluorescent OVA (DQ-OVA) (Santambrogio et al., 1999) was therefore used 
to demonstrate antigen loading and processing by airway eosinophils from OVA 
sensitised mice. In Figure 4.3, freshly isolated airway eosinophils from allergic 
C57BL/6 mice displayed increased fluorescence as a function of time following 
incubation with DQ-OVA. This denotes an ability of airway eosinophils to process DQ-
OVA, presumably by the action of endosomal and lysosomal proteases, which in turn 
generate fluorescent intracellular fragments of the parent protein. Upon investigation, 
eosinophils isolated from the allergic lung both incorporated and processed DQ-OVA 
(Figure 4.4), suggesting that eosinophils have the capacity to sample the extracellular 
milieu, and thereby take up and process aerosolised antigens within the airways.  
 
Prior to these experiments, eosinophils were already known to present antigen to T cells 
in vitro. Del Pozo et al., have previously demonstrated the ability of murine eosinophils 
to stimulate T cell clones and hybridomas following incubation with both simple (no 
requirement for intracellular processing) and complex (requirement for processing) 
antigens (Del Pozo et al., 1992). In the results presented in this Chapter, eosinophils 
from BALF of AAD C57BL/6 mice were initially tested for their ability to present the 
OVA peptide OVA323-339 (no requirement for intracellular processing) to OT-II 
splenocytes (Figure 4.5a). Peptide loaded and fixed eosinophils were shown to stimulate 
OT-II splenocyte proliferation in a dose dependent manner, however subsequent 
attempts to use live eosinophils to detect cytokine secretion were unsuccessful (not 
shown), and the reasons for this are further explored in Chapter 6. 
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Logically, the next step was to investigate live eosinophil interactions with T cells from 
allergic mice. Initially, airway eosinophils from mice with AAD were incubated with 
allergic splenocytes in the presence of exogenous antigen, and shown to augment 
splenocyte proliferation (Figure 4.5b). This is not the only reported augmentation of T 
cell responses attributable to eosinophils. Since this work was completed, the adoptive 
transfer of eosinophils to allergic IL-5/eotaxin-/- mice has been shown to restore IL-13 
production in T cells, possibly via a direct interaction as antigen presenting cells, and 
involving eosinophil release of IL-18 into the inflammatory microenvironment (Mattes 
et al., 2002).  
 
The ability of eosinophils to supplement allergic splenocyte responses shown in Figure 
4.5b prompted a more detailed evaluation of the interaction between eosinophils and 
antigen specific T cells, to determine if eosinophils could interact directly with 
responding T cells as antigen presenting cells. Eosinophils from the BALF of C57BL/6 
mice with AAD were co-cultured with purified CD4+ splenocytes from the same mice 
(Figure 4.8). In the presence of exogenous OVA, increasing numbers of eosinophils 
induced increasing amounts of IL-5 secretion, although significant levels of IL-13 and 
IL-4 were not detected under these culture conditions. 
 
It has previously been reported that both IL-4 and IL-5 production in splenocyte 
cultures from C57BL/6 mice are lower than those of BALB/c mice when stimulated 
with OVA in vitro (Morokata et al., 1999). Therefore the final experiment described in 
this Chapter was conducted using IL-5 transgenic eosinophils (Dent et al., 1990), and in 
vitro derived Th2 cells from the BALB/c background. This experiment was designed to 
determine Th2 cytokine production (IL-4, IL-5 and IL-13) from in vitro derived CD4+ T 
cells, using an enriched population of eosinophil APCs isolated from non-allergic mice, 
thus ensuring that the only available antigen was that which was added to the cultures. 
Figure 4.8 shows the ability of eosinophils acting as APCs to induce secretion of the 
Th2 cytokines IL-4, IL-5 and IL-13, in amounts comparable to that induced by 
mitomycin C treated splenocytes (as APC controls). To the author’s knowledge, this 
was the first observation of in vitro Th2 cytokine release when using eosinophils as 
APCs and in vitro derived Th2 cells. However, it is pertinent to note that eosinophils 
may also express these proinflammatory cytokines (Desreumaux et al., 1993; 
Dubucquoi et al., 1994; Lamkhioued et al., 1995; Nonaka et al., 1995; Bjerke et al., 
1996; Lamkhioued et al., 1996; Moller et al., 1996a; Moller et al., 1996b), and may 
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have contributed to cytokine release from antigen-reactive T cells. Interestingly, 
ligation of CD28 expressed by human eosinophils has recently been shown to induce 
the release of granule associated IL-13 (Woerly et al., 2002). Activated T lymphocytes 
in human peripheral blood express CD80 (B7/BB1) (Azuma et al., 1993), and identifies 
a possible mechanism for IL-13 release from CD28 expressing eosinophils interacting 
with CD80+ T lymphocytes. Ultimately, TCR engagement by MHC-II on eosinophils 
may promote Th2 cytokine release into the inflammatory microenvironment. 
 
In this Chapter, the capacity of eosinophils to act as antigen presenting cells has been 
investigated. It has been established that eosinophils from the allergic airway express 
MHC-II and costimulatory molecules necessary for effective antigen presentation to T 
cells (Figures 4.1 – 4.2), and that airway eosinophils are able to sample the extracellular 
milieu and to process exogenous antigen into smaller antigenic fragments (Figures 4.3-
4.4). Furthermore, eosinophils present OVA to CD4+ T cells, and promote IL-4, IL-5 
and IL-13 Th2 cytokine secretion in amounts similar to that of other (splenic) APCs 
(Figures 4.7-4.8). Collectively, these in vitro results show the capacity for eosinophils 
to act as APCs to antigen-specific T cells. By inference, eosinophils that are recruited to 
the allergic airways and draining lymphoid tissue during AAD progression may sample 
the extracellular milieu, and ultimately present OVA peptides to resident OVA-specific 
T cells. This putative interaction may be enhanced by increasing numbers of eosinophils 
that are recruited to this tissue, which promote T cell release of IL-4, IL-5, and IL-13 
and thereby exacerbate airways inflammation following repeated exposure to 
aeroallergen.  
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5.1 INTRODUCTION 
 
In mouse models of allergic airways disease, conventional sensitisation via i.p. injection 
with antigen/adjuvant and subsequent airways challenge with relevant antigen produces 
hallmark characteristics of asthma, including the appearance of antigen specific 
immunoglobulins in serum, peripheral blood eosinophilia, inflammatory cell infiltration 
and remodeling of the airways, and bronchospasm in response to methacholine 
challenge (Foster et al., 1996; Temelkovski et al., 1998; Wang et al., 1998; Inman et al., 
1999; Kumar et al., 2002). Non-conventional sensitisation to relevant antigen can also 
be achieved using the individual humoral and cellular components of allergic airway 
disease. For example, the passive transfer of allergen-specific IgE producing B cells to 
naïve mice can induce allergen-induced airway hyperresponsiveness (Lack et al., 1995), 
and transfer of allergen-specific IgE antibody alone is sufficient to induce both airway 
hyperresponsiveness and lung eosinophilia following airways exposure to relevant 
antigen (Oshiba et al., 1996). Alternatively, the transfer of antigen-specific IL-5 
producing T cell clones to naïve mice can induce lung eosinophilia and airways 
remodeling (Kaminuma et al., 1997), and also airways hyperresponsiveness in the 
absence of serum IgE (Li et al., 1998). Furthermore, IL-5 producing CD4+ T cells may 
be obtained from sensitised donor mice, and used to promote aeroallergen induced lung 
eosinophilia and airways hyperresponsiveness in naïve wild type (Wise et al., 1999) and 
also in IL-5 deficient recipients (Hogan et al., 1998c).  
 
Passive sensitisation with components of the allergic response provides invaluable 
insight into the participatory role of each component towards allergic airways disease 
progression and maintenance. Active sensitisation using antigen loaded cells may be 
used to identify those cells having the ability to prime for and to regulate Th2 
lymphocyte function, and which may potentially exacerbate allergic airways disease. 
For instance, macrophages loaded with antigen ex vivo can induce pulmonary 
eosinophilia when transferred (i.p.) to naïve recipients, in a manner which is sensitive to 
CD4 and CD8 blocking antibodies (Lambert et al., 1996). Similar elegant studies using 
antigen loaded dendritic cells injected into the airways of naïve mice have demonstrated 
the ability of these professional APCs to educate the naïve immune system and induce 
characteristic features of allergic airways disease including lung eosinophilia, 
generation of Th2 cytokines (IL-4, IL-5, and IL-13), airways remodeling (Lambrecht et 
al., 2000) and also airways hyperresponsiveness (Sung et al., 2001).  
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Human eosinophils obtained from the asthmatic lung display an altered phenotype when 
compared to blood eosinophils, including upregulation of surface HLA-DR, 
intercellular adhesion molecules, and activation markers including CD11b (Hansel et 
al., 1991; Sedgwick et al., 1992; Mengelers et al., 1994). In vitro evidence suggests that 
eosinophils acquire this phenotype during transendothelial migration, which induces 
autocrine GM-CSF production that may potentiate eosinophil survival (Yamamoto et 
al., 2000), and also upregulate HLA-DR expression (Lucey et al., 1989). Despite their 
capacity to express HLA-DR, there has been no evidence for the regulation of T cell 
function by airways eosinophils in allergic asthmatics, and similarly, no reported 
instances of the ability for antigen loaded eosinophils to prime for allergic disease of the 
lung in any animal model. As discussed in Chapter 4, eosinophils derived from the 
allergic mouse lung are known to express surface MHC class II, co-stimulatory B7.1 
and B7.2 molecules, and to take up and process relevant antigen in vivo. They also have 
the capacity to activate T cells, and to elaborate Th2 cytokine production. It was thus 
hypothesised that lung eosinophils derived from the allergic airways would be 
competent APCs, having the capacity induce Th2 mediated allergic airways disease 
when transferred to naïve mice.  
 
In the experiments described in this Chapter, eosinophils derived from the allergic 
mouse lung are shown to induce allergic airways disease when transferred to naïve 
mice, without any requirement for additional antigen loading ex vivo. Antigen loaded 
eosinophils derived from the IL-5 transgenic mouse are also shown to promote allergic 
airways disease in naïve recipient mice via altered Th2 lymphocyte function. 
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5.2 MATERIALS AND METHODS 
 
5.2.1 Animals. 
Wild type and IL-5 transgenic (Dent et al., 1990) C57BL/6 mice (male, 4-8 wk old), 
were obtained from the SPF unit of the ANU and housed in an approved containment 
facility. Mice were treated according to ANU animal welfare guidelines.  
 
5.2.2 Preparation of eosinophils. 
In order to measure their antigen presenting capacity in vivo, large numbers of 
eosinophils were obtained from allergic and non-allergic mice in the C57BL/6 
background prior to their adoptive transfer to naïve recipients. 
 
5.2.2.1 Preparation of eosinophils from the allergic lung.  
Male wild type C57BL/6 mice were sensitised and challenged with OVA as in Section 
3.2.5. BALF (see Section 2.2.4) was collected on day 31, and eosinophils were purified 
by FACS as in Section 2.2.5. The purity of the enriched population of eosinophils was 
>98% as determined by differential staining with May-Grunwald-Giemsa. Prior to 
transfer, eosinophils were resuspended in HBSS at a cell concentration of 1 x 106/100 µl 
and kept on ice.  
 
5.2.2.2 Preparation of non-allergy derived eosinophils. 
Male 4 wk old wild type C57BL/6 mice were treated with PMBS as in Section 2.2.2, 
and eosinophils purified from the PEC population using FACS as in Section 2.2.5. The 
purity of the enriched population of eosinophils was >98% as determined by differential 
staining with May-Grunwald-Giemsa. Prior to transfer, eosinophils were resuspended in 
HBSS at a cell concentration of 1 x 106/100 µl and kept on ice.  
 
In other experiments and where indicated, IL-5 transgenic C57BL/6 mice (Dent et al., 
1990) were sacrificed by CO2 asphyxiation and the peritoneal cavity lavaged as in 
Section 2.2.2, and eosinophils purified by FACS as in Section 2.2.5. The purity of the 
enriched population of eosinophils was >98% as determined by differential staining 
with May-Grunwald-Giemsa solution. As indicated, IL-5 transgenic eosinophils were 
incubated in HBSS containing 1 mg/ml OVA for 30 minutes at 37oC, before being 
washed (five times) in excess HBSS to remove any unincorporated OVA. Prior to 
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transfer, eosinophils were resuspended in HBSS at a cell concentration of 1 x 106/100 µl 
and kept on ice.  
 
5.2.3 Transfer of allergy derived eosinophils into naïve C57BL/6 recipient mice. 
Purified eosinophils (98% pure) from the airways of OVA sensitised and challenged 
C57BL/6 mice (Section 5.2.2.1) were injected into the peritoneal cavities of naïve 
C57BL/6 mice on days 0 and 7 (AAD EOS, 2 x 106). As a control, purified eosinophils 
from PMBS injected mice (Section 5.2.2.2) were also injected into the peritoneal 
cavities of separate naïve C57BL/6 mice on days 0 and 7 (PMBS EOS, 2 x 106). On 
days 0, 1, 8, 11 and 19, the peritoneal cavities from 3-4 mice in each group were 
lavaged following CO2 asphyxiation, and recoverable eosinophils were enumerated (as 
in Section 2.2.2). All eosinophil recipient mice were exposed to aerosolised antigen 
(OVA, 10 mg/ml in 0.9 % saline) for 3 x 30 minutes using a RapidFlo nebuliser bowl 
on days 12, 14, 16, and 18. Peripheral bloods were taken on days –1, 1, 4, 6, 8, 11, 13, 
15, 17, and both BALF and peripheral bloods taken for analysis on day 19.  
 
5.2.4 Transfer of non-allergy derived eosinophils into naïve C57BL/6 recipient 
mice. 
Purified C57BL/6 IL-5 transgenic mouse eosinophils (98% pure) incubated with OVA 
from Section 5.2.2.2 (Ag+ EOS, 2 x 106) were injected into the peritoneal cavities of 
naïve C57BL/6 mice on days 0 and 9. As a control, purified eosinophils that were not 
incubated in antigen (Ag- EOS, 2 x 106) were also injected into the peritoneal cavities of 
separate naïve C57BL/6 mice on days 0 and 9. All eosinophil recipient mice were then 
exposed to aerosolised antigen (OVA, 10 mg/ml in 0.9 % saline) for 3 x 30 minutes 
using a RapidFlo nebuliser bowl on days 15, 17, 19, and 21. Peripheral bloods were 
taken on days 14, 16, 18, 20, and peripheral blood, sera, BALF, lung and lymph node 
tissues collected for analysis on day 22.  
 
5.2.5 Collection and analysis of blood and bronchoalveolar lavage fluid.  
Peripheral blood films were stained with May-Grunwald-Giemsa solution, and 200-300 
leukocytes identified by morphological criteria. On the last day of each experiment, 
mice were sacrificed by cervical dislocation, and bronchoalveolar lavage performed as 
in Section 2.2.4.  
 
Chapter 5 Eosinophils As Antigen Presenting Cells In Vivo 78 
 
5.2.6 Histological analysis of lung tissue from IL-5 transgenic-eosinophil 
recipients. 
Mouse lungs from Section 5.2.4 were immediately removed and fixed in 10% 
phosphate-buffered formalin solution, pH 7.0 for at least 2 hours. Later, sections 
representing the central (bronchi-bronchiole) and peripheral (alveolar) airways were cut 
and immersed in 10% phosphate buffered formalin solution for a minimum of 72 hours. 
The samples were paraffin-embedded, sectioned and stained with Lendrum’s 
carbolchromotrope stain (Lendrum, 1944). Leukocytes were identified by 
morphological criteria and photographed. 
 
5.2.7 Lymph node cell culture. 
Peribronchial lymph nodes from Section 5.2.4 were harvested into ice cold HBSS and 
physically disaggregated. The isolated cells were centrifuged at 500 g at 4oC for 10 
minutes and the cell pellet was resuspended in 500 µl RBC lysis solution and incubated 
at 37oC for 5 minutes before the addition of 1 ml ice cold HBSS. The cells were then 
centrifuged again at 500 g at 4oC for 10 minutes, and the cell pellet resuspended in 500 
µl ice-cold PBS. Cell numbers were determined using a standard haemocytometer, and 
lymph nodes cells were then resuspended at 5 x 105 cells/100 µl in MLC medium 
containing 10% FCS. Lymph node cells were cultured at a density of 5 x 105/well for 96 
hours in the presence or absence of 200 µg OVA, in a total volume of 200 µl/well. 
Culture supernatants were then taken and assayed for IL-5 and IL-13. 
 
5.2.8 Cytokine analysis. 
IL-13 and IL-5 concentrations were determined in the supernatants from OVA-
stimulated lymph node cells by ELISA. Briefly, round bottomed immunoassay plates 
were coated with 50µl anti-mouse IL-13 (R&D Systems, Minneapolis, MN), or anti-
mouse IL-5 (TRFK5) and incubated at 4oC overnight. Plates were then blocked with 2% 
skim milk powder in PBS-Tween20 (0.04%) for 1 hour at 37oC, and incubated with 
serial dilutions of cultured supernatants, and IL-13, or IL-5 standards. Mouse IL-13 and 
IL-5 were detected with biotinylated anti-mouse IL-13 (R&D Systems, Minneapolis, 
MN), and anti-mouse IL-5 (BD PharMingen) respectively. Plates were then incubated 
with streptavidin-conjugated alkaline-phosphatase (Amersham International plc, 
Buckinghamshire, UK) for 1 hour at 37oC, washed, and alkaline-phosphatase substrate 
solution (Sigma Chemical Co. St Louis, MO) was added. Where necessary, reactions 
Chapter 5 Eosinophils As Antigen Presenting Cells In Vivo 79 
 
were stopped with 1M citric acid, or promptly analysed. Plates were read by a 
Microplate reader (BIO-TEK Instruments Inc., Winooski, VT) at 490 nm with reference 
to 405 nm. 
 
5.2.9 Ovalbumin specific IgG1 determination by ELISA. 
Serum samples were taken from the tail veins of eosinophil recipients from Section 
5.2.4 on days 0 and 22. OVA specific IgG1 was measures as in Section 2.2.8.  
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5.3 RESULTS 
 
5.3.1 Purified eosinophils from the allergic lung promote allergic disease of the 
lung when transferred to naïve C57BL/6 recipients. 
Eosinophils obtained from the lungs of mice with AAD or from mice with PMBS 
induced eosinophilia (2x106) were transferred to the peritoneal cavities of naïve 
recipients on days 0 and 7. Following the first i.p. injection on day 0, there was a 
significant difference in recoverable eosinophil numbers from the peritoneal cavities of 
AAD and PMBS eosinophil recipients (Figure 5.1a). In PMBS eosinophil recipients, 
about 6 x 105 eosinophils were recovered, suggesting 1.4 x 106 eosinophils were either 
adhering to tissues and organs within the peritoneal cavity, or were no longer residing in 
this compartment. This phenomena was more striking in AAD eosinophil recipients, in 
which only about 3 x 104 of transferred eosinophils were recovered. Following the 
second i.p. injection on day 7, there were more recoverable eosinophils in peritoneal 
lavage from PMBS recipients than from AAD recipients, however, this was no longer 
significantly different. Peripheral blood data (Figure 5.1b) for days 1 and 8 does not 
indicate that either population of eosinophils entered the blood stream following i.p. 
administration on days 0 or 7.  
 
Subsequent exposure to aerosolised OVA on days 12, 14, 16, and 18 did not induce any 
significant differences in peripheral blood eosinophil levels between AAD and PMBS 
eosinophil recipients at any time point (Figure 5.1b). It was noted that AAD eosinophil 
recipients had significantly increased peripheral blood eosinophils (5.7%) on day 19 in 
comparison to day –1 (1.5%). The repeated exposure of eosinophil recipients to 
aerosolised OVA induced a pulmonary eosinophilia in AAD eosinophil recipients only, 
as reflected by increased eosinophils/ml BALF (Figure 5.1c). No other cell types were 
significantly elevated between the two groups, although increased macrophages in 
BALF from PMBS eosinophil recipients was suggested  
 
 5.3.2 Purified eosinophils from IL-5 transgenic mice promote allergic disease of the 
lung when transferred to naïve C57BL/6 mice. 
Antigen loaded (Ag+ EOS ) and antigen negative (Ag- EOS) eosinophils from IL-5 
transgenic mice (2x106) were transferred i.p. to naïve C57BL/6 wild type recipients on 
days 0 and 9, and the recipients were subsequently exposed to aerosolised OVA on days 
15, 17, 19, and 21. Exposure to aerosolised OVA induced significant differences in 
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Figure 5.1. Eosinophil numbers in peritoneal lavage, peripheral blood and BALF of naïve eosinophil recipients. (a) Recoverable eosinophils in the 
peritoneal cavities of mice that received eosinophils from the lungs of mice with AAD (AAD EOS i.p.), and those that received PMBS induced 
eosinophils (PMBS EOS i.p.). (b) Peripheral blood eosinophils in AAD EOS i.p. and PMBS EOS i.p. recipients. (c) Cellular composition of BALF on 
day 19. Data represents mean ± SEM for samples taken from 3-5 mice on days 0-18, and 5-8 mice on day 19. Significant differences in means were 
determined by Student’s unpaired t test (P <0.05). * P <0.05 compared to PMBS eosinophil recipients. # P <0.05 for AAD eosinophil recipients on day 
19 compared to day –1.  
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peripheral blood eosinophil levels between Ag+ and Ag- eosinophil recipients at all 
measured time points (Figure 5.2a), and Ag+ eosinophil recipients had significantly 
increased peripheral blood eosinophils at all time points following exposure to OVA 
when compared to day 14. The repeated exposure of eosinophil recipients to aerosolised 
OVA on days 15, 17, 19 and 21 induced a pulmonary eosinophilia in Ag+ eosinophil 
recipients only, as reflected by increased eosinophils/ml BALF (Figure 5.2b). In 
addition, macrophages and neutrophils in BALF from Ag- eosinophil recipients were 
significantly elevated over Ag+ eosinophils. Notably, lung sections from Ag+ but not 
Ag- eosinophil recipients were characterized by a pronounced eosinophil infiltrate in 
and around the airways, mucus plugging, and cellular disruption of the airways 
epithelium (Figures 5.3 and 5.4) 
 
Draining lymph node cells from Ag+ and Ag- eosinophil recipients were harvested on 
day 22 and stimulated with exogenous OVA. Lymph node cells from Ag+ eosinophil 
recipients produced significantly greater amounts of IL-5 (230 ng/ml) and IL-13 (14 
ng/ml) in response to the addition of exogenous OVA than did Ag- eosinophil recipients 
(0 and 0.5 ng/ml respectively) (Figure 5.5a and b). Lymph nodes cells from Ag+ 
eosinophil recipients secreted both IL-5 and IL-13 without addition of exogenous OVA 
(condition C, Figure 5.5a and b), which was probably carried over from the previous 
exposure to aerosolised OVA on day 21 in vivo.  
 
5.3.4 Priming action of eosinophils does not induce antigen-specific IgG1 
antibodies.  
Serum from mice with AAD (Section 5.2.2.1), and from allergic lung (Section 5.2.3) 
and IL-5 transgenic eosinophil recipients (Section 5.2.5) was analysed for OVA specific 
IgG1 following repeated exposures to aerosolised antigen (OVA). Despite the 
pulmonary eosinophilia seen in AAD and Ag+ eosinophil recipients (Figures 5.1 – 5.4), 
only mice sensitised by i.p. injection of OVA in alum had any detectable serum OVA-
specific IgG1 (2.5 ±0.12 mg/ml) (data not shown).  
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Figure 5.2. Antigen pulsed eosinophils from IL-5 transgenic mice promote allergic disease of the lung in naïve recipients. (a) Peripheral blood 
eosinophils in naïve mice that received OVA-pulsed (Ag+) or OVA-free (Ag-) IL-5 transgenic eosinophils i.p. on days 0 and 9, and which were then 
exposed to aerosolised OVA on days 15, 17, 19 and 21. (b) Numbers of eosinophils/ml BALF in naïve mice that received Ag+ or Ag- IL-5 transgenic 
eosinophils on day 22. Numbers of eosinophils, macrophage and neutrophils were significantly different between Ag+ and Ag- eosinophil recipients. 
Data represents mean ± SEM for groups of 4 mice. Significant differences in means were determined by Student’s unpaired t test (P <0.05). # P <0.05 
compared to Ag- recipients on days 16-22, and Ag+ recipients on day 14. * P <0.05 compared to Ag- recipients. 
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Figure 5.3. Histological analysis of lung sections from antigen-pulsed IL-5 transgenic eosinophil recipients. (a) Histological section (10 x objective) 
typical of mice that received OVA-free (Ag-) IL-5 transgenic eosinophils on days 0 and 9, and which were subsequently challenged with OVA on days 
15, 17, 19 and 21. There is little evidence of airway plugging nor inflammatory infiltrate. (b) Histological section (10 x objective) typical of OVA-
pulsed (Ag+) eosinophil recipient mice. Note the pronounced peribronchial and perivascular infiltrate surrounding the airways and blood vessels, and 
occluded airway typical of goblet cell hyperplasia. Lung tissue was stained with Lendrum’s carbolchromotrope stain. 
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Figure 5.4. Histological analysis of lung sections from antigen-pulsed IL-5 transgenic eosinophil recipients. (a) Histological section (40 x objective) 
typical of mice that received OVA-free (Ag-) IL-5 transgenic eosinophils on days 0 and 9, and which were subsequently challenged with OVA on days 
15, 17, 19 and 21. There was no airway plugging with eosinophils nor mucus, however a lone eosinophil may be seen in the peribronchial tissue 
underlying the band of smooth muscle surrounding this airway. (b) Histological section (40 x objective) typical of OVA-pulsed (Ag+) eosinophil 
recipient mice. Eosinophils were found to populate the peribronchial tissue underlying the airways smooth muscle. Lung tissue was stained with 
Lendrum’s carbolchromotrope stain. 
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Figure 5.5. Transfer of antigen pulsed eosinophils to naïve mice promotes antigen specific cytokine production airways draining lymph nodes 
following exposure to aerosolised antigen. Lymph node cells from OVA-pulsed (Ag+) and OVA-free (Ag-) IL-5 transgenic eosinophil recipient mice 
were cultured according to the following conditions: A, Ag- eosinophil recipients, no exogenous OVA; B, Ag- recipients + exogenous OVA; C, Ag+ 
recipients, no exogenous OVA; D, Ag+ recipients + exogenous OVA. (a) IL-5 cytokine release from OVA stimulated lymph node cells. (b) IL-13 
cytokine release from OVA stimulated lymph node cells. Data represents mean ± SEM for triplicate wells of pooled lymph node cells from 4 mice. 
Significant differences in means were determined by Student’s unpaired t test (P <0.05), and are indicated by bars (¬).  
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5.4 DISCUSSION 
 
In this Chapter, the capacity for antigen loaded eosinophils to induce allergic disease of 
the airways in naïve recipient mice has been evaluated. Eosinophils located in allergic 
human tissues have previously been shown to contain intracellular IL-5 (Broide et al., 
1992; Moller et al., 1996a), and IL-4 (Nonaka et al., 1995; Moller et al., 1996b), and in 
mice, eosinophils may be responsible for the initial burst of IL-4 necessary for 
subsequent Th2 response to parasite infection (Sabin et al., 1996). Eosinophils obtained 
from the BALF of mice with AAD were initially chosen in the experiments described 
here, as these cells were known to express the necessary costimulatory molecules for 
effective antigen presentation (Chapter 4 and Figures 4.1-4.2), and to take up and 
process antigen (OVA) deposited in the allergic airways (Chapter 4 and Figure 4.4). 
 
Naïve recipient mice received 2 x 106 eosinophils from the allergic lung or from PMBS 
treated mice (antigen free) on days 0 and 7. When recoverable eosinophils in the 
peritoneal cavity were analysed on day 1, it was surprising to note that PMBS 
eosinophil recipients had significantly greater numbers of eosinophils residing in the 
peritoneal cavity (Figure 5.1a) than did AAD eosinophil recipients. This may have been 
due to AAD derived eosinophil trafficking from this cavity, although peripheral blood 
levels on day 1 did not suggest removal via blood. Peripheral blood levels did not differ 
greatly between the two groups (Figure 5.1b), although it is noted that only peripheral 
blood levels in AAD eosinophil recipients were significantly greater on day 19 
following the aerosol regime, than when compared to day –1. Analysis of BALF (Figure 
5.1c), revealed that AAD eosinophil recipients had increased eosinophil infiltrate of the 
airways following exposure to aerosolised antigen, and mimics the findings of lambert 
et al., who transferred antigen pulsed APCs (1x106 macrophages/mouse i.p. on days 
zero and 6) to naïve mice, which subsequently developed CD4-dependent allergic 
disease of the lung (Lambert et al., 1996). The results described in this Chapter are 
considered to be the first observation of antigen loaded eosinophils ability to prime for 
allergic disease of the lungs in naïve mice.  
 
The experimental model was lengthened by 3 days to address the lack of a peripheral 
blood eosinophilia observed when using eosinophils obtained from the allergic lung to 
prime for allergic airways disease in naïve mice. Moreover, the use of non-allergy 
derived eosinophils would also ensure that the observed results were a true reflection of 
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the eosinophils ability to prime for T cell responses, and not due to contaminating T 
lymphocytes from BALF of allergic mice (typically less than 0.1%). Figure 5.2a shows 
that this improved model produced a peripheral blood eosinophilia that was 
significantly greater in Ag+ compared to Ag- recipients at each time point following 
exposure to aerosolised antigen. On day 22, only Ag+ eosinophil recipients had a 
pronounced pulmonary eosinophilia as measured by BALF (Figure 5.2b), while Ag- 
recipients had significantly greater numbers of macrophage and neutrophils. Stimulation 
of lymph node cells harvested on day 22 with relevant antigen (OVA) showed 
appreciable amounts of IL-5 and IL-13 release from Ag+ recipients when compared to 
Ag- controls (Figure 5.5). Secretion of both IL-5 and IL-13 without addition of OVA 
was noted in Ag+ recipient lymph node cells, and was probably carried over from recent 
exposure to antigen in vivo. The priming of T cell responses in vivo using professional 
APCs (dendritic cells, DC), pulsed ex vivo with antigen has been reported (Lambrecht et 
al., 2000; Sung et al., 2001). Lambrecht et al. injected 1x106 OVA-pulsed DC into the 
airways of naïve mice that were subsequently exposed to aerosolised OVA on days 14-
20, and noted pulmonary eosinophilia, pronounced cellular infiltrate within histological 
sections, and also IL-4 and IL-5 secretion from mediastinal lymph node cells cultured 
with OVA. The eosinophil content of BALF, and peribronchial and perivascular 
eosinophil-rich infiltrates observed in OVA-pulsed DC recipients exposed to 
aerosolised OVA is similar to that seen in this Chapter for Ag+ eosinophil recipients 
(Figures 5.2 – 5.4), and typical of wild type mice i.p. sensitised with OVA/alum and 
subsequently challenged via the airways (Foster et al., 1996).  
 
In the experiments presented in this Chapter, the transfer of antigen carrying eosinophils 
to naïve recipients subsequently exposed to aerosolised antigen did not generate 
detectable antigen specific IgG1 in serum at any of the time points indicated. The use of 
OVA-pulsed DC to promote allergic disease of the lung in mice also fails to induce 
serum OVA-specific IgG1 (Sung et al., 2001) and IgE (Lambrecht et al., 2000), and 
may be attributed to the lack of free OVA available for stimulation of naïve B cells. 
 
In summary, eosinophils obtained from the allergic airway have been observed to prime 
for allergic disease of the lung in naïve mice, without any need for additional antigen 
loading ex vivo. The ability to prime the naïve immune system has further been 
confirmed using antigen pulsed eosinophils obtained from IL-5 transgenic mice, which 
led to pronounced inflammatory infiltrate of the airways and measurable Th2 cytokine 
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secretion from draining lymphoid tissues, in levels similar to those seen when mice are 
conventionally immunised and challenged with relevant antigen. These data and that of 
Chapters 2-4 suggest that eosinophils recruited to inflammatory tissues may actively 
sample the local microenvironment, and present processed antigen to tissue resident 
memory T cells within the lung and the draining lymphoid tissues. This en masse serial 
triggering of T lymphocytes by cells that are traditionally viewed as non-professional 
APCs can further promote Th2 inflammatory cytokine production including IL-5 and 
IL-13 release, and potentially exacerbate already established allergic responses. It is 
interesting to note that eosinophils have since been implicated in the regulation of IL-13 
production from CD4+ T cells and induction of airways hyperresponsiveness. This 
regulation is currently thought to be mediated by eosinophil derived IL-18 (Mattes et 
al., 2002), and further supports a fundamental link between the innate (eosinophils) and 
adaptive (T cells) immune responses for the regulation of Th2 cytokine production.  
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6.1 INTRODUCTION 
 
In Chapter 4, eosinophils acting as antigen presenting cells were shown to induce 
proliferation of OT-II transgenic splenocytes in an antigen and dose dependent fashion. 
Subsequent experiments designed to measure cytokine secretion resulting from such 
interactions failed to show any production of IL-13 nor IL-5 in cell culture supernatants. 
Instead, minimal amounts of IFN-γ were surprisingly detected (results not shown). The 
OT-II transgenic TCR recognises OVA323-339 peptide, which has been identified as an 
immunodominant T cell epitope that preferentially skews naïve T cell responses 
towards Th2 cytokine secretion (Janssen et al., 1999; Janssen et al., 2000). Therefore, it 
was decided to characterise the OT-II mouse using an established mouse model of 
AAD, in an attempt to define both in vivo and in vitro responses to relevant antigen.  
 
The OT-II transgenic mouse was engineered using both genomic and complimentary- 
DNA from a CD4+ MHC class II I-Ab-restricted OVA323-339 specific T cell hybridoma, 
originally derived from a C57BL/6 mouse that was primed in vivo with whole OVA in 
complete Freund’s adjuvant (CFA) (Barnden et al., 1998). The TCR expressed by OT-II 
CD4+ T cells comprises Vβ5 and Vα2 elements, and like the T cell clone from which 
they were derived, are responsive to OVA323-339 stimulation. Critical T cell contact 
residues for OT-II transgenic T cell receptors have been mapped to amino acids 331, 
333, and 336, of which 333 (E) is the primary TCR contact residue located in the C 
terminus of OVA323-339 (Robertson et al., 2000).  
 
Little is known about the phenotype of the OT-II transgenic mouse, although OT-II 
CD4+ T cells have been utilised for their ability to specifically recognise OVA323-339. 
For instance, OT-II transgenic cells have been used to study cross-presentation 
efficiency of cell-associated versus soluble OVA in mice (Li et al., 2001), to investigate 
the role of splenic dendritic cells in priming for adaptive CD4+ T cell responses to OVA 
(Castiglioni et al., 2003), to study the influence of suppressor of cytokine signaling-1 
(SOCS-1) on T cell activation and homeostasis (Cornish et al., 2003), and to study 
negative selection in the thymus (Zhan et al., 2003). To the best of the author’s 
knowledge, the OT-II transgenic mouse has not been characterised in any allergy 
model. 
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In this Chapter, the OT-II transgenic mouse is partially characterised in a mouse model 
of AAD, and is found to be refractory to Th2 mediated allergic disease induction and 
progression. On further investigation, OT-II CD4+ T cells carrying the transgenic TCR 
are found to be programmed for IFN-γ secretion in response to stimulation with OVA, 
and can be used to attenuate airways eosinophilia when transferred to allergic wild type 
mice. This ability to reduce airways eosinophilia does not however, translate to lowered 
tissue eosinophilia, airways hyperreactivity nor reduced OVA-specific serum 
immunoglobulin (IgG1). 
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6.2 MATERIALS AND METHODS 
 
6.2.1 Animals. 
C57BL/6 (male, 4 wk old) and OT-II mice (N10 C57BL/6, male*, 4 wk old) (Barnden 
et al., 1998), were obtained from the SPF unit of the ANU and housed in an approved 
containment facility. Mice were treated according to ANU animal welfare guidelines. 
*All OT-II males are transgenic, as the transgene is linked to the Y-chromosome.  
 
6.2.2 Sensitisation and airways challenge of OT-II transgenic mice. 
Both wild type C57BL/6 and OT-II transgenic mice were sensitised as in Section 3.2.5 
(OVA i.p.), with the following changes: a subset of non sensitised control mice were 
injected with only saline and Alhydrogel (SAL i.p.). All mice were then airways 
challenged as in Section 3.2.5. Peripheral blood smears were collected on days 23, 25, 
27, 29, and 31, and analysed as in Section 5.2.5. All mice were sacrificed on day 31, 
with BALF collected and analysed as in Section 2.2.4, serum collected for OVA 
specific IgG1 analysis as in Section 2.2.8, and spleens excised for cytokine analysis. 
Spleens were disaggregated using sterile wire gauze (0.5mm) and suspended in ice cold 
PBS. Erythrocytes were then lysed, and the washed splenocytes were resuspended at 
107 cells/ml in MLC medium containing 10% heat-inactivated FCS, 2 mM L-glutamine, 
and 50 mg/L neomycin sulfate. Splenocytes from each group were then plated out at a 
density of 2 x 106 cells/well in round-bottom tissue culture plates, with added 
exogenous OVA (100 µg/well). Following 72 hours of culture, cell-free supernatants 
were removed and stored at –70oC for later cytokine analysis. 
 
6.2.3 Isolation and stimulation of OT-II CD4+ splenocytes.  
OT-II transgenic mice were sacrificed by cervical dislocation and their spleens excised. 
Spleens were then disaggregated using sterile wire gauze (0.5mm) and splenocytes 
suspended in ice cold PBS. Erythrocytes were then lysed, and the washed splenocytes 
(~ 1 x 108) were suspended in 90 µl HBSS/5% FCS with 10 µl anti CD4 mAb (L3T4) 
coated microbeads and incubated for 20 minutes at 6-12oC. Suspensions were then 
centrifuged at 500 x g for 5 minutes at 4oC and the resultant cell pellet resuspended in 1 
ml PBS/0.5 % BSA. Bead-bound CD4+ cells were then isolated using high-gradient 
magnetic MiniMacs separation columns (MACS separation, Miltenyi Biotec GmbH, 
Bergisch Gladbach, Germany) as per manufacturers instructions. Isolated cells were 
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then washed and resuspended in MLC medium/10% FCS at 5 x 107 cells/ml. The CD4- 
fraction (unbound cells) were retained as a source of antigen presenting cells (APCs). 
Briefly, CD4- cells (5 x 107 cells/ml) were incubated in the presence or absence of 
OVA323-339 peptide (100mM, ISQAVHAAHAEINEAGR), and mitomycin C (25µg/ml) 
in MLC medium/10% FCS for 30 minutes at 37oC. Cells were then washed 3 times in 
fresh media, and resuspended at 5 x 107 cells/ml. Isolated OT-II CD4+ cells (1 x 106) 
were then co-cultured with non- and peptide-loaded APCs (5 x 105) in 96-well flat-
bottom tissue culture plates (Nunc), in a total volume of 200 µl MLC medium/10% FCS 
at 37oC for 72 hours. As additional controls, OT-II CD4+ cells were incubated (a) alone, 
(b) with 100mM added OVA323-339 peptide, or (c) with immobilised anti-CD3 
monoclonal antibody (100µg/well). Supernatants were then collected for cytokine 
analysis.  
 
To measure CD4+ splenocyte proliferative responses to OVA323-339 peptide, identical 
tissue culture plates (as above) were centrifuged at 300 x g for 5 minutes at RT 
following 48 hours of co-culture, and spent media replaced with fresh media (200 µl) 
containing tritiated thymidine (3H-thymidine, 1µCi/well). At 72 hours of co-culture, the 
contents of each well were harvested onto a glass fibre filter (Packard, Canberra) using 
a Filtermate 196 cell harvester (Packard, Canberra). Fibre mats were then assembled in 
the appropriate cassette with MicroScint-O fluid (Packard, Canberra) and tritiated 
thymidine incorporation as represented by counts per minute (CPM) measured using a 
Packard TopCount NXT (Packard Instrument Company INC, IL).  
 
6.2.4 Adoptive transfer of OT-II CD4+ cells to wild type allergic mice. 
Wild type C57BL/6 mice were sensitised and challenged as in Section 3.2.5, with the 
following changes. Mice were i.p. sensitised on day 0 only, and challenged via the 
airways on days 12, 14, 16, and 18. A subset of mice were adoptively transferred with 2 
x 106 CD4+ splenocytes from OT-II transgenic mice (enriched as in Section 6.2.3) via 
the tail vein (total volume 200 µL in PBS) on day 0. Peripheral blood smears were 
collected on days 11, 13, 15, 17, and 19, and analysed as in Section 5.2.5. All mice were 
sacrificed on day 19, with BALF collected and analysed as in Section 2.2.4, serum 
taken for OVA specific IgG1 analysis as in Section 2.2.8, and lung sections taken for 
histological analysis as in Section 5.2.6.  
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Spleens were also excised on day 19 and disaggregated using sterile wire gauze 
(0.5mm) and, splenocytes suspended in ice cold PBS before lysis of erythrocytes. 
Whole spleen cell preparations were then incubated in flat-bottom 96-well tissue culture 
plates (Nunc) at a density of 2 x 106 cells/well, in a total volume of 200µl MLC 
medium/10% FCS at 37oC for 72 hours. Prior to incubation, antigen (OVA) was added 
at different concentrations (0, 1, 10 and 100 µg/well). Immobilised anti-CD3 
monoclonal antibody (100 µg) was also added to a subset of wells as a non-specific 
positive control. Supernatants were then collected for cytokine analysis.  
 
6.2.5 Measurement of airways hyperreactivity.  
Individual mice were placed in a whole body barometric plethysmograph (BUXCO 
Electronics, Troy, NY) interfaced with a personal computer through a differential 
pressure transducer. Mice were exposed to an aerosol of sterile double distilled water 
for 2 minutes before a 3 minute recording period to obtain a baseline Penh (enhanced 
pause) response. Changes in airways reactivity were measured as Penh using the function 
as described (Hamelmann et al., 1997b): 
 
Penh = [(Te/0.3Tr)-1] x [2Pef/3Pif] 
 
Where  Penh  enhanced pause 
  Te expiratory time (seconds) 
  Tr relaxation time (seconds) 
  Pef peak expiratory flow 
  Pif  peak inspiratory flow 
 
After the first (water) dose, mice were exposed to increasing concentrations of β-
methacholine in ddH20 (3.125 – 50 mg/ml) using the 2 minute exposure and 3 minute 
recording periods as described above for baseline. For each individual mouse, Penh 
recordings were obtained and averaged before collating with other mice in each group. 
 
6.2.6 Detection of adoptively transferred OT-II CD4+ cells in wild type allergic mice.  
Wild type C57BL/6 mice were sensitised and challenged and adoptively transferred 
with OT-II CD4+ cells as in Section 6.2.4 with the following changes. Prior to adoptive 
transfer, OT-II CD4+ cells (5 x 107/ml in PBS) were incubated in carboxyflourescein 
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diacetate succinimidyl ester (also known as CFSE, 5 µM – a kind gift from C.R. Parish, 
JCSMR, ANU) for 15 minutes at RT in 1 ml PBS (Weston and Parish, 1990; Parish, 
1999). The cells were then washed in PBS/10% FCS to inhibit further dye loading, 
before resuspension in PBS and adoptive transfer to wild type allergic hosts. Mice were 
sacrificed on day 19, and lungs, spleens, and peribronchial lymph nodes were 
individually excised. The tissues were separately homogenised in HBSS/10% FCS at 
4oC, and the resulting cell suspensions were then filtered through sterile nylon mesh 
(70µM) before centrifugation at 500 g for 5 minutes at 4oC. Following red blood cell 
lysis, 1 x 105 cells from each tissue were then incubated with phycoerythrin (PE)-
conjugated anti-mouse CD4 (clone L3T4) for 30 minutes on ice. Cells were then FCS 
underlaid, centrifuged at 500 × g for 5 min at 4° C, and the resulting cell pellets 
resuspended in ice-cold PBS before analysis by flow cytometry. The cell homogenates 
were protected from incident light during each step. Adoptively transferred fluorescent 
cells in each tissue were then detected with a Becton and Dickinson FACScan® flow 
cytometer in conjunction with Cellquest (Becton and Dickinson, San Jose, CA) and 
WinMDI software packages (kindly provided by J. Trotter, Scripps Research Institute, 
La Jolla, CA). 
 
6.2.7 Cytokine analysis. 
IL-13 and IL-5 concentrations were determined as in Section 5.2.8. For IFN-γ detection, 
round bottomed immunoassay plates were coated with 50ng anti-mouse IFN-γ (clone 
R46A2), and incubated at 4oC overnight. Plates were then blocked with 2% skim milk 
powder in PBS-Tween20 (0.04%) for 1 hour at 37oC, and incubated with serial dilutions 
of cultured supernatants, or IFN-γ standard. IFN-γ was then detected with biotinylated 
rat anti-mouse IFN-γ (clone XMG1.2, BD PharMingen). Plates were then incubated 
with streptavidin-conjugated alkaline-phosphatase (Amersham International plc, 
Buckinghamshire, UK) for 1 hour at 37oC, washed, and alkaline-phosphatase substrate 
solution (Sigma Chemical Co. St Louis, MO) was added. Where necessary, reactions 
were stopped with 1M citric acid, or promptly analysed. Plates were read by a 
Microplate reader (BIO-TEK Instruments Inc., Winooski, VT) at 490 nm with reference 
to 405 nm. 
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6.3 RESULTS 
 
6.3.1 OT-II transgenic mice fail to develop characteristic markers of AAD when 
subjected to a mouse model of asthma.  
Following sensitisation and airways challenge with OVA, OT-II transgenic mice did not 
exhibit the characteristic peripheral blood eosinophilia (greater than 5%), nor 
pulmonary eosinophilia (as measured in the BALF) typically seen in wild type mice 
(Figure 6.1), although eosinophils in BALF from both OVA sensitised and saline 
control OT-II mice were significantly greater than that of wild type saline controls 
(Figure 6.1b). Elevated numbers of lymphocytes in the BALF of OT-II mice were also 
noted following airway challenge, irrespective of sensitisation to OVA, and were also 
significantly greater than that of WT saline controls (Figure 6.1b).  
 
Both IL-13 and IL-5 secretion were significantly reduced in OT-II splenocytes 
stimulated with OVA, in comparison to allergic wild type mice (Figure 6.2a and b), and 
serum OVA-specific IgG1 levels were virtually undetectable in sensitised OT-II mice 
(Figure 6.2c).  
 
6.3.2 OT-II transgenic CD4+ splenocytes secrete IFN-γ when stimulated with 
OVA323-339 peptide. 
Significant cell proliferation (as measured by 3H-thymidine incorporation) was 
observed when OT-II CD4+ splenocytes were co-incubated with mitomycin C 
inactivated APCs previously loaded with OVA323-339 peptide (Figure 6.3a). Under 
identical culture conditions, appreciable amounts of IFN-γ were released, while both IL-
13 and IL-5 were both below detection limits (Figure 6.3b). In both instances, 
incubation with anti-CD3 monoclonal antibody induced both non-specific proliferation 
and release of IFN-γ from OT-II CD4+ cells.  
 
 6.3.3 IFN-γ producing CD4+ splenocytes from OT-II mice can attenuate pulmonary 
eosinophilia when adoptively transferred to wild type allergic mice, and reside 
in the spleen and draining lymphoid tissues. 
An attenuated model (1 x i.p. sensitisation with OVA) was chosen to identify any subtle 
changes in the characteristic markers of allergic airways disease that may be attributed 
to adoptively transferred OT-II CD4+ cells. Analysis of peripheral blood showed no 
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Figure 6.1. OT-II transgenic mice fail to develop characteristic markers of allergic airways disease. (a) Peripheral blood eosinophils in OVA sensitised and 
challenged wild type (WT OVA i.p.) and OT-II mice (OT-II OVA i.p.). Wild type (WT SAL i.p.) and OT-II (OT-II SAL i.p.) saline controls are shown for 
comparison. (b) Eosinophil and lymphocyte composition of BALF of WT OVA i.p. and OT-II OVA i.p. mice. Data represents mean ± SEM for groups of 7-
9 mice. Significant differences in means were determined by Student’s unpaired t test (P <0.05). * P<0.05 when compared to WT OVA i.p. and WT SAL i.p.  
** P<0.05 when compared to WT SAL i.p.  
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Figure 6.2. Spleen cell responses to OVA, and serum OVA-specific IgG1 in OVA sensitised and challenged OT-II mice. (a) OVA stimulation of whole 
splenocytes from OVA sensitised and challenged OT-II mice (OT-II OVA i.p.) reveals a lack of significant IL-13 secretion (not above background) 
when compared to OVA sensitised and challenged wild type mice (WT OVA i.p.). (b) IL-5 secretion from WT OVA i.p. and OT-II OVA i.p. 
splenocytes stimulated with OVA. (c) WT OVA i.p. mice have detectable OVA-specific IgG1, which is virtually absent in OT-II OVA i.p. mice. 
Serum OVA-specific IgG1 was below detectable limits in wild type (WT SAL i.p.) and OT-II (OT-II SAL i.p.) saline controls. Data represents mean ± 
SEM for groups of 4 mice. Significant differences in means were determined by Student’s unpaired t test (P <0.05). * P<0.05 when compared to WT 
OVA i.p. mice.  
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Figure 6.3. CD4+ T lymphocytes from naïve OT-II transgenics release IFN-γ in response to OVA323-339 peptide stimulation. (a) Tritiated thymidine 
incorporation (as represented by counts per minute, CPM) in enriched OT-II CD4+ T cells incubated in the presence of mitomycin treated APCs (APC) 
and/or OVA323-339 peptide (PEP). Cells have also been stimulated with anti-CD3 as a positive control. (b) IFN-γ release from enriched OT-II CD4+ T 
cells incubated in the presence of mitomycin treated APCs and/or OVA323-339 peptide. Cells have also been stimulated with anti-CD3 as a positive 
control. Of the measured cytokines (IL-5, IL-13 and IFN-γ), only IFN-γ was detected. Data represents mean ± SEM for triplicate wells. Significant 
differences in means were determined by Student’s unpaired t test (P <0.05). * P<0.05 when compared to CD4+, CD4+/APC, and CD4+/PEP. ** 
P<0.05 when compared to CD4+.  
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effect for adoptively transferred OT-II CD4+ cells until day 19, when OT-II recipients 
had significantly greater levels of eosinophils in peripheral blood compared to allergic 
controls (Figure 6.4a). Analysis of BALF revealed a significant reduction in 
eosinophils, but no significant change in total lymphocyte numbers when OT-II CD4+ 
cells were adoptively transferred to allergic mice (Figure 6.4b). Nor was there any 
significant change in airways response to methacholine challenge (Figure 6.4c). Serum 
OVA-specific IgG1 levels were similar between wild type allergic mice and OT-II CD4+ 
recipients (Figure 6.5a), indicating that in this model at least, OT-II CD4+ T cells could 
not influence OVA-specific IgG1 production.  
 
When whole splenocytes were incubated with exogenous OVA in vitro, only OT-II 
CD4+ recipients displayed detectable IFN-γ release in response to stimulation (Figure 
6.5b), which suggested that the adopted OT-II T cell population retained the functional 
response to OVA previously observed in vitro. Analysis of histological sections 
revealed that lung sections from OT-II CD4+ recipients were virtually indistinguishable 
from allergic controls (Figure 6.6).  
 
In a parallel experiment, the labeling of OT-II CD4+ splenocytes with CFSE prior to 
adoptive transfer revealed that OT-II CD4+ splenocytes migrated to the host spleen and 
peribronchial lymph nodes, following sensitisation and airway challenge (Figure 6.7). 
Very low numbers of adoptively transferred OT-II CD4+ splenocytes could also be 
detected in lung homogenates (results not shown). 
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Figure 6.4. Adoptive transfer of OT-II CD4+ T cells to OVA sensitised and challenged mice: attenuation of pulmonary eosinophilia. (a) Peripheral 
blood eosinophils in wild type OVA sensitised and challenged mice (WT OVA) and OT-II CD4+ T cell recipients (WT OVA/OT-II). 
(b) Eosinophil and lymphocyte composition of BALF in WT OVA and WT OVA/OT-II mice. (c) Airways hyperreactivity to methacholine in WT 
OVA and WT OVA/OT-II mice. A non allergic mouse (Control) is shown for comparison. Data represents mean ± SEM for groups of 6-7 mice. 
Significant differences in means were determined by Student’s unpaired t test (P <0.05). * P<0.05 when compared to WT OVA mice. 
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Figure 6.5. Adoptive transfer of OT-II CD4+ T cells to OVA sensitised and challenged mice: effects on OVA-specific IgG1 and IFN-γ secretion in the 
spleen. (a) Serum OVA-specific IgG1 levels in OVA sensitised and challenged wild type (WT OVA) and OT-II CD4+ T cell recipients (WT OVA/OT-
II). Data represents mean ± SEM for groups of 4 mice. (b) IFN-γ secretion from whole spleen cell preparations stimulated with OVA (µg/well) or 
immobilised anti-CD3 monoclonal antibody. Data represents mean ± SEM for triplicate wells. Significant differences in means were determined by 
Student’s unpaired t test (P <0.05)* P<0.05 when compared to day 11. 
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Figure 6.6. Histological analysis of lung sections from OVA sensitised and challenged mice adoptively transferred with OT-II CD4+ T lymphocytes. 
(a) Histological section (20 x objective) typical of OVA sensitised and challenged mice. Note the pronounced peribronchial and perivascular infiltrate 
surrounding the airways and blood vessels, and occluded airway typical of goblet cell hyperplasia. (b) Histological section (40 x objective) typical of 
OVA sensitised and challenged mouse adoptively transferred with OT-II CD4+ T lymphocytes. In all sections examined, OT-II recipients were not 
readily distinguished from control mice. Lung tissue was stained with Lendrum’s carbolchromotrope stain. 
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Figure 6.7. OT-II transgenic CD4+ T lymphocytes migrate to the spleen and peribronchial lymph nodes when transferred to antigen sensitised and 
challenged wild type hosts. Lymphocytes were gated on the basis of forwards and side scatter profiles (R1, upper plots). CFSE (FL1-H channel) and 
CD4+ (FL2-H channel) double positive cells (upper right quadrants) are adoptively transferred OT-II CD4+ T lymphocytes, and represent 0.03 and 
0.09% of gated cells in spleen and PBLN tissue respectively.  
Chapter 6 Characterisation of the OT-II transgenic mouse in a mouse model of allergic airways disease 94 
 
6.4 DISCUSSION 
 
The OT-II transgenic mouse was initially obtained to study putative antigen-dependent 
interactions between eosinophils and T lymphocytes, in the same manner as T cell 
hybridomas have been used by others (Del Pozo et al., 1992). Early experiments with 
eosinophils, OT-II splenocytes, and relevant peptide were disappointing, because 
observed proliferative responses did not correlate with detectable Th2 cytokine release 
(see Chapter 4). Therefore, OT-II transgenic mice were characterised in an allergic 
airways disease model to gain some insight into the way in which these animals 
responded to relevant antigen in vivo. OT-II mice failed to develop the characteristic 
peripheral blood eosinophilia normally seen in wild type mice following sensitisation 
and subsequent airways challenge with OVA (Figure 6.1a). Analysis of BALF revealed 
appreciable lymphocyte infiltration of the airways in both saline and OVA sensitised 
OT-II mice, but attenuated levels of eosinophils in BALF when compared to wild type 
sensitised and challenged controls (Figure 6.1b), and both IL-13 and IL-5 secretion 
from whole splenocytes was significantly reduced (Figure 6.2a and b). Serum OVA-
specific IgG1 was also notably absent in OT-II mice (Figure 6.2c). Collectively these 
data suggested that OT-II transgenic mice were refractory to allergic disease induction 
and progression when using this model of allergic airways disease.  
 
The OT-II transgenic T cell is CD4+, and bears the Vα2/Vβ5-TCR which enables it to 
respond to the OVA323-339 peptide (Barnden et al., 1998; Robertson et al., 2000). 
Investigation of the cytokines secreted by OT-II CD4+ T lymphocytes in response to 
stimulation with peptide-pulsed APCs revealed an appreciable secretion of IFN-γ, but 
not IL-13 nor IL-5 (Figure 6.3b). To the author’s best knowledge, this is the first 
reported instance of appreciable IFN-γ secretion from OT-II transgenic cells obtained 
from naïve mice. 
 
IFN-γ can attenuate antigen-induced eosinophil recruitment to the airways (Iwamoto et 
al., 1993; Kung et al., 1995), and has been implicated in the regulation of eosinophil 
migration from lung tissue to the airways lumen in IL-4 deficient mice (Cohn et al., 
2001). The ability of IFN-γ to influence Th2 mediated allergic disease could be linked 
to its ability to suppress IL-4 induced commitment of Th cells to the Th2 phenotype 
(Pene et al., 1988), and also its ability to suppress both IL-4 and IL-5 production by 
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CD4+ Th2-type lymphocytes (Demeure et al., 1994). Therefore, the ability of IFN-γ 
secreting OT-II CD4+ T lymphocytes to counterbalance Th2 mediated allergic airways 
disease was investigated.  
 
OT-II CD4+ T lymphocytes were administered to naïve hosts concomitant with i.p. 
sensitisation, and mice were subsequently exposed to a mild regime of airways exposure 
to OVA. On investigation, OT-II CD4+ T cell recipient mice were found to have 
significantly reduced numbers of eosinophils in BALF. Peripheral blood eosinophil 
levels were similar between allergic mice and OT-II recipients, although it was noted 
that OT-II recipients had significantly increased levels of eosinophils in blood on day 
19, which may have represented a “backing up” of eosinophils in the blood 
compartment due to altered recruitment to the allergic lung. Eosinophils are known to 
express functional IFN-γ receptors (Ochiai et al., 1999), and in this Chapter, transferred 
OT-II CD4+ T cells were observed to reside in the pulmonary draining lymph nodes and 
to a lessor extent in the lung tissue. Therefore, OT-II cells secreting IFN-γ in response 
to presentation of OVA by endogenous APCs within these host tissues may have 
modulated eosinophil function and infiltration into the allergic lung, such that 
eosinophil infiltration of the airways lumen was inhibited. Analysis of histological 
sections revealed that inflammatory cell infiltrate in the lungs of OT-II recipients were 
virtually indistinguishable from allergic controls, suggesting that although BALF 
eosinophils were reduced, eosinophil infiltration of lung tissue was not impaired. In 
addition, the airway response to methacholine challenge, and serum OVA-specific IgG1 
responses in OT-II recipients remained intact, despite the reported ability of IFN-γ to 
suppress IL-4 mediated IgG1 production (Snapper and Paul, 1987; Finkelman et al., 
1988a), and for Th1 cells to reduce AHR in the rat (Huang et al., 2001). Collectively, 
these data suggest that transferred IFN-γ secreting OT-II T cells can influence 
eosinophil infiltration into the airways lumen, but are not able to counterbalance allergic 
airways disease induction and progression in this animal model. IFN-γ has been shown 
to inhibit eotaxin synthesis by dermal fibroblasts in vitro (Miyamasu et al., 1999), and 
therefore the release of IFN-γ from adoptively transferred OT-II CD4+ T cells in 
response to inhaled OVA may have reduced eotaxin synthesis within the airways 
epithelium. 
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It is possible that significantly increasing the numbers of adoptively transferred OT-II T 
cells during sensitisation could attenuate other characteristic markers of AAD. In this 
way, substantially greater amounts of IFN-γ production during disease induction 
(sensitisation) could influence the adaptive immune response such that the developing 
Th2 phenotype is either greatly suppressed, or even absent. The therapeutic value of 
such a strategy in human asthma may be limited however, as allergic asthma is usually 
diagnosed after the fact – that is following significant development of a Th2 type 
response to a normally innocuous environmental antigen. In this regard, attempts to 
counterbalance the disease using Th1 type T cells may not be ideal, particularly when 
levels of eosinophils in the lung parenchyma remains refractory to such treatment 
(Huang et al., 2001 and this Chapter). Instead, interventional therapies based simply on 
IFN-γ or its regulation within the lung may be beneficial. Indeed, the delivery of IL-12, 
a potent regulator of IFN-γ to the airways mucosa can suppress measurable parameters 
including parenchymal eosinophils in allergic mice (Hogan et al., 1998b; Sur et al., 
2000a; Sur et al., 2000b). However, the systemic administration of recombinant human 
IL-12 does not alter airways hyperreactivity nor the late asthmatic reaction in mild 
asthmatic patients, despite significant reduction in sputum and peripheral blood 
eosinophils (Bryan et al., 2000).  
 
In summary, the OT-II mouse has been partially characterised in a mouse model of 
asthma, and is refractory to allergic airways disease induction and progression. When 
stimulated in vitro, OT-II transgenic T cells have been observed to secrete appreciable 
amounts of IFN-γ, and are able to attenuate eosinophil infiltration of the airways, but 
not AHR or lung inflammation when transferred to allergic hosts. The mechanism 
whereby adoptively transferred OT-II CD4+ cells may attenuate pulmonary eosinophilia 
may be related to the ability of large amounts of IFN-γ to bias an existing response 
towards Th1 cytokine production, and through the inhibition of established Th2 
responses and eosinophil recruitment. However, it must be noted that transgenic TCR 
mice are not always suitable to study disease or disease models, given the specificity of 
the TCR to a single T cell epitope, and the potential for commonly used antigens to 
contain more than one antigenic peptide. 
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7.1 INTRODUCTION 
 
The adaptive immune system has evolved to mount responses to foreign antigen, whilst 
at the same time remaining unresponsive to self. Billingham and colleagues first 
demonstrated acquired tolerance in 1953, wherein the administration of allogeneic cells 
to neonatal mice enabled them to accept allogeneic skin grafts as adults (Billingham et 
al., 1953). Neonatal immunity has previously been attributed to clonal deletion and/or 
anergy (Nossal, 1983; Gammon et al., 1986; Qin et al., 1989), but more recent evidence 
suggests that immune deviation is the basis for neonatal tolerance. The lymph nodes 
that drain immunogen bearing tolerant grafts have since been shown to produce a 10-
100 fold higher ratio of IL-4 to IFN-γ (Chen and Field, 1995), and the administration of 
IL-12 (Donckier et al., 1998), IFN-γ (Chen et al., 1996), or antibodies to IL-4 (Gao et 
al., 1996) during tolerance induction can prevent transplantation tolerance in mice, 
suggesting that immune-deviation from a Th1 to a protective Th2 is the basis for 
tolerance in these models. However, Th1 responses to non-self are not totally inhibited. 
A/J tolerant BALB/c mice show diminished Th1 CD4+ and CD8+ cell immunity (IFN-γ 
production) to A/J in vitro, whilst displaying enhanced CD4+ Th2 responses (IL-4 
production). When CD4+ cells are removed from splenic cultures, IL-2 can restore the 
ability of CD8+ cells to proliferate and secrete IFN-γ in response to A/J antigen, which 
suggests that tolerance relies, in part, on the inhibition of cell immunity by regulatory 
CD4+ Th2 cells (Field and Gao, 1998). 
 
Neonatal responses to environmental antigens are of particular interest when trying to 
understand the predisposition towards allergic disease in humans. For instance, reduced 
IFN-γ production by antigen stimulated cord blood mononuclear cells is a risk factor for 
the development of allergic disorders in later life (Kondo et al., 1998), and it has been 
shown that stimulation of cord blood cells with common environmental allergens results 
in predominantly Th2 type cytokine secretion, suggesting that a predisposition towards 
allergy may reside in an inability to deviate such responses from Th2 to Th1 (Prescott et 
al., 1998; Prescott et al., 2003). 
 
T cell maturation in the thymus has been characterised as a very destructive process, in 
which only about 2% of CD4+CD8+ double positive (DP) cells will mature into 
CD4+and CD8+ single positive (SP) cells (Robey and Fowlkes, 1994; Fink and Bevan, 
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1995; Jameson and Bevan, 1998). The process involves the “positive selection” of those 
DP cells whose TCRs have a mild to low level recognition of self peptide/MHC 
complexes on cortical epithelial cells, effectively rescuing them from “death by neglect” 
(Fink and Bevan, 1995; Jameson and Bevan, 1998). These cells may then progress from 
the cortex to the medulla, which is populated with bone marrow derived APCs (Sprent, 
1995), and permeable to soluble antigens in the blood (Surh and Sprent, 1994). Contact 
with high affinity peptides within either the medulla or the cortex leads to strong TCR 
signaling, and rapid apoptosis of the developing DP/SP cells. This is suggested to be 
one of the central tenets of “negative selection”, and avoidance of autoimmune 
reactions in the continually evolving adaptive immune system.  
 
Recently, a mouse model of allergic airways disease was used to determine the effects 
of neonatal antigen delivery in mice (Hogan et al., 1998a). A medium dose of insoluble 
OVA (100 µg) in incomplete Freund’s adjuvant (IFA) administered s.c. could prime for 
Th2-mediated AAD in adult mice, whilst soluble OVA (100 µg in PBS) could not 
(although these mice still developed AAD following sensitisation and challenge with 
OVA). Interestingly, very low doses of soluble OVA (10 µg) could also prime for Th2-
mediated AAD, without the requirement for OVA sensitisation of adult mice. 
Conversely, a high dose of soluble antigen (1 mg OVA) during neonatal development 
was shown to anergise both Th1 and Th2 adult responses to OVA, regardless of 
sensitisation. This high dose of soluble OVA totally negated proliferative spleen cell 
responses to OVA, and may have been indicative of clonal deletion of OVA-reactive 
cells. In their article, Hogan et al. introduced the concept of effective dose, and 
postulated that IFA may have sequestered antigen such that a lower effective dose was 
administered, and led to Th2 responses in the same way as did very low doses of soluble 
antigen (Hogan et al., 1998a). As such, low effective dose was shown to predispose 
adult mice to Th2 mediated AAD, whilst high soluble dose led to anergy in both Th1 
and Th2 compartments.  
 
In Chapter 6, naïve OT-II transgenic T cells having an easily detectable TCR were 
shown to secrete IFN-γ when stimulated with OVA. Using this knowledge of the adult 
phenotype, OT-II neonates were given high doses of soluble OVA, with a view to 
determining the effects of high affinity antigen administration upon the phenotype and 
fate of TCR transgenic cells. 
Chapter 7 Neonatal Antigen Delivery Induces Th-2 Mediated Allergic Airways Disease In The OT-II Transgenic Mouse 100 
 
7.2 MATERIALS AND METHODS 
 
7.2.1 Animals. 
C57BL/6 (males, 4 wk old) and OT-II mice (timed pregnant females, N10 C57BL/6, 7-8 
wk old) (Barnden et al., 1998), were obtained from the SPF unit of the ANU and housed 
in an approved containment facility. Mice were treated according to ANU animal 
welfare guidelines.  
 
7.2.2 Antigen treatment of mice. 
Within hours of birth on day 1, OT-II neonates were administered 1 x s.c. injection of 1 
mg OVA in 50 µL saline (OVAN mice). As a control, age matched OT-II litters also 
received 50 µL of saline vehicle (SALN mice). All mice were then sex-determined and 
weaned on day 30. It should be restated that all male OT-II mice carry the transgene, 
which appears to be linked to the Y chromosome.  
 
7.2.3 Detection of CD4+/Vβ5 double positive cells using flow cytometry. 
OT-II transgenic T cells are CD4+, and express the Vα2/Vβ5 TCR which is specific for 
OVA323-339 (Barnden et al., 1998; Robertson et al., 2000), and may be detected in the 
thymus and the spleen, using antibodies to either Vα2 or Vβ5 in conjunction with anti-
CD4 (Bill et al., 1990; Barnden et al., 1998).  
 
A subset of mice from OVAN and SALN groups (n=3) were sacrificed on day 30, and 
spleens excised and harvested into ice cold HBSS and physically disaggregated using 
sterile wire gauze (0.5mm). The isolated cells were centrifuged at 500 g at 4oC for 10 
minutes and the cell pellet resuspended in 500 µl RBC lysis solution and incubated at 
37oC for 5 minutes, before the addition of 1 ml ice cold HBSS. 1 x 105 freshly isolated 
splenocytes were then incubated with biotinylated mouse anti-mouse Vβ5 (Bill et al., 
1990) (Clone MR9.4) in 50 µl HBSS for 30 minutes on ice. 1 ml HBSS was then added, 
and cells FCS underlaid before being centrifuged at 500 × g for 5 min at 4° C. The cell 
pellet was then incubated with streptavidin-FITC and phycoerythrin (PE)-conjugated 
anti-mouse CD4 (clone L3T4) for a further 30 minutes on ice. Cells were again FCS 
underlaid, centrifuged at 500 × g for 5 min at 4° C, and the cell pellet resuspended in 
ice-cold HBSS before analysis by flow cytometry. Analysis was performed on a Becton 
and Dickinson FACScan flow cytometer using Cellquest (Becton and Dickinson, San 
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Jose, CA) and WinMDi software packages (kindly provided by J. Trotter, Scripps 
Research Institute, La Jolla, CA). Approximately 10,000 cells were analyzed for each 
sample. 
 
7.2.4 Sensitisation and challenge with OVA. 
Both OVAN and SALN treated OT-II mice (males) were sensitized by i.p. injection 
with 50 µg OVA/1 mg Alhydrogel (Commonwealth Serum Laboratories (CSL), 
Parkville, Australia) in 0.9% sterile saline on days 30 and 42. For comparison, age-
matched wild type C57BL/6 mice were also i.p. sensitised with OVA (WT OVA i.p.). 
On days 54, 56, 58 and 60, all mice were aeroallergen challenged as in Section 3.2.5. 
Peripheral blood smears were collected on days 53, 55, 57, 59, and 61, and analysed as 
in Section 5.2.5. All mice were sacrificed on day 61, with BALF collected and analysed 
as in Section 2.2.4, serum collected for OVA specific IgG1 analysis as in Section 2.2.8, 
lung sections taken for histological analysis as in Section 5.2.6, and spleens excised for 
stimulation with OVA and cytokine analysis. 
 
7.2.5 Stimulation of OVAN and SALN treated mouse splenocytes with OVA.  
Spleens from i.p. sensitised and challenged OVAN and SALN mice were separately 
disaggregated using sterile wire gauze (0.5mm) and suspended in ice cold PBS. 
Erythrocytes were then lysed, and the washed splenocytes were resuspended at 107 
cells/ml in MLC medium containing 10% heat-inactivated FCS, 2 mM L-glutamine, and 
50 mg/L neomycin sulfate. Splenocytes from each group were then plated out at a 
density of 2 x 106 cells/well in round-bottom tissue culture plates, both with and without 
addition of exogenous OVA (100 µg/well). Following 72 hours of culture, cell-free 
supernatants were removed and stored at –70oC for later cytokine analysis. 
 
7.2.6 Cytokine analysis. 
IL-13 and IL-5 concentrations in stimulated splenocyte supernatants were determined as 
in Section 5.2.8. IFN-γ was detected as in Section 6.2.7. 
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7.3 RESULTS 
 
7.3.1 Ovalbumin administration to OT-II neonates does not alter CD4+/Vβ5 double 
positive T cell population. 
The administration of OVA to OT-II neonates could potentially alter the proportion of 
OVA-transgenic CD4+/Vβ5 double positive cells in the adult periphery. To explore this 
possibility, antibodies to both CD4 and Vα2 were used to verify the presence of 
transgenic CD4+/Vβ5 double positive cells in the adult spleen. On investigation, it was 
noted that both OVAN and SALN mice retained significant numbers of transgenic 
CD4+/Vβ5 double positive cells within the spleen (Figure 7.1), suggesting that neonatal 
OVA administration did not deplete transgenic CD4+ T cells in OT-II mice.  
 
7.3.2 Ovalbumin administration to OT-II neonates promotes Th2-mediated allergic 
airways disease in adult mice.  
Following sensitisation and airways challenge with OVA, peripheral blood eosinophil 
levels were similar between OT-II OVAN and comparative WT mice following 
repeated airways exposure to OVA (Figure 7.2a). Analysis of BALF revealed a 
prominent airways eosinophilia in OT-II OVAN mice which was not significantly 
different from that of sensitised and challenged WT mice (Figure 7.2b). Of particular 
note was the restoration of serum OVA-specific IgG1 in OT-II OVAN mice (Figure 7.2 
c), a feature which is noticeably absent in both OT-II SALN mice and OT-II mice in 
general (see Chapter 6). Analysis of histological sections revealed that OT-II SALN 
treated mice had notable inflammatory infiltrate surrounding the airways and blood 
vessels, with some eosinophil infiltration of this tissue (Figure 7.3). In OT-II OVAN 
mice, there was a heavy inflammatory infiltrate throughout the lung, including the 
parenchyma and particularly surrounding the airways and blood vessels (Figure 7.4). 
Numerous eosinophils were also seen throughout OT-II OVAN lung sections, and also 
what appeared to be bronchoalveolar lymphoid tissue structures associated with the 
small airways. Ovalbumin stimulation of whole spleen cell populations from i.p. 
sensitised and challenged OT-II OVAN mice produced appreciable IL-13 and IL-5 
secretion, but not IFN-γ (Figure 7.5a-c). Only splenocytes from OT-II SALN mice 
retained the capacity to secrete appreciable amounts of IFN-γ in response to OVA 
stimulation (Figure 7.5c).  
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Figure 7.1. Neonatal exposure to ovalbumin does not deplete transgenic CD4+ T cells in OT-II mice. (a) CD4+ splenocytes from OVA sensitised and 
challenged wild type mice (WT OVA i.p.) were gated (R1) on the basis of size (forward scatter, FSC-H) and staining with antibody to CD4 (FL2-H). (b) WT 
OVA i.p. splenocytes stained with anti-CD4 antibody and mouse anti-mouse Vα2 (clone MR9.4, FL1-H channel). Single-CD4 positive cells reside in the 
upper left quadrant, while low numbers of naturally occurring Vα2/CD4 double positive cells reside in the upper right quadrant. Percentages denote the 
proportion of gated cells (from R1) in each quadrant. (c) Splenocytes from OT-II mice treated with saline as neonates (OT-II SALN), contain normal 
numbers of Vα2/CD4 double positive cells (upper right quadrant). (d) OT-II mice treated with soluble OVA as neonates (OT-II OVAN) have normal 
numbers of Vα2/CD4 double positive cells in the spleen when compared to OT-II SALN controls. Data is representative of 3 animals per group. 
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Figure 7.2. Neonatal exposure to ovalbumin promotes allergic airways disease in OT-II mice. (a) Peripheral blood eosinophilia in OVA sensitised and 
challenged OT-II transgenic mice, exposed to soluble OVA (OT-II OVAN) or saline vehicle (OT-II SALN) as neonates. Data for OVA sensitised and 
challenged wild type mice (WT OVA i.p.) are also shown for comparison. (b) Eosinophil and lymphocyte numbers in BALF. (c) Serum OVA-specific 
IgG1 levels. Data represents mean ± SEM for groups of 6-7 mice. Significant differences in means were determined by Student’s unpaired t test (P 
<0.05). * P <0.05 when compared to OT-II OVAN and WT OVA i.p. mice.  
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Figure 7.3. Histological analysis of lung sections from OT-II mice treated with saline as neonates. (a) Histological section (4 x objective). Note the 
peribronchial and perivascular infiltrate surrounding the airways and blood vessels, whilst the parenchyma is relatively intact. (b) There is a large 
inflammatory infiltrate surrounding the blood vessels (20 x objective). (c) Most of the infiltrating cells appear to be lymphocytes, although a significant 
number of eosinophils may be seen in association with inflammatory cells surrounding the airways and blood vessels (40 x objective). Lung tissue was 
stained with Lendrum’s carbolchromotrope stain. 
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Figure 7.4. Histological analysis of lung sections from OT-II mice treated with soluble ovalbumin as neonates. (a) Histological section (4 x objective). 
Note the very pronounced peribronchial and perivascular infiltrate surrounding the airways and blood vessels, and spreading throughout the 
parenchyma. (b) There is a large inflammatory infiltrate surrounding the blood vessels (10 x objective). (c) Most of the infiltrating cells appear to be 
lymphocytes, and a large number of eosinophils may be seen (20 x objective). What appears to be bronchoalveolar lymphoid tissue may be seen in top 
left. Lung tissue was stained with Lendrum’s carbolchromotrope stain. 
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Figure 7.5. Neonatal exposure to ovalbumin promotes Th-2 cytokine release from ovalbumin stimulated OT-II spleen cells. (a) IL-13 release from 
spleen cells in response to ovalbumin (OVA) stimulation. Spleen cells were sourced from i.p. sensitised and challenged OT-II transgenic mice exposed 
to ovalbumin (OT-II OVAN) or saline vehicle as neonates (OT-II SALN). Cytokine levels from cells incubated without added exogenous OVA also 
shown (Control). (b) IL-5 release from OT-II OVAN and OT-II SALN spleen cells in response to stimulation with OVA. (c) IFN-γ release from OT-II 
OVAN and OT-II SALN spleen cells in response to stimulation with OVA. Data represents mean ± SEM for triplicate wells. Significant differences in 
means were determined by Student’s unpaired t test (P <0.05). * P <0.05 when compared to OT-II OVAN mice.  
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7.4 DISCUSSION 
 
In Chapter 6, the OT-II mouse was shown to be refractory to AAD induction and 
progression. This may be attributed to significant IFN-γ production by transgenic CD4+ 
cells in response to OVA during sensitisation, and is an interesting finding given that 
OVA323-339 peptide is as an immunodominant T cell epitope that preferentially skews 
naïve T cell responses towards Th2 cytokine secretion (Janssen et al., 1999; Janssen et 
al., 2000). High doses of soluble OVA administration to wild type neonatal mice has 
previously been shown to induce anergy in both Th1 and Th2 compartments (Hogan et 
al., 1998a), and may have been indicative of clonal deletion of antigen reactive T cells. 
To test if administration of high doses of antigen during neonatal development led to 
anergy or clonal deletion, OT-II neonates were given high doses of OVA, and 
subsequently characterised as adults. Upon investigation, OVA administration to OT-II 
neonates was shown to have no effect on splenic CD4+/Vβ5+ T cell populations in 
comparison to mice injected with vehicle (Figure 7.1). This result prompted a further 
analysis of the effects of neonatal antigen administration upon AAD induction and 
progression in the OT-II mouse, with a view to understanding the phenotypic fate of 
transgenic T cells. Surprisingly, soluble OVA administration to OT-II neonates 
promoted AAD induction and progression in i.p. sensitised and airways challenged 
adults, which was accompanied by increased IL-13 and IL-5, and decreased IFN-γ 
production from OVA stimulated splenocytes (Figures 2-5). Restoration of serum OVA 
specific IgG1, was also a surprising result, and implied that IL-4 secretion was also a 
possible feature of this immune deviation (Snapper and Paul, 1987; Finkelman et al., 
1988a; Finkelman et al., 1990).  
 
These observations suggest two possibilities (at least) for immune deviation in the OT-
II mouse. (1) The development and emergence of an OVA-specific Th2 subset that can 
both promote AAD and suppress the IFN-γ producing transgenic T cells, or (2) total 
reprogramming of the transgenic T cell response to OVA. In the first instance, the 
transgenic T cell represents almost 90 % of the CD4+ population and remains within the 
T cell repertoire of OT-II OVAN mice (Figure 7.1). Their relative abundance and IFN-γ 
secretion in response to OVA (Chapter 6) does not support the hypothetical emergence 
of a separate Th2 T cell population having the capacity to suppress this abundant 
population of OVA transgenic T cells. 
Chapter 7 Neonatal Antigen Delivery Induces Th-2 Mediated Allergic Airways Disease In The OT-II Transgenic Mouse 104 
 
It is proposed that the OT-II TCR transgenic T cell may have been reprogrammed 
towards the Th2 phenotype in response to soluble OVA administration during ontogeny. 
Medullary thymic epithelial cells can present soluble OVA to T cells in the thymus 
(Mizuochi et al., 1992), and it is possible that TCR transgenic cells that were 
developing in the thymus would have been negatively selected following the 
administration of OVA bolus to OT-II neonates, as the interaction between presented 
OVA peptides and developing TCR transgenic cells would be a high affinity 
interaction. Therefore, those cells that were developing in the thymus during and soon 
after OVA administration in OT-II OVAN mice may not have contributed to the 
observed phenotype in adult mice. Instead, the observed result may have been due to the 
reprogramming of the already mature TCR transgenic T cells that were circulating 
through the periphery at that time. Wild type neonates have a reduced capacity to 
produce IL-12 and IFN-γ (Chen et al., 1996; Donckier et al., 1998), and develop Th2 
type cytokine responses to exogenous antigens (Gao et al., 1996). The OT-II neonate 
may be similar in this respect, as antigen encounter by TCR transgenic T cells in the 
periphery during ontogeny appears to have led to peripheral reprogramming of these 
cells towards the Th2 phenotype, which then promoted the development of allergic 
airways inflammation in adult mice.  
 
In summary, neonatal antigen administration in the OT-II mouse suggests that there is 
no intrinsic defect in the transgenic T cell’s ability to produce IL-5 and IL-13. In the 
unmanipulated adult, significant IFN-γ production is a pre-programmed response that 
leaves the animal refractory to AAD induction and progression. This may be overcome 
by neonatal administration of soluble OVA, which is proposed to reprogram those T 
cells circulating in the periphery to become Th2 cells. Further experiments may validate 
this proposed mechanism. 
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This thesis has explored the ability for eosinophils to respond to antigen deposition in 
the naïve lung and to modulate CD4+ T cell function. In particular, the spatial and 
temporal distribution of mouse eosinophils within the allergic lung and lymphoid 
tissues was examined, concomitant with analysis of eosinophil function as antigen 
presenting cells both in vitro and in vivo. 
 
8.1 INNATE IMMUNITY OF THE NAÏVE LUNG  
 
Allergic responses to innocuous environmental antigens may represent a misdirected 
activation of the effector arm of the immune system (Th2), which that has evolved to 
combat parasite infections. Culley et al. recently hypothesised that the mechanism of 
eosinophil recruitment during parasite infection may be related to those seen during 
allergic inflammation (Culley et al., 2002). In their study, the appearance of parasite 
larvae in lung tissue following primary infection with Necator americanus induced 
eotaxin and macrophage inflammatory protein 1α (MIP-1α) production. Importantly, 
the levels of these eosinophil chemoattractants were no different between naïve and 
immune mice, and both developed a pronounced pulmonary eosinophilia that was 
dependent on IL-5 (Culley et al., 2002). Eosinophils have previously been identified as 
the primary source of IL-4 in response to the i.p. administration of parasite eggs (Sabin 
and Pearce, 1995; Sabin et al., 1996). Furthermore, eosinophils recruited to the lung 
during N. brasiliensis infection are a major source of IL-4, and their appearance 
coincides with the induction of a Th2 response to this parasite (Shinkai et al., 2002). 
Thus, the naïve lung secretes selective chemoattractants during primary responses to 
parasites, which promote the recruitment of IL-4 producing eosinophils that can 
participate in the generation of protective immune responses. 
 
In Chapter 2, substantial evidence is provided for a similar mechanism of eosinophil 
recruitment to the naïve mouse lung, which operates in response to antigen (OVA) 
deposition. Eosinophil recruitment was only observed in PMBS treated mice that had a 
substantial pool of eosinophils located distally within the peritoneal cavity, suggesting 
that significant IL-5 generation in response to antigen was not a feature of the IES. The 
IES in naïve mice exposed to aerosolised OVA was significantly attenuated in eotaxin 
deficient mice, implicating this selective chemoattractant in what is suggested to be an 
innate response to antigen deposition in the naïve mouse lung. Notably, eotaxin plays a 
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role in the homeostatic regulation of eosinophils and thus has the potential to function 
as a rapid response signal to foreign antigen. Ordinarily, this mechanism would go 
unnoticed in naïve mice lacking a distal pool of eosinophils, although detailed analysis 
of histological sections of the lungs of naïve wild type and eotaxin deficient mice may 
further illuminate the operation of the IES at baseline.  
 
It has recently been recognised that commercial OVA preparations contain bacterial 
endotoxin (Watanabe et al., 2003), and LPS (a component of endotoxin), is known to 
induce granulocyte recruitment via eotaxin and RANTES expression in the mouse lung 
(Larsson et al., 2000). However, while LPS administration induces both eotaxin and 
RANTES expression, antibodies to either of these molecules do not inhibit eosinophil 
recruitment (Penido et al., 2001). In Chapter 2, the IES was significantly attenuated in 
PMBS treated mice that were deficient for eotaxin, and therefore the mechanism of 
recruitment cannot readily be attributed to endotoxin contamination of the OVA 
preparations that were used.  
 
It would be interesting to further characterise the downstream effects of the IES 
described in Chapter 2. GM-CSF is an eosinopoietic cytokine (Arm and Lee, 1992), 
implicated in eosinophil survival in vivo (Corrigan et al., 1995; Park et al., 1998). GM-
CSF transgene expression in the airways induces a transient pulmonary eosinophilia, 
and concurrent exposure to aerosolised OVA promotes allergic sensitisation via the 
airways in naïve mice (Stampfli et al., 1998). Thus, one question that could be answered 
is this: were PMBS-treated mice subsequently sensitised following repeated exposures 
to OVA antigen? There is some evidence for this in Figure 2.10, wherein PMBS treated 
mice at the completion of the experiment had detectable OVA specific IgG1. It was 
found that repeated PMBS injections were not tolerated in BALB/c mice, and at the 
time this study was conducted, IL-4 deficient mice were not available in the C57BL/6 
background. Therefore, it would be very interesting to repeat these experiments in 
PMBS treated wild type and IL-4 deficient animals, with a view to determining the 
contribution of the IES, IL-4 and eosinophils to allergic sensitisation via the airways. 
Detailed examination of histological sections from both lung and lymph node tissue 
before, during, and after antigen exposure would also be very informative, when 
combined with immunohistochemistry and detection of IL-4 relative to eosinophils. 
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In summary, it seems that the naïve lung can generate eotaxin and possibly other 
factors, in response to antigen deposition, which can recruit eosinophils to pulmonary 
tissues. Under these conditions, there is no IL-5 available to promote the maturation and 
release of eosinophils from bone marrow, and the phenomena goes virtually unnoticed 
at baseline. In PMBS treated mice however, there are abundant eosinophils located in 
the peritoneal cavity that can rapidly respond to this signal. Further experiments are 
necessary to better define the IES and its role in immune surveillance and in priming of 
the adaptive response. 
 
8.2  ANTIGEN PRESENTATION BY EOSINOPHILS 
 
The ability of eosinophils to quickly respond to antigen deposition in the naïve airways 
prompted a detailed analysis of the temporal and spatial distribution of eosinophils in 
the lung and draining lymph nodes of allergic mice. Eotaxin is constitutively expressed 
in the lung (Rothenberg et al., 1995b; Humbles et al., 1997), and in Chapter 3, low 
levels of eosinophils were found to reside in BALF and lymph node tissues of sensitised 
mice prior to airways challenge. Using a model of allergen challenge, eosinophil 
numbers in the draining lymph nodes of sensitised mice were significantly elevated 3 
hours after the first exposure to allergen, which actually preceded observed elevations 
in BALF and blood eosinophil levels (Figure 3.2).  
 
Further investigation revealed that a sustained antigen challenge regime promoted a 
significant eosinophil infiltration of the lung and draining lymph node tissues, which 
persisted well after the cessation of airways challenge. Programmed cell death or 
apoptosis mediated by Fas is currently thought to be the process by which tissue 
eosinophilia is resolved (Woolley et al., 1996), and both macrophage and small airways 
epithelial cells may ingest apoptotic eosinophils (Stern et al., 1992; Walsh et al., 1999). 
Interestingly, deficiency in Fas has been shown to extend tissue eosinophilia and AHR 
in a mouse model of allergic airways inflammation (Duez et al., 2001), and defects in 
Fas signaling may underlie the chronic eosinophilic inflammation seen in asthmatic 
individuals (Tsuyuki et al., 1995). In sensitised mice, IL-5 is expressed in the draining 
lymph nodes soon after allergen challenge (Gajewska et al., 2001), and may contribute 
to prolonged eosinophil persistence in this tissue.  
 
Chapter 8 General Discussion 109 
 
Notably, electron microscopy revealed that eosinophils residing in lymphoid tissue 
exhibited a low level of activation, with the loss of crystalloid granule cores and matrix 
from eosinophilic granules (Figure 3.4b). Accordingly, it was hypothesised that 
eosinophils residing in the lung prior to-, or those that were recruited following allergen 
provocation may actively sample the extracellular environment before translocating to 
the draining lymph nodes via the afferent lymphatics.  
 
Analysis of eosinophil surface molecule expression showed that eosinophils derived 
from the allergic lung possess the molecular machinery (MHC-II, CD80, and CD86), 
necessary for effective antigen presentation to T lymphocytes (Chapter 4). Furthermore, 
these cells were able to internalise and process complex antigen both in vitro and in vivo 
within the allergic lung (Figure 4.3 and 4.4). Importantly, eosinophils co-incubated with 
in vitro derived Th2 cells promoted the release of IL-4, IL-5 and IL-13 (Figure 4.8), 
which are cytokines that have been implicated in the development of Th2 mediated 
allergic inflammation (Snapper and Paul, 1987; Swain et al., 1990), and eosinophil 
recruitment to tissues (Ying et al., 1997b; Webb et al., 2000; Woltmann et al., 2000; 
Kumar et al., 2002). Therefore, eosinophils which have previously been shown to 
populate the lung and draining lymph node tissues following allergen challenge can 
interact with memory T cells via presentation of relevant antigen in the context of 
MHC-II, concurrent with the delivery of appropriate costimulatory signals.  
 
In the future, these in vitro experiments may be extended by analysis of eosinophil 
ability to prime for Th2 and even Th1 responses. For instance, the methodology of 
Section 4.2.9 may be suitably adapted to incorporate eosinophils as the antigen 
presenting cells that drive Th T cell production. In the presence of appropriate 
antibodies, either Th1 or Th2 CD4+ T cells may be generated from naïve T cells in 
vitro, and would further our knowledge of eosinophil function during immune 
surveillance. In these future experiments, it would be very interesting to use separate 
Th1-like and Th2-like eosinophil populations that have been identified previously 
(Lamkhioued et al., 1996), which may further exhibit preferential Th1 or Th2 priming 
capacities in vitro. These studies may further link innate (eosinophils) and adaptive (T 
cell) responses. 
 
Alternatively, the EliCell assay developed by Bandeira-Melo et al., may be used to 
further define the antigen presenting capacity of eosinophils (Bandeira-Melo et al., 
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2003). This recently developed microscopic assay has been used to identify cytokine 
release by individual eosinophils in response to environmental stimuli, when placed in a 
semi-solid growth medium. The assay may be suitably adapted to study the cognate 
interactions between antigen loaded eosinophils and naïve or antigen-specific T cells, 
and the cellular source of relevant cytokines, particularly IL-4, may be delineated. 
Furthermore, the semi-solid growth medium may be adapted to contain antibodies to 
cell surface molecules, including MHC-II, CD80/CD86, and ICAM-1, to further 
characterise the contribution of these molecules to antigen presentation by eosinophils. 
In addition, the semi-solid medium may be supplemented with proteins and other cell 
types (e.g. endothelial cells) that mimic in vivo allergic tissue conditions. For example, 
fibronectin has previously been shown to promote eosinophil survival in vitro (Anwar et 
al., 1993), and the addition of this molecule to the semi-solid growth medium seems 
logical when attempting to study eosinophil function ex vivo. 
 
In Chapter 5, eosinophils loaded with OVA antigen ex vivo promoted the development 
of Th2 mediated allergic airways inflammation when administered to naïve mice. 
Eosinophil recipient mice exhibited significant peripheral blood and pulmonary 
eosinophilia in response to airways challenge with relevant antigen, and stimulation of 
lymph nodes cells revealed significant Th2 cytokine production (IL-5 and IL-13). 
Importantly, OVA specific IgG1 was not detected in the serum of eosinophil recipients 
at the end of the experiment, and indicated a lack of free OVA available for stimulation 
of naïve B cells.  
 
A significant component of this thesis has been submitted for peer review, and 
subsequently published in an internationally recognised journal (MacKenzie et al., 
2001). Recently, Van Rijt et al., have refuted the ability for eosinophils to present 
antigen to naïve T cells, and maintain that dendritic cells are superior in activating T 
cells within the draining lymphoid tissues of the lung (Van Rijt et al., 2003). In their 
study, Van Rijt et al., demonstrate that unlike dendritic cells, eosinophils instilled into 
the naïve airways are unable to stimulate the proliferation of OVA TCR transgenic T 
cells residing in the draining lymph nodes. This lack of function may however, be an 
artifact of their stringent purification procedure which, despite the best intentions, still 
only produced an eosinophil population of greater than >96% purity. The FACS sorted 
eosinophils used by Van Rijt et al., were enriched from the BALF of allergic BALB/c 
mice on the basis of size, granularity, and CCR3hi/CD11cintermediate surface molecule 
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expression. Whilst these two surface markers would certainly contribute to attaining a 
highly enriched eosinophil population, it should be noted that incubating eosinophils 
with antibodies to these surface molecules – particularly CCR3, may alter the activation 
status of these cells by non-specific receptor activation. For instance, eotaxin induces 
aggregation of guinea pig eosinophils in vitro (Griffiths-Johnson et al., 1993), is an 
activator of the respiratory burst (Elsner et al., 1996), and mobilises preformed IL-4 
from the eosinophilic granules of human eosinophils (Bandeira-Melo et al., 2001). 
Importantly, antibody-mediated ligation of surface molecules expressed by human 
eosinophils (CD28) induces cytokine release (Woerly et al., 2002), and may alter any 
subsequent eosinophil responses to the microenvironment. Therefore, the purification 
procedure used by Van Rijt et al., may have been detrimental to eosinophil function, 
and notably, they neglect to demonstrate translocation of their enriched eosinophils to 
the draining lymphoid tissues. In contrast, the freshly isolated eosinophils used in the 
experiments described in this thesis were FACS sorted on the basis of size (forwards 
scatter), granularity (side scatter), and the ability to polarize light, which reliably 
produced cell populations of >98% purity. These cells were duly capable of regulating 
CD4+ T cell function in vitro, and in vivo.  
 
In summary, intimate communication between eosinophils and T lymphocytes in 
allergic tissue may exacerbate allergic inflammation in vivo, through the production of 
Th2 cytokines (Figure 8.1). It is shown that eosinophils recruited to the allergic lung 
may take up and process antigen following repeated exposure to aeroallergen, and either 
present antigenic peptides to antigen–specific T cells within lung tissue, or traffic to the 
draining lymph node and present antigenic peptides to resident T cells. Ultimately, IL-4, 
IL-5 and IL-13 may be released in response to eosinophil immunomodulatory events, 
which may act distally (e.g. IL-5) to promote further eosinophilpoiesis, or locally (e.g. 
IL-4, IL-5 and IL-13), to exacerbate eosinophilic inflammation and airways 
hyperresponsiveness.  
 
Alternatively, cognate interactions between antigen presenting eosinophils and antigen-
specific T cells may serve to limit antigen-specific T cell function. Previously, 
eosinophils in the lungs of mice with allergy-independent pulmonary eosinophilia were 
demonstrated to release MBP following antigen deposition in the lung, and 
significantly, the depletion of CD4+ T cells attenuated this MBP release (Mould et al., 
2000). More recently, antigen-activated CD4+ memory T cells were shown to mediate 
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Figure 8.1. Proposed mechanism for eosinophil acquisition of aeroallergen and presentation to antigen specific T cells. (a) Eosinophils encounter 
antigen in the allergic lung, which is then processed in situ. They may either remain in the allergic lung, or traffic via the afferent lymphatic system to 
the draining lymph nodes. (b) Eosinophils (E) located within lung or draining lymphoid tissue present peptide antigens to CD4+ T cells (T) in the 
context of MHC class II. Such immunomodulatory events may induce IL-4, IL-5 and IL-13 Th2 cytokine secretion and promote disease exacerbation. 
In addition, CD28 ligation on the eosinophil cell surface by T cell expressed B7 molecules may also promote the release of preformed cytokines from 
eosinophils.  
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eosinophil degranulation within the lungs of N. brasiliensis infected mice, but only in 
the context of relevant antigen (Shinkai et al., 2002). Thus, antigen-activated CD4+ T 
cells may mediate eosinophil degranulation in the lung, possibly as a result of 
bidirectional signaling events. The release of cytotoxic granule proteins during cognate 
interactions may then limit the activity of T cells, and also result in localised tissue 
damage. Again, the recently developed EliCell assay may be used to illuminate T cell 
mediated degranulation by eosinophils during cognate interactions. In particular, 
differing concentrations of antigen may be added to the semi-solid growth media in 
order to demonstrate antigen induced eosinophil degranulation mediated by CD4+ T 
cells.  
 
In conclusion, the work presented in this thesis explores the ability of eosinophils to 
participate as antigen presenting cells during allergic inflammation. The experiments 
and results described herein suggest that eosinophils recruited to pulmonary tissues may 
collectively act to modulate CD4+ T cell function via antigen presentation and the 
induction of Th2 cytokine release. This has particular relevance for human atopic 
diseases, including asthma. It has already been recognised by others that eosinophils 
obtained from the lungs of allergic asthmatics display increased HLA-DR expression 
(Sedgwick et al., 1992), and that human eosinophils are clearly capable of presenting 
complex antigens to memory T cells (Weller et al., 1993, Weller et al., 1997). 
Therefore, the eosinophil may provide a bridge between the innate and adaptive 
immune systems. Thus this cell may play a role in immune surveillance, normally 
populates the gastrointestinal mucosa, and is responsive to helminth parasite infections. 
Eosinophils may also play a small yet functional role in the education/priming of naïve 
T cells, and may transiently amplify memory T cell responses to allergen, and thereby 
exacerbate allergic disease.  
 
8.3  THE OT-II MOUSE AND POSSIBLE FUTURE EXPERIMENTS.  
 
Towards the end of this study, the OT-II mouse was procured with a view to 
investigating interactions between antigen presenting eosinophils and antigen-specific T 
cells. Initial experiments suggested that eosinophils could present antigen to OT-II T 
cells, however no detectable Th2 cytokine production could be measured despite 
specificity of the transgenic TCR for the Th2 skewing OVA323-339 peptide (Janssen et 
al., 1999; Janssen et al., 2000). The OT-II mouse was subsequently characterised using 
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a mouse model of allergic airways inflammation, and was found to be refractory to 
disease induction, which was attributed to significant IFN-γ release from T cells in 
response to stimulation with OVA (Chapter 6).  
 
T cell therapies have been effectively used to restore anti viral responses in 
immunocompromised patients (Heslop et al., 1996; Rooney et al., 1998), and the 
infusion of opposing Th1 cells in order to attenuate Th2 mediated allergic disorders is 
an exciting prospect. For instance, the adoptive transfer of antigen-specific Th1 cells 
that secrete IFN-γ has previously been shown to attenuate characteristics of allergic 
airways disease in animal models, including reduced pulmonary eosinophilia and 
airways hyperresponsiveness (Cohn et al., 2001; Huang et al., 2001). Subsequent 
attempts at using adoptively transferred IFN-γ secreting OT-II CD4+ T cells to reduce 
allergic airways disease in C57BL/6 mice gave mixed results. While the recruitment of 
eosinophils to the airways lumen was certainly inhibited, recruitment to lung tissue, 
airways hyperresponsiveness and OVA specific immunoglobulin were left intact. This 
suggests that such immunotherapies based on homogenous populations of T cells with 
opposing cytokine responses to allergen may be of little therapeutic value, although it is 
acknowledged that using cells derived from transgenic animals that only recognise a 
single T cell epitope may not be an ideal foundation on which to predict future results. 
 
The availability of antibodies directed against the OT-II TCR Vβ5 element enabled a 
brief and interesting investigation into the effects of neonatal antigen administration, 
which has previously been shown to inhibit both Th1 and Th2 responses (Hogan et al., 
1998a). Soluble OVA administration to OT-II neonates was shown to modulate adult 
responses to sensitisation and challenge with OVA, and led to the restoration of 
pulmonary eosinophilia, Th2 cytokine production, and OVA-specific IgG1 to levels 
equivalent to those seen in OVA sensitised and challenged wild type mice. In Chapter 7, 
it was suggested that antigen delivery to OT-II neonates reprogrammed circulating T 
cells in the periphery during ontogeny, and that these cells were responsible for later 
development of allergic airways disease in OVA sensitised and challenged adults. It is 
reasonable to think that subsequent de novo production of TCR transgenic T cells in 
OVAN treated OT-II adults may still lead to mature T cells exiting from the thymus 
with the observed phenotype (IFN-γ secretion) seen in unmanipulated OT-II mice. 
Therefore, it is quite possible that in OVAN treated OT-II mice, subsequent i.p. 
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sensitisation and challenge with OVA led to the suppression and/or immunomodulation 
of these recent de novo produced thymic emigrants, by the Th2 type TCR transgenic 
cells (and their descendents) that were reprogrammed in the neonatal periphery. Future 
experiments using elispot assays and individual peripheral CD4+/Vβ5+ DP T cells may 
confirm the presence of two distinct populations of TCR transgenic T cells in the 
unsensitised OT-II OVAN mouse: one population that may secrete IFN-γ in response to 
OVA and which is representative of recent thymic emigrants, and an older population 
comprising those peripheral T cells and their descendents that were reprogrammed in 
the neonatal periphery, and which secrete IL-5 and IL-13 in response to OVA. 
 
This question remains: why did a large soluble dose of OVA delivered to OT-II 
neonates not induce the previously observed anergy seen in wild type mice (Hogan et 
al., 1998a)? In the wild type mouse, maturing thymocytes specific for OVA peptides 
may only represent a small fraction of all developing thymocytes. Administration of 
soluble OVA may have led to the negative selection of those cells that were developing 
in the thymus at that time (Liblau et al., 1996), and the retention of OVA peptides by 
thymic medullary APCs may have prolonged the negative selection of the subsequently 
developing OVA-specific T cells. The (few) mature OVA-specific T cells in the wild 
type neonatal periphery may have been overwhelmed by such a large dose of soluble 
antigen and been subject to clonal exhaustion and apoptosis (Boehme and Lenardo, 
1993; Radvanyi et al., 1993; Nagata and Golstein, 1995; Iezzi et al., 1998). In the OT-II 
neonate, a disproportionately large number of OVA-specific TCR transgenic T cells 
may be expected to reside in the periphery, and these cells may have been impervious to 
such an overwhelming dose of soluble antigen by virtue of their sheer numbers, and 
possibly synchronised responses afforded by the possession of a common TCR. In 
Figure 8.2, a mechanism is proposed wherein OT-II CD4+ T cells may be 
reprogrammed during ontogeny. Future experiments may reveal that OVA 
administration to OT-II neonates can promote the induction of allergic inflammation of 
the lung (when subsequently exposed to inhaled allergen) without the requirement for 
sensitisation to OVA. 
 
In summary, the availability of the OT-II mouse has provided a brief but unique 
opportunity to study neonatal responses to exogenous antigen during neonatal ontogeny. 
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Figure 8.2. Proposed mechanism for reprogramming in the OT-II neonate exposed to a high dose of soluble OVA. In the wild type neonate, a high dose of 
soluble OVA (WILD TYPE OVAN) may promote the negative selection of OVA-specific thymocytes, and this process may continue into adulthood due to 
the retention of OVA peptides by medullary APCs. In the wild type periphery, the few recent thymic emigrants that are OVA-specific are overwhelmed by 
the large amount of soluble antigen, and either die or become anergic through clonal exhaustion. The wild type OVAN mouse is therefore refractory to 
allergic airways disease (AAD) induction and progression, and Th1 responses are also attenuated. In the OT-II neonate, negative selection in the thymus may 
also occur, and may also continue well into adulthood. There are many OVA-specific TCR transgenic T cells in the periphery, which are not overwhelmed 
by large amounts of soluble antigen. Instead, they may be collectively reprogrammed towards the Th2 phenotype. This promotes AAD induction and 
progression in OVAN treated OT-II mice.  
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Future experiments may illuminate the mechanism for reprogramming of the transgenic 
T cell during the neonatal period, and further our understanding of neonatal immunity. 
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RESPONSE TO EXAMINERS WRITTEN REPORTS, APRIL 2004. 
 
 
EXAMINER 1: 
 
Comment on Chapter 2. The experimental design and its interpretation imply that 
eosinophils detected in the lung fluid have arrived there via trafficking through the 
peritoneum. Do you know this is really the case? 
 
Response: The data provided in Figure 2.1 show the difference in recoverable 
eosinophils from the peritoneal cavity both prior to (day 0) and following (day 8) 
exposure to aerosolised OVA on previous days 1, 3, 5, and 7. Looking to Figure 2.2, 
only WT PMBS treated mice developed a significant peripheral blood eosinophilia 
following exposure of the naïve airways to OVA, suggesting that a humoral factor may 
act to draw eosinophils from the distal peritoneal pool into the bloodstream. Analysis of 
BALF in Figure 2.3 shows that both WT and EKO PMBS treated mice had significant 
numbers of eosinophils in BALF, although this response was greatly amplified in WT 
PMBS treated mice.  
 
In this model, it is the repeated injections of PBMS that induce the peritoneal 
eosinophilia in naïve mice, and which may be attributed to mast cell degranulation 
(Pincus, 1978). On discontinuation of the PMBS injections, I think that the eosinophils 
located within the peritoneum may endure alternative fates including: (1) non-specific 
egress via the blood and subsequent removal via apoptosis in the periphery, or (2), 
remain in the peritoneal cavity prior to subsequent removal via apoptosis in that 
compartment. Some eosinophils may invade the surrounding tissues, and histochemical 
analysis of surrounding tissues may be illuminating. The data presented in Figures 2.2 
and 2.3 would suggest that antigen deposition in the naïve airway can elicit a humoral 
factor, possibly eotaxin, that can attract eosinophils from the peritoneal compartment to 
the lung, via blood. The alternative is that eosinophils may be recruited from other 
tissues or even from the bone marrow, however this is unlikely and the WT Control data 
in Figures 2.1-2.3 do not support any notion that antigen deposition in the lung may 
drive eosinophil accumulation in the absence of this distal and responsive pool. 
Nonetheless, adoptive transfer of fluorescently labelled eosinophils to the peritoneum of 
WT PMBS and WT Control mice may be an informative exercise in future experiments, 
and confirm egress from the peritoneal cavity via blood and subsequent recruitment to 
the naïve lung.  
 
Comment on Chapters 3&4. While you have presented evidence suggesting that 
eosinophils can function as antigen presenting cells in vivo, how effective are they when 
put up against the classic antigen presenting cells (i.e…dendritic cells, etc)? Do you 
think eosinophils fill a specific niche in time? space (i.e…nature of organ)? nature of 
antigen? 
 
Response: Eosinophils are poor antigen presenting cells in comparison to classic APCs 
(Del Pozo et al., 1992; Mawhorter et al., 1994), and yet I still believe that the evidence 
presented in this thesis shows that large numbers of antigen loaded eosinophils may 
serially trigger T cell receptors (Valitutti and Lanzavecchia, 1997), and exacerbate 
inflammation type responses e.g. following repeated antigen deposition within the 
allergic airways mucosa. This exacerbation may occur locally within lung tissue, as well 
as distally in draining lymphoid tissues (see for example figures 3.3 and 3.4). 
Ultimately, modulation of T cell function by this inefficient yet highly prevalent 
granulocyte having APC function is considered to have effects on eosinophil activation 
status in the lung, and also on subsequent eosinophilpoiesis and recruitment, which is 
mediated by such factors as T cell (and possibly eosinophil) derived IL-4, IL-5 and IL-
13.   
 
Do I think eosinophils fill a specific niche in time? Yes, but only in that they may 
(following initial recruitment), reside in inflamed tissues for the duration of their short 
lives. If, during the period in which they reside, that tissue is exposed to further antigen, 
then large numbers of eosinophils with antigen presenting capacity may continue to 
modulate T cell function en masse, be they memory or naïve T cells.  
 
As to the nature of the antigen, the experiments in this thesis dealt solely with a soluble 
antigen (OVA), which has no intrinsic enzymatic property. Many of the known 
allergens are soluble proteins having intrinsic enzymatic properties. For instance Fel d 1 
antigen derived from cat saliva is a soluble antigen having associated fibronectin-
degrading ability (Ring et al., 2000), and may be carried by airborne house dust 
particles (Ormstad et al., 1998). Similarly, Der p 1 antigen from house dust mites has 
some associated proteolytic activity, and may also modulate the balance between IL-4 
and IFN-γ (Comoy et al., 1998). It would be interesting to study the ability of 
eosinophils to present soluble antigens with such associated intrinsic activities.  
 
Comment on Chapters 6&7. These chapters are a bit short on experimental data, and 
while your chapter discussions and overall discussions not “future experiments”, it 
might be useful, just as a post-thesis exercise, to outline precisely what those future 
experiments might be. 
 
Response: I agree with the examiners sentiments. This suggested exercise may be 
undertaken in collaboration with Prof. Foster at some time in the future. However, I 
would prefer not to publish any planned future experimental procedures here in any 
detail, with a view to protecting future research efforts/directions. 
 
 
 
EXAMINER 2 
 
Comment on Chapter 1. In Chapter 1, page 8, 2nd paragraph. It was unclear how a lack 
of protective immunity in IL-5 KO mice can be concluded from studies showing no 
difference in recovery rates between non-immunized controls and IL-5 KO mice? 
 
Response: Le Goff et al., (Le Goff et al., 2000), demonstrated that “Mice genetically 
deficient in IL-5 were unable to generate a protective immune response when 
vaccinated with irradiated larvae, whereas C57BL/6 mice were fully protected from 
challenge infection” (excerpt from the abstract). My intention was to draw the readers 
attention to the fact that eosinophils may play a role in the development of protective 
immunity – aside to their purported roles in innate immunity and parasite clearance 
(Weller, 1994; Ovington and Behm, 1997), which are actively being challenged (Dent et 
al., 1997).  
 
Comment on Chapter 1. 3rd last line, page 24. A square bracket appears in the line. 
 
Response: I propose to remove said square bracket. 
 
Comment on Chapter 1. 1st line page 26. The sentence begins by referring to studies in 
the 1990’s, yet a paper from 1981 is cited? 
 
Response: I propose to change the paragraph to “In the late 1900's…” 
 
Comment on Chapter 1. It may have been helpful to give the reader an indication of 
the relative efficiency of different APC’s including eosinophils with respect of antigen 
presentation. Particularly in the context of presentation to naïve and memory T cells? 
 
Response: The readers attention is drawn to the response to comments of Chapters 3 
and 4, raised by Examiner 1 (supra). In addition to these comments, it appears that 
eosinophils may be a potential source of early IL-4 in naïve responses to parasite eggs 
(Sabin and Pearce, 1995; Sabin et al., 1996), and may dictate the early development of a 
Th2 type response in parasite models.  
 
Comment on Chapter 2. In Chapter 2, the candidate uses polymyxin B to raise the 
levels of eosinophils in the peritoneal cavity. As a consequence, ovalbumin exposure to 
the lung results in eosinophil recruitment to this site. There is no rationale for the use of 
polymyxin B nor how it raised eosinophil levels in the peritoneal cavity. The study of 
Pincus refers to studies in guinea-pig and this agent induces mast cell degranulation. Is 
this the proposed mechanism in these studies? This rationale should have been given in 
the introduction. 
 
Response: Polymyxin B has previously been used routinely in Prof. Fosters laboratory 
to induce eosinophils in the peritoneal cavity, providing an easily obtainable source of 
these cells for in vitro and in vivo experiments (Mould et al., 1997). Polymyxin B is 
thought to induce mast cell degranulation, the downstream effects of which lead to 
eosinophil accumulation (Pincus, 1978). I am not aware if anybody has since elucidated 
the exact mechanism of polymyxin B-generated eosinophilia, other than identifying IL-
5 as being necessary (studies in IL-5 deficient mice, Dr. Klaus Matthei - personal 
communication). It is interesting to note that polymyxin B is known to bind endotoxin 
(James et al., 1996), although LPS contamination of polymyxin B for injections is 
unlikely. 
 
Comment on Chapter 2. Is the effect of ovalbumin on eosinophil recruitment observed 
if another agent is used to augment in the peritoneal cavity (eg IL-5 or PAF)? 
 
Response: Unknown. I think it might be important to use a stimulus that does not 
generate a large peripheral blood eosinophilia (bolus IL-5 administered i.p. may do 
this), and to use a stimulus which gives reproducible eosinophilia in large numbers of 
naïve mice. At the time, polymyxin B injections provided the means with which to do 
this. 
 
Comment on Chapter 2. Is it possible that polymyxin B is inducing the inflammatory 
mediators systemically (eg eotaxin, IL-5), which then facilitates eosinophil recruitment 
to the lung? 
 
Response: Yes of course, although it should be remembered that despite eotaxin 
deficient animals having similar numbers of eosinophils in the peritoneal cavity, 
pulmonary eosinophilia was significantly attenuated in comparison to wild type mice 
following exposure of the naïve airways to ovalbumin aerosol (see Figures 2.1(a) and 
2.3(a)). Only polymyxin B treated mice had significant pulmonary eosinophilia 
following exposure of the naïve airways to ovalbumin aerosol, as wild type controls 
(WT Control) mice (not exposed to polymyxin B) did not. 
 
Comment on Chapter 2. It is unclear from the figures whether WT controls refer to 
animals not treated with polymyxin but exposed to ovalbumin? If animals were not 
exposed to ovalbumin, then please indicate the levels of lung eosinophils enumerated in 
BAL fluid. 
 
Response: The mice were not treated with polymyxin but exposed to ovalbumin. There 
were no eosinophils recovered in BAL for these mice. 
 
General comment. Non paired t test was frequently used to determine statistical 
significance between groups. In a number of situations more than two treatment groups 
were present and therefore, an analysis of variance followed by an appropriate multiple 
comparison test (eg Bonferroni) should have been used. While the conclusions drawn 
will not change, the data analysis would be more appropriate. 
 
Response: From GraphPad Prism  (Ver 2.01) helpfile: “The only advantage of the 
Bonferroni method is that it is well known and easy to understand. Its disadvantage is 
that it is too conservative, leading to P values that are too high and confidence intervals 
that are too wide.” Whilst the examiner favors this test, there was no special inducement 
to use it. As the examiner has indicated, the conclusions drawn would not change. 
 
Comment on Chapter 5. Page 83. The candidate considers the possibility that 
contamination by T cells could not account for the effects observed when eosinophils 
from antigen-sensitized mice were transferred into recipients. Would in not have been 
possible to undertake control experiments with anti-CD4 during purification to 
eliminate contamination by T cells? 
 
Response: Yes it was possible with hindsight, and the suggested controls would have 
adequately answered the question as to T cell contamination. 
 
Comment on Chapter 8. Page 110. ‘microscopical’ should be replaced with 
‘microscopic’. 
 
Response: I propose to change said word to "microscopic". 
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